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Statins are widely used as cholesterol-lowering drugs that selectively inhibit the 
enzyme HMG-CoA reductase and block cholesterol biosynthesis. Recent studies 
show that statins induce apoptotic cell death in several types of cancer cells. However, 
the underlying molecular mechanisms are still unclear. In this study, we showed that 
simvastatin activated the mitochondrial death pathway and inhibited colony-forming 
ability of HCT116 colorectal cancer cells. Exogenously added mevalonate or 
geranylgeranylpyrophosphate (GGPP), but not farnesylpyrophosphate (FPP), in 
combination with simvastatin prevented the growth-inhibitory effect of simvastatin. 
The findings corroborated well with geranylgeranyltransferase I inhibitor GGTI-298 
treatment exhibiting similar effects as simvastatin, as opposed to farnesyltransferase 
inhibitor FTI-277, which had minimal effects on cell viability. These data suggest 
that simvastatin exerts effects via inhibition of the mevalonate pathway and by 
modulating the functions of its downstream geranylgeranylated proteins, such as Rho 
GTPases. Simvastatin treatment led to increased levels of unprenylated RhoA, Rac1 
and Cdc42, which were delocalized from the lipid rafts of the plasma membrane and 
accumulated in the cytosol. Intriguingly however, instead of inhibiting the functions 
of Rho GTPases as was expected with loss of prenylation, simvastatin caused a 
paradoxical increase in the GTP-bound form of RhoA, Rac1 and Cdc42 in HCT116 
cells. The unprenylated RhoA and Rac1-GTP retained at least part of its functional 
activities, as evidenced by their ability to mediate production of superoxide and 
activate JNK pathway in response to simvastatin treatment. Notably, blocking 
superoxide production attenuated JNK activation as well as cell death elicited by 
simvastatin treatment. Furthermore, we also discovered that simvastatin induced the 
expression of extra-long form of Bim (Bim-EL) in a JNK-dependent manner, while 
 ix 
suppression of Bim-EL expression significantly blocked simvastatin-induced 
apoptosis. Taken together, our study demonstrates that simvastatin-induced apoptosis 
in HCT116 colorectal cancer cells is mediated via the RhoA/Rac1-superoxide-JNK-
Bim signaling cascade. Further studies done in SHEP-1 neuroblastoma cells also 
implicated multiple aforementioned players in mediating simvastatin’s cytotoxic 
effects. Overall, data from this study not only provides compelling evidence for 
simvastatin’s anti-cancer activities, also suggests the importance of the identified 
molecular mechanism in other simvastatin-sensitive cancer cell types.    
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1. Statins overview 
Statins are clinically used to treat hyperlipidemia, a disease characterized by the 
unusual elevation of lipids such as cholesterol and triglycerides in the bloodstream. 
Statins can effectively control the blood cholesterol level in two ways. On one hand, 
it reduces the endogenous synthesis of cholesterol by competitively inhibiting 3-
hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-limiting 
enzyme of the mevalonate pathway that is responsible for synthesizing cholesterol in 
the liver (Weekes 1975). On the other hand, statins also enhance cholesterol 
clearance from the blood through upregulating low-density-lipoprotein (LDL) 
receptors in hepatic cells, which is the primary mechanism for removing cholesterol 
from circulation (Slater, McKinney et al. 1984; Lamon-Fava, Diffenderfer et al. 
2007). 
 
1.1 Types of statins 
The first known statin was mevastatin (compactin, ML-236B), a natural inhibitor of 
HMG-CoA reductase isolated from Penicillium citrinium in 1976 (Endo, Kuroda et al. 
1976). Despite its effectiveness towards cholesterol inhibition, the drug was never 
marketed because of its unacceptable hepatotoxicity. Subsequently, lovastatin, a 
more potent fungal metabolite was isolated from a strain of Aspergillus terreus in 
1979 and became the first statin approved for clinical use. Lovastatin was then 
chemically modified to form a semi-synthetic derivative, simvastatin (Alberts 1990). 
In 1986, pravastatin (CS-514) was identified in a bacterium called Nocardia 
autotrophica (Yoshino, Kazumi et al. 1986). The chemical structure of these three 
statins is closely related. Since then, several synthetic statins have become 
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commercially available, namely fluvastatin, atorvastatin, cerivastatin, and most 
recently, pitavastatin and rosuvastatin (Illingworth and Tobert 2001). However, 
cerivastatin was withdrawn from the market in 2001 due to fetal muscle toxicity 
(Furberg and Pitt 2001). These drugs differ in potency, key pharmacokinetic and 
pharmacological properties. Shepherd et al has listed the rank of potency in 
decreasing orders as: rosuvastatin, atorvastatin, simvastatin, lovastatin, pravastatin, 
and fluvastatin (Shepherd, Hunninghake et al. 2003). The potency of the drugs was 
orchestrated by a few factors: dose, their active or lactone form and the lipophilicity. 
Lovastatin and simvastatin are the only statins administered as lactone pro-drugs, 
which then enzymatically hydrolysed into their active and hydroxy-acid form 
(Corsini, Maggi et al. 1995); while the other statins are taken directly in their active 
form. The differences in chemical structure also affect the solubility of statins. 
Pravastatin is extremely hydrophilic, and fluvastatin has intermediate characteristics, 
whereas the rest are lipophilic (Blumenthal 2000). The lipophilicity governs the 
hepatoselectivity of statins and their inhibitory effect on HMG-CoA reductase. 
Hydrophilic statins enter the hepatocytes by carriers and primarily targeted to the 
liver; while uptake of lipophilic statins is through passive diffusion and these statins 
show efficient activities at both hepatic and extrahepatic sites (Hamelin and Turgeon 
1998). For example, simvastatin has been shown to enter endothelial cells (Corsini, 
Bellosta et al. 1999). In this study, we chose the lipophilic simvastatin to study its 






Figure A: Chemical Structure of simvastatin in its active and carboxylated form. Picture is taken 
from Millipore website. 
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1.2 Pleiotropic effects of statins  
Besides being a huge success as therapeutic agents for hyperlipidemia, statins also 
display benefits in both primary and secondary prevention of coronary heart diseases 
by reducing the blood cholesterol level, which is a major risk factor for 
atherosclerotic diseases (Gordon and Kannel 1971; Sytkowski, Kannel et al. 1990; 
1994; Shepherd, Cobbe et al. 1995; Sacks, Pfeffer et al. 1996; 1998; Downs, 
Clearfield et al. 1998; 2002; Sever, Dahlof et al. 2003). However, recent 
experimental and clinical evidences suggest that the positive outcome on 
cardiovascular diseases may also be attributed by the cholesterol-independent 
“pleiotropic” effects of statins, including improved endothelial function (Anderson, 
Meredith et al. 1995; Treasure, Klein et al. 1995; O'Driscoll, Green et al. 1997; Laufs, 
La Fata et al. 1998), inhibition of cardiac hypertrophy (Lefer, Campbell et al. 1999; 
Scalia, Gooszen et al. 2001; Takemoto, Node et al. 2001; Node, Fujita et al. 2003), 
decreased oxidative stress and vascular inflammation (Kwak, Mulhaupt et al. 2000; 
Vaughan, Gotto et al. 2000; Scalia, Gooszen et al. 2001; Stalker, Lefer et al. 2001), 
inhibition of platelet reactivity and thrombogenic response (Hale, Craver et al. 1998; 
Huhle, Abletshauser et al. 1999) and stabilization of atherosclerotic plaques (Koh 
2000; Crisby, Nordin-Fredriksson et al. 2001). Statin-induced upregulation and 
activation of endothelial nitric oxide synthase (eNOS) is suggested to be the key 
mechanism involved in the protection of the cardiovascular system (Balakumar, 
Kathuria et al. 2012). Furthermore, statins have also shown positive effects on bone 
formation, the immune and central nerve systems (Yeung and Tsao 2002).  
 
Many of the pleiotropic effects of statins can be traced back to the inhibition of the 
downstream isoprenoid intermediates of the mevalonate pathway, such as 
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farnesylpyrophosphate (FPP) and geranylgeranylpyrophosphate (GGPP) (Figure B). 
These isoprenoids serve as lipid attachments for approximately 1% of all cellular 
proteins, for example the γ-subunit of heterotrimetic G-proteins, heme-A, nuclear 
lamins, and small guanosine triphosphate-binding protein Ras superfamily proteins 
(Liao and Laufs 2005). In particular, many reports have suggested that the observed 
pleiotropic effects of statins are due to the inhibition of the proper membrane 
localization and functions of the Ras superfamily proteins (Goldstein and Brown 
1990; Liao and Laufs 2005). For examples, it was reported that statin-mediated 
upregulation of eNOS was due to inhibition of isoprenoids synthesis and the 
subsequent prevention of prenylation of small GTPase Rho (Laufs and Liao 1998; 










Figure B: Overview of the mevalonate pathway: important products, enzymes and targets of 
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1.3 Anti-tumor effects of statins: bench to bedside 
Mounting experimental data has demonstrated that statins exert cytostatic and pro-
apoptotic properties in a panel of cancers, including breast carcinoma, prostate 
carcinoma, colorectal carcinoma, lung carcinoma, glioblastoma, osteosarcoma, acute 
myeloid leukemia (AML), multiple myeloma and skin carcinoma (Chan, Oza et al. 
2003; Ukomadu and Dutta 2003; Jiang, Zheng et al. 2004; Demierre, Higgins et al. 
2005; Campbell, Esserman et al. 2006; Fromigue, Hay et al. 2006; Hwang, Na et al. 
2011). Statins inhibit cell proliferation by arresting cancer cells in the G1 or S, and 
occasionally G2/M phases by modulating cell cycle regulatory proteins (Jakobisiak, 
Bruno et al. 1991; Crick, Andres et al. 1998). For example, it was shown that statins 
regulate G1/S arrest in colorectal cancer cells by upregulating p21 and p27 
expression and downregulating CDK2 activity (Ukomadu and Dutta 2003). Besides 
the effects of statins on proliferation, they also induce apoptosis in cancer cells. 
Although the understanding of the functional mechanisms underlying these effects of 
statins are still limiting, some current work has suggested a few possibilities on how 
statins tilt the balance of pro-survival and pro-apoptotic signals. For example, 
lovastatin induces apoptosis in AML cells by downregulating the pro-survival Raf-
MEK-ERK pathway (Wu, Wong et al. 2004); in another case, statins trigger 
apoptosis in osteosarcoma cells by abrogating ERK signaling and Bcl-2 protein 
expression downstream of RhoA inhibition (Fromigue, Hay et al. 2006). Other 
reports has also suggested that statins mediate apoptotic response by activating FAS 
(CD-95) apoptotic signaling downstream of disruption of cholesterol-enriched lipid 
rafts (Gniadecki 2004). Furthermore, the cytostatic and cytotoxic effects of statins are 
observed to be more prominent in malignant cells compared to non-malignant cells, 
which was proposed to be due to the higher expression of HMG-CoA reductase and a 
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greater need for mevalonate-derived isoprenoids in cancer cells than normal cells 
(Hentosh, Yuh et al. 2001). Nonetheless, statins are promising treatment options with 
higher therapeutic index that target cancer cells with better specificity (Wong, 
Dimitroulakos et al. 2002; Jakobisiak and Golab 2003). Besides being an effective 
single-agent, various reports also demonstrated that statins could potentiate the 
effects of commonly used anti-cancer drugs such as cisplatin, doxorubicin and 5-
fluorouracil (Feleszko and Jakobisiak 2000; Martirosyan, Clendening et al. 2010; 
Taylor-Harding, Orsulic et al. 2010). More significantly, statins can also sensitize 
cells that are previously resistant to chemotherapy and radiation therapy (Wang, 
Collie-Duguid et al. 2002; Li, Appelbaum et al. 2003). For example, both lovastatin 
and simvastatin are shown to fully reverse cell adhesion-mediated drug resistance 
(CAM-DR) in multiple myeloma cells (Schmidmaier, Baumann et al. 2004). These 
positive in vitro observations also highlight that statins may be valuable adjuvant in 
combinational therapies to treat cancers.  
 
Other than the effects of statins in proliferation and apoptosis, studies in multiple 
cancer models have also demonstrated their ability to interfere with invasion and 
metastasis in both in vitro and in vivo studies. For instance, studies using mouse 
mammary cancer models showed that both lovastatin and simvastatin reduced tumor 
formation and metastasis (Alonso, Farina et al. 1998; Farina, Bublik et al. 2002). 
Similar observations were also established in melanoma cells, where statins inhibited 
invasion and metastasis by preventing RhoC activities (Collisson, Kleer et al. 2003).  
 
Nonetheless, the clinical efficacy of anti-tumor effects of statins is still controversial. 
Some epidemiological studies have correlated extended statin use with reduced 
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cancer risk, while some retrospective studies that monitored cancer risk as a 
secondary outcome have concluded otherwise (Moorman and Hamilton 2007). It is 
important to note the drawbacks of retrospective studies, which is the inherent bias of 
confounding factors such as unhealthy life style that contributes not only to 
hyperlipidemia and cardiovascular diseases, but also to cancer risk. On the other hand, 
some prospective observational studies have shown significant statin-mediated 
reduction in the incidence of a few cancers, including carcinomas of breast, prostate, 
lung, colorectal and pancreas (Blais, Desgagne et al. 2000; Poynter, Gruber et al. 
2005; Shannon, Tewoderos et al. 2005; Boudreau, Yu et al. 2007; Khurana, Bejjanki 
et al. 2007; Khurana, Sheth et al. 2007). Yet, other studies fail to draw such 
conclusions (Kaye and Jick 2004). There are multiple factors that may contribute to 
the discrepancy in those observational studies, such as differences in study 
methodology and lack of insights in the underlying mechanism of action in in vitro 
systems. It is suggested that large prospective randomized trials will be a better 
design to determine the preventive and therapeutic effects of statins in cancers. 
Despite the abovementioned discrepancies, statins are still attractive targets of 
research in the search of cancer-specific and efficient anti-cancer agents. In addition, 
statins can be introduced into clinical practice quickly and enjoy a favorable safety 
profile with uncommon but well-characterized side effects such as myotoxicity 
(Vamvakopoulos 2005; Moorman and Hamilton 2007). Nevertheless, better 
understanding of the mechanisms involved will be necessary to identify conditions 
and molecular features required for statin-mediated anti-cancer effects and to 




1.4 Statin effects in colorectal cancer 
Statins have been found to inhibit colorectal cancer progression in both cell line and 
animal models. Some mechanistic insights have emerged to explain the observed 
effects in cancer cell lines. Despite constitutively-active Ras is frequently observed in 
colorectal cancer and involved in the cancer development, studies have found that the 
mutational status of Ras might not be of importance in mediating statins’ cytostatic 
and cytotoxic effects in colorectal cancer cell lines. Instead, multiple reports have 
suggested that the protein geranylgeranylation process and their downstream Rho 
proteins are important in statin-mediated apoptotic effects (Attoub, Noe et al. 2000; 
Agarwal, Halmos et al. 2002). Another possible mechanism involves the anti-
inflammatory effects of statins, which is found to be effective to prevent colorectal 
cancer associated with inflammation. Furthermore, all the current in vivo mouse-
model studies have demonstrated that statin treatment consistently reduced colorectal 
tumor formation (Demierre, Higgins et al. 2005).  
 
Although the results from observational studies on statin use and colorectal cancer 
risk are intriguing, quite a number of studies do suggest preventive effects of statins 
against colorectal cancer (Boudreau, Yu et al. 2010). For instance, a 35–43% 
reduction in colorectal cancer risk following statin use was observed in two meta-
observational studies reported (Poynter, Gruber et al. 2005; Farwell, Scranton et al. 
2008). Another large case-control study was conducted to examine the clinical 
outcomes in colorectal cancer patients, the results showed that long-term statin use 
correlated with less-advanced cancer, lower incidence of metastases, and a better 
survival rate compared to non-users (Siddiqui, Nazario et al. 2009).  
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2 Programmed cell death  
Programmed cell death (PCD) is natural physiological process, which involves in 
morphogenesis, maintenance of tissue homeostasis and removing unwanted cells that 
may be in excess, damaged or mutated. Hence, when the tight regulation of PCD 
goes loose, it leads to pathological consequences such as the development of cancer. 
Accumulating evidence suggests that drugs that can restore functional PCD hold 
particular importance in the development of cancer therapies. Recently, many studies 
have divided PCD into three main types: apoptosis (type I), autophagy (type II) and 
necrosis (type III), based on their differences in morphological appearances, death 
inducing signals or caspase activation status.  
 
2.1 Apoptosis 
2.1.1 Characteristics and physiological role of apoptosis 
The term “Apoptosis” was first proposed by Kerr et al in 1972; it was described as a 
novel cell death process distinct from necrosis (Kerr, Wyllie et al. 1972). Apoptotic 
cells are characterized by morphological hallmarks, such as cell shrinkage, 
membrane blebbing, nuclear chromatin condensation (pyknosis) and DNA 
fragmentation (karyorrhexis) (Wyllie, Kerr et al. 1980). At the early stage of 
apoptosis, changes like externalization of phosphatidylserine happens without 
compromising cell membrane integrity (Fadok, Voelker et al. 1992). Eventually, cells 
break and form apoptotic bodies, which are membrane-bound cellular fragments. 
Apoptotic bodies contain intact organelles enclosed by membranes, which are rapidly 
engulfed by surrounding phagocytic cells without triggering any inflammatory 
responses (Kurosaka, Takahashi et al. 2003). 
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Apoptosis is involved in various physiological processes. During embryogenesis, 
apoptosis mediates the formation of inter-digit spaces allowing for proper separation 
of fingers (Jacobson, Weil et al. 1997). Apoptosis also takes part in eliminating 
pathogen-invaded cells in order to facilitate wound-healing (Greenhalgh 1998), or 
removing lymphocytes that synthesize inactive or autoimmune antibodies (Opferman 
and Korsmeyer 2003). Clearly, deregulation of the apoptotic pathways can 
potentially result in various diseases. For example, excessive apoptosis can cause 
autoimmune diseases and cancer, while neurodegenerative diseases such as 
Parkinson’s and Alzheimer’s disease are considered to be due to insufficient 
apoptosis (Jellinger 2001; Zornig, Hueber et al. 2001; Olanow 2007). 
 
2.1.2 Molecular mechanisms of apoptosis 
Apoptosis is a highly regulated and controlled cell death program involving complex 
interplay of multiple molecular factors. Under different triggers, cells activate 
different apoptotic signaling pathways, which are broadly characterized as the 
extrinsic/death receptor pathway and the intrinsic/mitochondrial pathway (Figure C). 
However, despite the diversity in the initiating stimuli, cells undergo apoptosis 
display remarkably uniform morphological and biochemical alterations, suggesting 
the presence of a common execution phase. It was then identified that a particular 
class of proteases, the caspases, are responsible for the characteristic cellular 






Figure C: Apoptotic signaling and the molecular players. 
The extrinsic pathway is exemplified by the activation of death receptor after ligand binding, leading 
to the recruitment and activation of caspase-8 by the adaptor protein FADD. While the intrinsic 
pathway is triggered by cellular insults, damage or infection, in response to which BH3-only proteins 
such as Bax are mobilized to initiate mitochondrial outer membrane permeabilization (MOMP) and 
release of mitochondria residing factors. Subsequent formation of apoptosome then stimulates 
activation of caspase-9 and downstream effector caspases. Two pathways are interlinked by caspase-8-
mediated cleavage of Bid, which results in translocation of t-Bid to the mitochondria and MOMP 
(Modified from Macfarlane and Williams, 2004 (MacFarlane and Williams 2004)).  
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2.1.2.1 Caspases  
Caspases (cysteine aspartate-specific protease) was first discovered in the nematode 
Caenorhabditis elegans, where it was known as the cell death gene CED-3 (Yuan, 
Shaham et al. 1993). The mammalian family members are highly homologus to 
CED-3. It contains many members, majority of the family members (caspase-2, -3, -
6, -7, -8, -9, and -10) participate in the apoptosis signaling (Cohen 1997), whilst 
caspase-1, 4, 5 and 12 are involved in cytokine processing and inflammation 
(Martinon and Tschopp 2007), and the functions of caspase-11 and -13 are less 
established. Despite the differences in their functions, the caspase family members 
share some common properties, for example, they all have a conservative penta-
peptide active site containing a cysteine residue; as their name indicates, they are 
cysteine proteases that recognize a tetra-peptide site in their substrates and cleave 
after the Asp residue of the peptide. In addition, they are synthesized in an inactive 
form (zymogen or proenzyme) and regulated post-translationally to ensure rapid 
activation upon trigger (Kamens, Paskind et al. 1995; Alnemri, Livingston et al. 1996; 
Nicholson and Thornberry 1997). 
 
Caspases that participate in apoptosis can be further grouped as initiator caspases 
(caspase-2, - 8, -9 and -10) and effector caspases (caspase-3, -6 and -7). Unlike the 
short pro-domains possessed by effector caspases, initiatior caspases possess a long 
pro-domain containing Death Effector Domain (DED) for caspase-8 and -10, or 
Caspase Recruitment Domain (CARD) for caspase-2 and -9. Upon pro-apoptotic 
stimuli trigger, these special domains allow the recruitment of the initiator caspases 
into complexes such as the death-inducing signaling complex (DISC) for caspase-8 
and -10 , the apoptosome for caspase-9, and the PIDDosome for caspase-2 (Peter and 
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Krammer 2003; Tinel and Tschopp 2004; Shi 2008). The recruitment is followed by 
the oligomerization and autocatalytic activation of the initiator caspases (Wilson, 
Black et al. 1994; Kumar and Colussi 1999). On the other hand, activation of the 
effector caspases is mediated through cleavage of their inactive pro-forms by initiator 
caspases. Once activated, the effectors caspases in turn cleave a variety of key 
cellular substrates and accounts for the morphological and biochemical changes 
occurred during cell death (Nicholson 1999). One of the earliest substrates cleaved by 
caspase-3 or -7 is poly-ADP-ribose polymerase (PARP) (Casciola-Rosen, Nicholson 
et al. 1996), a nuclear protein implicated in DNA repair. The effector caspases also 
mediate the cleaveage of other cellular substrates involved in membrane blebbing 
(Rho-associated kinase 1 (ROCK1), p-21 activated kinase (PAK), and gelsolin), 
DNA fragmentation (caspase-activated Dnases), maintenance of cellular structures 
(cytokeratin-18, fodrin, actin), and nuclear shrinkage (lamin) (Fischer, Janicke et al. 
2003). 
 
2.1.2.2 Bcl-2 family member 
Besides caspases, apoptosis is also controlled by a highly conserved family of 
proteins: Bcl-2 proteins. The mammalian Bcl-2 family contains at least 20 members. 
Despite their full sequences share low levels of homology; all of them contain at least 
one conserved Bcl-2 homology (BH) domain (BH1 to 4) that is essential for protein-
protein interactions (Yin, Oltvai et al. 1994). Bcl-2 family is divided into two groups: 
the anti-apoptotic and the pro-apoptotic members (Gross, McDonnell et al. 1999). 
Bcl-2, B-cell lymphoma-extra large (Bcl-XL), Bcl-W and myeloid cell leukemia 
sequence 1 (Mcl-1) represent the anti-apoptotic members of Bcl-2 family. All of 
them contain all 4 BH domains (except for Mcl-1 lacking a BH4 domain), also a 
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hydrophobic COOH-terminal transmembrane domain that allows them to target to 
the nucleus envelope, the endoplasmic reticulum (ER) or the outer mitochondrial 
membrane (OMM). Under normal physiological conditions, Bcl-2 locates in the outer 
mitochondria membrane to maintain the mitochondria membrane integrity and 
prevent the release of apoptogenic factors from the mitochondria. Sub-fraction of 
ER-localized Bcl-2 is found to play a role in ER stress-induced apoptosis, whereby it 
modulates ER calcium homeostasis through enhancing calcium transport across the 
ER membrane (Foyouzi-Youssefi, Arnaudeau et al. 2000). Compared to Bcl-2, the 
other anti-apoptotic family members Bcl-xL, Bcl-W and Mcl-1 have not been studied 
extensively; it is observed that their anti-apoptotic role is restricted to specific tissues. 
For example, both Mcl-1 and Bcl-xL are found to be highly expressed in the liver and 
together they mediate the hepatic integrity during liver development. In addition, 
Mcl-1 is shown to control cortical neurogenesis and mediate neuron survival 
following DNA damage; while mice with mutant Bcl-W showed progressive and 
almost complete degeneration of the testes (Ross, Waymire et al. 1998; Ross, Amy et 
al. 2001; Russell, Warren et al. 2001; Arbour, Vanderluit et al. 2008; Hikita, 
Takehara et al. 2009). 
 
On the other hand, the pro-apoptotic members can be further sub-divided into two 
groups: the Bcl-2-associated X (Bax) family proteins and the BH3-only proteins 
(Cory and Adams 2002). The Bax family proteins include Bax, Bcl-2 homologous 
antagonist killer (Bak) and Bcl-2-related ovarian killer (Bok). They all contain BH1, 
BH2 and BH3 domains. Under physiological conditions, Bax normally resides in the 
cytoplasm while Bak exists as integral mitochondria membrane protein. Upon 
apoptosis, Bax will translocate and oligomerize in the OMM to form a pore structure, 
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whereas Bak forms larger aggregates that compromises mitochondrial membrane 
integrity (Eskes, Desagher et al. 2000; Kroemer, Galluzzi et al. 2007). 
Oligomerization of Bax/Bak contributes to the mitochondrial outer membrane 
permeabilization (MOMP), either by forming channels allowing cytochrome c 
release (Antonsson, Montessuit et al. 2000; Dejean, Martinez-Caballero et al. 2005) 
and/or by interacting with components of the mitochondrial permeability transition 
pore complex (PTPC), such as voltage-dependent anion-selective channel protein 1 
(VDAC1), which is followed by the opening of the pores allowing the efflux of pro-
apoptotic proteins into the cytosol (Shimizu, Narita et al. 1999). Whereas Bax and 
Bak are widely distributed and interact with all anti-apoptotic proteins, Bok showed 
restricted tissue distribution in the reproductive tissues (ovary, testis and uterus) and 
selective heterodimerization with Mcl-1, but not Bcl-2, Bcl-xL, and Bcl-W (Hsu, 
Kaipia et al. 1997). Scattered studies have suggested that BOK can substitute the 
function of Bax in DNA damage-triggered intrinsic apoptosis in cancer cells, which 
might be related to its special ability to translocate into the nucleus (Yakovlev, Di 
Giovanni et al. 2004; Bartholomeusz, Wu et al. 2006).    
 
Lastly, the pro-apoptotic BH3-only proteins include BH3 interacting domain death 
agonist (Bid), Bcl-2 interacting mediator (Bim), Bcl-2 antagonist of cell death (Bad), 
Noxa and p53-upregulated mediator of apoptosis (Puma). As the name suggests, 
these proteins only contain the BH3 domain. They exhibit pro-apoptotic functions by 
neutralizng the pro-survival Bcl-2 proteins. In addition, it is found that BH3-only 
proteins Bid and Bim are also direct activators of Bax/Bak to promote Bax/Bak-
mediated membrane permeabilization (Kuwana, Bouchier-Hayes et al. 2005). 
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2.1.2.3.2 Biology of BIM 
The physiological role of Bim was unveiled by deletion studies, where knockout of 
Bim resulted in accumulation of lymphoid and myeloid cells, disturbed development 
of immune system and developed autoimmune kidney diseases. These Bim knockout 
lymphocytes also demonstrated resistance to a certain set of apoptotic signals 
including cytokine deprivation, calcium ion flux and microtubule perturbation, but 
showed sensitivity to other insults such as glucocorticoids and DNA damage 
(Bouillet, Metcalf et al. 1999; Bouillet, Huang et al. 2000; Bouillet, Cory et al. 2001; 
Bouillet, Purton et al. 2002; Hildeman, Zhu et al. 2002). Three main forms of Bim 
(Bim-EL, Bim-L and Bim-S) are expressed due to alternative spicing, with Bim-EL 
being the most prominent form in most cell types (O'Reilly, Cullen et al. 2000). Both 
transcriptional and post-translational regulations determine the expression level and 
activity of Bim. Upregulation of Bim protein level to mediate apoptosis has been 
observed in multiple cell types, such as in neuronal cells upon nerve growth factor 
deprivation. Past work has also identified transcriptional factors responsible for Bim 
transcription, such as the activation of the c-Jun, FOXO, and Myb transcription 
factors (Biswas, Shi et al. 2007). Besides transcriptional control, Bim can also be 
regulated by phosphorylation. Several kinases such as AKT, ERK and JNK have 
been shown to phosphorylate Bim to mediate different effects. For examples, ERK-
mediated phosphorylation of Bim results in proteosomal degradation and inhibition 
of its pro-apoptotic effects (Luciano, Jacquel et al. 2003). In contrast, JNK-dependent 
Bim phosphorylation potentiates apoptosis (Putcha, Le et al. 2003). Lastly, the 
activity of Bim is also regulated by its interaction with cytoskeletal structures. It is 
found that both Bim-EL and Bim-L are sequestered by the dynein light chain LC8 
under normal conditions. Upon stress or apoptotic trigger, they will be released to 
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exert its pro-apoptotic effects. Bim-S lacks the interaction motif and does not bind to 
LC8, which potentially explains why Bim-S possesses the highest killing potency 
observed among the three members (Puthalakath and Strasser 2002). The tumor 
suppressor role of Bim has been suggested based on the findings that loss of Bim 
function promotes oncogenesis (Labi, Erlacher et al. 2006). Hence, drugs that are 
able to induce or enhance Bim expression may have therapeutic advantage to induce 
apoptosis in cancer cells. 
 
2.1.2.3 Intrinsic pathway 
Intrinsic pathway are induced by a wide range of non-receptor-mediated stimuli such 
as hypoxia, reactive oxygen species (ROS), UV irradiation, cytotoxic drugs and 
growth factors withdrawal, which produce intracellular signals that perturbate the 
integrity of mitochondrial membrane. Mitochondrial membrane permeabilization 
(MMP) event is the decisive condition for cell death induction in this pathway 
(Kroemer, Galluzzi et al. 2007). The mechanisms of MOMP induction involve the 
formation of pores in the mitochondrial membrane discussed in the earlier session. 
MOMP is frequently associated with the dissipation of the inner mitochondrial 
membrane potential (Goldstein, Waterhouse et al. 2000; Green and Kroemer 2004) 
and the release of other sequestered pro-death proteins from the intermembrance 
space (IMS) into the cytosol. In particular, cytosolic translocation of cytochrome c, 
which normally functions as an electron shuttle in the mitochondrial respiratory 
chain, together with the apoptotic protease activating factor-1 (Apaf-1) and 
procaspase-9, form the “apoptosome” in a nucleotide dATP/ATP dependent manner 
(Chinnaiyan 1999). Apoptosome formation results in autoactivation of caspase-9 that 
is responsible for the subsequent activation of executioner caspases (-3, -6 and -7) 
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and eventually leads to cell demise. Besides cytochrome c, Smac/DIABLO and 
HtrA2/Omi are also IMS proteins released into the cytosol upon apoptosis; these 
proteins exert their pro-apoptotic functions by antagonizing the inhibitor of apoptosis 
(IAP) family of proteins, such as XIAP, c-IAP1, c-IAP2 and survivin (van Loo, van 
Gurp et al. 2002; Schimmer 2004) 
 
2.1.2.4 Extrinsic pathway 
Apoptotic signaling can be initiated by extracellular signals from neighboring or 
distant cells, which have been identified as cytokines belonging to the tumor necrosis 
factor (TNFα) superfamily ligands. These ligands bind to the cell surface death 
receptors that belong to the TNF receptor gene superfamily. Some of the best-
characterized death receptors and cognate ligands include FasR/FasL (CD95/APO-1), 
TNFR1/TNFα, DR3/Apo3L, DR4/TRAIL-R1, and DR5/TRAIL-R2 (Elmore 2007). 
Ligation of the specific ligand with the death receptors permits trimerization of the 
receptors and recruitment of the cytoplasmic adapter proteins, such as Fas-associated 
death domain (FADD) and tumor necrosis factor receptor type 1-associated death 
domain protein (TRADD) (Hsu, Xiong et al. 1995; Wajant 2002). FADD then allows 
for the recruitment of procaspase-8 via associations of their death effector domains, 
the resultant multi-protein complex is referred to as the death-inducing signaling 
complex (DISC). The close proximity of the recruited procaspase-8 molecules then 
triggers their autocatalytic activation (Kischkel, Hellbardt et al. 1995). 
 
Following the activation of caspase-8, death signals are conducted in two distinct 
manners, depending on whether the events are occurring in a type I or type II cell 
(Ozoren and El-Deiry 2002). In type I cells, activation of caspase-8 alone is sufficient 
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to activate the downstream effector caspases (caspase-3, -6, -7), which results in cell 
death. On the other hand, in type II cells, caspase-8 activation is insufficient to 
directly elicit downstream caspase cascade; instead, it requires amplification via the 
mitochondrial apoptotic pathway. It has been suggested that Bid, a member of the 
BH3-only Bcl-2 family protein, mediates the crosstalk between the extrinsic and 
intrinsic pathway. Bid is proteolytically cleaved by caspase-8, and the 
cleaved/truncated bid (t-Bid) then translocates to the mitochondria and binds to Bax 
and Bak, resulting in their oligomerization and MOMP, which is followed by release 
of pro-apoptic factors such as cytochrome c and subsequent activation of caspase-9 
and -3 (Scaffidi, Fulda et al. 1998). In short, type I cells are independent of 
mitochondria, whereas type II cells are mitochondria-dependent. In accordance with 
its role in suppressing MOMP, overexpression of the anti-apoptotic protein Bcl-2 is 
able to block apoptosis in type II cells, but not type I cells (Fulda, Meyer et al. 2002; 
Ozoren and El-Deiry 2002; Barnhart, Alappat et al. 2003).  
 
2.2 Autophagy 
Evolutionarily, autophagy is a process of self-cannibalization, which is highly 
conserved among eukaryotes. Autophagy is found to be active at a low level in 
almost all cells, where it maintains tissue homeostasis by replacing old or eradicating 
damaged cellular components or organelles with new ones. Besides its homeostatic 
function, autophagy also safeguards cell survival by providing constituents for energy 
generation under conditions such as starvation or growth factor withdrawal (Klionsky 
and Emr 2000). However, in some settings, it is considered as a mode of PCD named 
autophagic cell death, where higher-than-normal autophagy activities are observed 
(Maiuri, Le Toumelin et al. 2007). Unlike apoptosis, autophagic cell death is 
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independent of capases (Tsujimoto and Shimizu 2005); in fact, this form of cell death 
has been shown in cells with defects in apoptotic signaling or in the presence of 
caspase inhibitors (Shimizu, Kanaseki et al. 2004; Yu, Alva et al. 2004). In terms of 
morphology, cells undergoing autophagic cell death may present with chromatin 
condensation or membrane blebbing; however, there is no DNA fragmentation or 
formation of apoptotic bodies (Codogno and Meijer 2005). Instead, cells are 
accompanied by massive accumulation of double-membraned autophagic vesicles in 
the cytoplasm. The double- or multi-membrane–bound structure, called the 
autophagosome engulfs various cellular constituents, and subsequently fuses with 
lysosomes to become autolysosomes, where the sequestered cellular components are 
digested (Klionsky 2004). So far, the most important molecular component of the 
autophagic machinery consists of the autophagy-related genes (Atg); they encode 
proteins that are essential for the operation of autophagy. Over 30 ATG genes are 
identified in yeast with at least 11 orthologs in mammalian systems (ATG1, 3-10, 12 
and 16). Notably, ATG8 is called light chain 3 (LC3) in mammals. The conversion of 
LC3 to LC3-II formation has been used as a reliable marker to assess the 
autophagosome formation in mammalian cells, where the relative amount of LC3-II 
formation reflects the abundance of the autophagosomes (Kabeya, Mizushima et al. 
2000; Kabeya, Mizushima et al. 2004). 
 
2.3 Necrosis 
Necrosis was initially known as a nonregulated and accidental process where cells 
undergo an energy-independent type of cell death.  Necrosis is distinctive from other 
types of PCD as it lacks the involvement of caspases and lysosomes (Sun and Peng 
2009). In terms of morphology, some of the key features of a necrotic cell include 
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swelling of intracellular organelles (oncosis) like mitochondria, ER and Golgi, which 
is followed by plasma membrane rupture and subsequent breakdown and release of 
intracellular contents into the extracellular milieu (Majno and Joris 1995). The 
release of cytoplasmic contents then results in inflammatory responses, which has 
been found to promote tumor growth (Vakkila and Lotze 2004). Increasing evidence 
suggests that necrosis is a programmed course of events, as a result of interplay 
between several signaling pathways. For example, PARP-1 and apoptosis-inducing 
factor (AIF) are found to be essential in alkylating DNA damage-induced necrosis, 
and calpains and Bax are identified as intermediate molecular links (Moubarak, 
Yuste et al. 2007). Another study identified receptor interacting protein kinase (RIP 
kinase) as a critical mediator in TNF-induced necrosis; it functions to deplete ATP 
and impair mitochondrial functions, eventually lead to cell death (Temkin, Huang et 
al. 2006).  
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3. Rho GTPase family  
The Rho GTPase subfamily of proteins belongs to the Ras superfamily. They mediate 
various housekeeping functions in the cells, such as cell morphology, polarity, 
adhesion, motility, membrane trafficking, cytoskeleton organization, proliferation, 
survival and cell death (Van Aelst and D'Souza-Schorey 1997; Schmitz, Govek et al. 
2000; Aznar and Lacal 2001). They act as molecular switches by existing either in an 
inactive GDP-bound form or an active GTP-bound form. Active GTP-bound Rho 
proteins would then interact with their respective effectors to exert cellular functions 
(Jaffe and Hall 2005). Studies done on three classical Rho GTPases: RhoA, Rac1 and 
Cdc42 have provided insights into linking Rho GTPases with various physiological 
and pathological processes like embryonic development, immune and inflammation 
responses, tissue morphogenesis, tumorigenesis and metastasis. In this section of 
introduction, we will focus on these three Rho GTPases.  
 
3.1 Regulation of Rho GTPases: GDP/GTP cycling 
Rho GTPases are guanosine triphosphatases (GTPases), where only GTP-bound form 
can bind to its effectors to transmit signals. The cycling of GDP to GTP is mediated 
by guanine nucleotide exchange factors (GEFs) (Figure D). Whitehead et al. 
identified the first mammalian RhoGEF called Dbl in Diffuse B-cell lymphoma, and 
Dbl was found to be an oncogene (Whitehead, Campbell et al. 1997). Soon more 
RhoGEFs in the Dbl family were discovered and every member displayed different 
specificity towards the members of Rho GTPase family. For example, Vav is a GEF 
for RhoA, Rac1 and Cdc42; while Tiam1 is a Rac-specific GEF (Han, Das et al. 1997; 
Hordijk, ten Klooster et al. 1997). All the Dbl family members contain a Dbl-
homology (DH) domain and a C-terminal pleckstrin homology (PH) domain. On the 
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contrary, GTPase-activating proteins (GAPs) work in the opposite way of GEFs to 
inactivate Rho GTPases by facilitating GTP hydrolysis.   
 
Other than GEFs and GAPs, a special set of proteins named guanine nucleotide 
dissociation inhibitors (GDIs) is also involved in regulation of Rho GTPases. 
RhoGDIs are expressed in three forms; RhoGDIα is the most ubiquitously-expressed 
member (Fukumoto, Kaibuchi et al. 1990), while RhoGDIβ exists primarily in 
haematopoietic cells (Lelias, Adra et al. 1993). The third member RhoGDIγ is found 
in low abundance and localized to the Golgi apparatus (Zalcman, Closson et al. 
1996). RhoGDIs possess dual functions both in the cytosol and at the membrane. On 
one hand, they form cytosolic complexes with GDP-bound Rho GTPases and prevent 
exchange of GDP to GTP. On the other hand, they also deliver and extract Rho 
proteins from membrane interface (Dransart, Olofsson et al. 2005). All three families 
of proteins work together to modulate the activity of Rho GTPases; deregulation of 
which would result in inappropriate activation of Rho GTPases and contribute to 





















Figure D: The Rho GTPase switch.  
Rho GTPases undergo post-modifications such as prenylation by geranylgeranyltransferases 
(GGTases), which facilitate their membrane-targeting. The GDP-GTP cycling of Rho GTPases are 
regulated by guanine nucleotide exchange factors (GEFs) and GTPase-activating proteins (GAPs). In 
addition, guanine-nucleotide dissociation inhibitors (GDIs) negatively regulate the cycling of Rho 
GTPases at membrane surfaces and in the cytosol. The active and GTP-bound form of Rho GTPases 
interacts with downstream effector molecules to regulate various cellular responses. (Modified from 















3.2 Lipid modification of Rho GTPases 
Other than the cycling of GTP/GDP, another important basis for the functionality of 
Rho GTPases is believed to be their distinct subcellular localization. Most of Rho 
GTPases undergo a three-step post-translational modification to localize to the 
plasma membrane or endomembranes. The modifications are signaled by the 
carboxyl-terminal CAAX motif (C represents cysteine, A represents an aliphatic 
amino acid, and X is any amino acid), which is present in the majority of identified 
Rho GTPases (Roberts, Mitin et al. 2008). This CAAX motif is recognized and first 
modified by prenyltransferases, which add an isoprenoid lipid to the C residue. 
Depending on the X residue of the CAAX motif, Rho GTPases can be modified by 
either farnesyltransferase (FTase) or geranylgeranyltransferase I (GGTase-I) to add a 
15-carbon farnesyl or 20-carbon geranylgeranyl lipid, respectively (Reid, Terry et al. 
2004). For example, RhoA, Rac1 and Cdc42 are geranylgeranylated exclusively, 
Rnd1-3 are farnesylated, while RhoB can undergo either farnesylation or 
geranylgeranylation. Following the isoprenylation step, the AAX part of the CAAX 
motif is cleaved off by the Ras-converting enzyme 1 (Rce1) endoprotease 
(Boyartchuk, Ashby et al. 1997; Ashby 1998). Lastly, a methyl group is added to the 
prenylated C residue by isoprenylcysteine-O-carboxyl methyltransferase (Icmt) 
(Hrycyna, Sapperstein et al. 1991; Sebti and Der 2003). Taken together, these 
modifications make the Rho GTPases more hydrophobic to assist their membrane 
association. It is generally accepted that drugs that inhibit the modifications of the 
CAAX motif, such as statins that block prenylation, would affect the localization and 




3.3 Rho GTPases: their effectors and functions  
Following the activation of Rho GTPases, they then interact with their respective 
downstream effectors to mediate the biochemical and biological functions such as 
cytoskeletal reorganization, gene transcription, regulation of enzymatic activities, cell 
cycle progression, cell morphogenesis and cell migration. It is believed that the 
unique interaction region between each effector and the Rho family member 
contributes to the diverse downstream responses (Bishop and Hall 2000; Jaffe and 
Hall 2005). Table 1 shows a list of selected effectors for RhoA, Rac1 and Cdc42 and 
their respective functions inside the cells. For example, one of the most classical 
functions of Rho proteins involves the cytoskeleton remodeling, which directly 
impacts cell migration. RhoA, Rac1 and Cdc42 control specific sets of effectors to 
mediate actin organization. Rac1 promotes lamellipodia formation via p21-activated 
kinase (PAK) and WAVE complex, while Cdc42 activation leads to the formation of 
another structure known as filopodia via its downstream effector PAK and Wiskott–
Aldrich syndrome protein (WASP). In addition, RhoA activation results in the 
detachment of focal adhesions and formation of stress fibers via the effectors 
mammalian homologue of the Drosophila gene Diaphanous 1 (mDia) and Rho-
associated kinases (ROCK) (Frame and Brunton 2002). The coordinated regulation of 
Rho GTPases to form different structures governs the directional movements of cells. 
In addition, some of downstream effector proteins can also regulate Rho activities by 
feedback mechanisms. For example, PAK1 was found to phosphorylate RhoGDI and 
resulted in dissociation of Rac from RhoGDI, which was proposed to be a 
mechanism for Cdc42-mediated Rac activation in cells stimulated by platelet-derived 
growth factor (PDGF) or epidermal growth factor (EGF) (DerMardirossian, 
Schnelzer et al. 2004).  
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ROCK I, II Actomyosin contraction, transformation, transcription (SRF) 
mDia Actin polymerizatioin 
PRK1/PKN Endocytosis, p38γ MAPK activation, transcription (MEF2C) 
Citron Cytokinesis 
Rac1 
PAK1, 2, 3 JNK activation, transformation 
MLK2, 3 JNK activation 
PAR6 Cell polarity, transformation 
p67Phox NADPH oxidation, transcription (NFκB) 
IQGAP1, 2 Adherens junctions 
POSH JNK activation, transcription (NFκB) 
IRSp53 Actin polymerization 
Cdc42 
PAK1, 2, 3 JNK activation, transformation 
MLK2, 3 JNK activation 
PAR6 Cell polarity, transformation 
N-WASP, WASP Actin polymerization 
MRCK1, 2 Actin organization 
 
Table 1: Effectors and functions of Rho GTPases (RhoA, Rac1 and Cdc42). 
Abbreviations: mDia, mammalian homologue of the Drosophila gene Diaphanous 1; IQGAP, IQ-
motif-containing GTPase-activating protein; JNK, JUN N-terminal kinase; MAPK, mitogen-activated 
protein kinase; MRCK: microtubule affinity regulating kinase; MEF2C, myocyte-enhancer factor 2C; 
MLK, mixed-lineage kinase; NF-κB, nuclear factor of κB; PAK, p21-activated kinase; PAR, 
partitioning defective; PIST, PD2 domain protein interacting specifically with TC10; PKN, protein 
kinase N; POSH, plenty of SH3 domains; ROCK, RHO-associated coiled-coil-forming kinase; SRF, 
serum response factor; WASP, Wiskott–Aldrich syndrome protein. Table is modified from Sahai and 





3.4 Rho GTPases in cancer 
Rho GTPases are found to be involved in every stage of cancer progression including 
acquiring unlimited proliferation potential, gaining resistance to apoptosis, 
angiogenesis, invasion and metastasis. One line of evidence comes from the abundant 
information showing overexpression or hyperactivity of Rho GTPases in many types 
of human cancers (Jaffe and Hall 2002; Sahai and Marshall 2002; Gomez del Pulgar, 
Benitah et al. 2005) (Table 2). In some cases, the expression level of Rho proteins 
correlates positively with the severity of the cancer (Fritz, Just et al. 1999; Kamai, 
Arai et al. 2001). Surprisingly, mutations in Rho proteins are rarely observed in 
human cancers. One exception is the finding of a splice variant of Rac1 called Rac1b 
in colorectal and breast carcinomas (Singh, Karnoub et al. 2004).  
Dysregulation of Rho GTPases in human tumors 
Rho 
GTPase 
Regulation Tumor Types 
RhoA 
Overexpression 
Breast, SCC, Colorectal, Lung (SCLC), Testicular, 
Ovarian, Gastric, Liver, Bladder 
High signalling activity 
Melanoma, Pancreas, Neuroblastoma, Prostate, Leukemia 
AML, Sarcoma, SCC, Colorectal, Lung (SCLC), Ovarian, 




Breast, SCC, Colorectal, Lung (NSCLC), Testicular, 
Gastric 





Overexpression Breast, SCC, Colorectal, Testicular 
High signalling activity Melanoma 
Table 2: Dysregulation of Rho GTPases (RhoA, Rac1 and Cdc42) in human tumors.  
Abbreviations: SSC (squamous cell carcinoma), SCLC (small cell lung cancer), NSCLC (non-small 
cell lung cancer), AML (acute myeloid leukemia). Table is modified from Gomez del Pulgar, Benitah 
et al, 2005 (Gomez del Pulgar, Benitah et al. 2005). 
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The transforming potential of Rho GTPases has been demonstrated utilizing 
constitutively-active mutants of RhoA, Rac1 and Cdc42. Conversely, inactivating 
mutants of these Rho proteins abrogated Ras-mediated transformation of fibroblasts, 
suggesting that oncogenesis is coordinated by both Ras and Rho signaling networks 
(Khosravi-Far, Solski et al. 1995; Qiu, Chen et al. 1995; Qiu, Chen et al. 1995; Qiu, 
Abo et al. 1997; Roux, Gauthier-Rouviere et al. 1997). Multiple effectors of Rho 
GTPases are identified to contribute to the transformation process. For instance, PAK 
family proteins, which are downstream effectors of Rac and Cdc42, are reported to 
mediate Rac- and Ras-mediated transformation (Osada, Izawa et al. 1997). It is 
proposed that the underlying mechanism involves the PAK-dependent activation of 
c-Jun N-terminal kinase (JNK) and p38 pathways (Bagrodia, Derijard et al. 1995; 
Zhang, Han et al. 1995; Brown, Stowers et al. 1996). Further exploration also 
suggests PAK-independent activation of JNK and p38 activity downstream of Rac 
and Cdc42 activation via other effectors, such as Plenty of SH2 domain (POSH) 
(Tapon, Nagata et al. 1998). Transcription regulation is another mode to mediate the 
transforming activity of Rho GTPases. For example, activation of transcription factor 
nuclear factor kappa B (NF-kB) is found to mediate RhoA, Rac1 and Cdc42’s 
oncogenic potential (Sulciner, Irani et al. 1996; Finco, Westwick et al. 1997).  
 
3.5 Rho GTPases in regulating apoptosis  
As opposed to the observation of the transforming activity of Rho GTPases, their role 
in inducing apoptosis has also been reported both in vitro and in vivo. Several key 
players have since been identified in mediating Rho-induced apoptotic responses. For 
instance, Rac1 induces apoptosis in fibroblasts by upregulating ceramide and Fas-L 
level upon serum starvation, and the increase of Fas-L is mediated by transcription 
control involving JNK and NF-kB (Embade, Valeron et al. 2000). As mentioned 
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earlier that both JNK and NF-kB are positive regulators of Rho-mediated 
transformation process, the discrepancy suggests that both factors have dual functions 
in both transformation and apoptosis depending on the cellular contexts and stimuli. 
In addition, some evidence has also suggested that the caspase-mediated cleavage of 
effector PAK2 and protein kinase N (PKN) regulates the morphological changes and 
signal transduction in apoptotic cells respectively (Lee, MacDonald et al. 1997; 
Rudel and Bokoch 1997; Takahashi, Mukai et al. 1998). Another factor POSH is also 
identified to be a strong inducer of apoptosis by regulating JNK and NF-kB pathway 
(Tapon, Nagata et al. 1998). Similar to Rac1, RhoA overexpression also induces 
apoptosis in multiple cell lines by increasing ceramide levels depending on Bcl-2 
level (Esteve, Embade et al. 1998); however, the effectors remain to be identified. 
Furthermore, Cdc42-mediated apoptosis in Jurket T-lymphocytes is suggested to be 
due to activation of JNK signaling pathway (Chuang, Hahn et al. 1997). Future 
studies are required to understand the roles of specific effectors in Rho-mediated 
transformation and apoptosis, the identification of which could allow specific 





4. Reactive oxygen species 
4.1 ROS overview: types and their physiological roles 
Oxygen is required for normal aerobic metabolism of cells. It can travel freely across 
cellular membranes and form a variety of oxygen-derive free radicals and non-
radicals, which are termed as Reactive oxygen species (ROS). ROS are generated 
when the unpaired electrons of oxygen go through electron transfers and form 
partially reduced oxygen derivatives. Oxygen-derived free radicals are defined as 
chemical species that are capable of existence on their own and contain one or more 
unpaired electrons, such as superoxide anion (O2
-
), singlet oxygen, peroxy radical, 
nitric oxide (NO) and hydroxyl radical (OH.). On the other hand, examples for non-




Every type of ROS requires different reactions and shows different reactivity. 
Superoxide is not very reactive and it is highly compartmentalized to the site of 
production. Superoxide can be converted to hydrogen peroxide under the catalysis of 
superoxide dismutases (SODs). Instead, hydrogen peroxide can move freely across 
membranes (Fridovich 1978). Hydrogen peroxide is an important intermediate to 
produce more reactive ROS such as hydroxyl radical through the Fenton reaction 
which involves reductive homolytic cleavage in an iron-dependent manner 
(Andreyev, Kushnareva et al. 2005). When high concentrations of nitric oxide and 
superoxide are present in the cells, they can react to produce another powerful 
oxidant, peroxynitrite. Nitric oxide-derived oxidants are also called Reactive nitrogen 
species (RNS), which are found to induce nitrosative stress in the cells (Beckman and 
Koppenol 1996). However, this thesis will be focused on ROS. Physiologically, 
ROS-mediated oxidative stress can contribute to aging, neurodegeneration, 
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inflammation, atherosclerosis and chemotherapeutic effects etc. Recent research has 
also suggested its role in oncogenesis (Waris and Ahsan 2006).  
 
4.2 Sources of ROS 
4.2.1 Mitochondrial electron transport chain 
One of the major sources of ROS comes from the mitochondria electron transport 
chain (ETC). The ETC consists of multiple components (Complex I-IV), from which 
electrons are passed through to oxygen followed by reduction reaction to produce 
water (Kakkar and Singh 2007). However, a small amount of electrons directly leaks 
to oxygen and leads to superoxide formation as a byproduct. It is estimated that 1-4% 
of oxygen might be incompletely reduced to superoxide (Betteridge 2000; Orrenius 
2007). Studies have been devoted to identify specific sites of the ETC involved in 
ROS production. It has been observed that Complex I (NADH Hydrogenase) is the 
main site responsible for mitochondrial superoxide production via a single electron 
transfer to oxygen under normal physiological conditions (Cadenas, Boveris et al. 
1977; Han, Williams et al. 2001). Besides that, Complex III (Ubiquinol/cytochrome c 
oxidio-reductase) are reported to produce superoxide especially under ischemic or 
apoptotic conditions (St-Pierre, Buckingham et al. 2002; Tahara, Navarete et al. 2009; 
Kang and Pervaiz 2012). Superoxide generated is then quickly converted to hydrogen 
peroxide by mitochondrial-localized manganese superoxide dismutase (MnSOD) 
(Buettner, Ng et al. 2006). Subsequently, hydrogen peroxide goes through the Fenton 
reaction and forms hydroxyl radical, a highly reactive and cytotoxic radical 
(Andreyev, Kushnareva et al. 2005). Other than the ETC, a few other mitochondrial 
enzymes are also reported to be able to generate superoxide (Chan and Bielski 1974; 
Chan and Bielski 1980; Andreyev, Kushnareva et al. 2005), such as the Krebs cycle 
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enzymes α-ketoglutarate dehydrogenase and pyruvate dehydrogenase (Starkov, 
Fiskum et al. 2004; Tretter and Adam-Vizi 2004). However, the precise mechanism 
involved in superoxide
 
formation is still unclear. To keep the intracellular ROS level 
in check, mitochondria also possess a few anti-oxidant mechanisms such as MnSOD, 
glutathione peroxidase (Gpx1) and peroxiredoxin (PrxIII) (Droge 2002).  
 
4.2.2 NADPH oxidase complex  
Another main mechanism for ROS production involves the nicotinamide adenine 
dinucleotide phosphate oxidases (NADPH oxidases or NOX), which are 
flavoenzymes responsible for transferring electrons across biological membranes. 
The earliest observation was made in phagocytes in 1933. The phagocyte respiratory 
burst was later identified as a function of NADPH oxidase to generate superoxide. It 
is also the first example of an enzyme system to generate ROS as the primary 
function (Rossi and Zatti 1964; Babior, Kipnes et al. 1973). Subsequently, the 
phagocyte NADPH oxidase NOX2, transmembrane protein p22phox, cytosolic 
subunits p47phox, p40phox and p67phox, together with small GTP-binding protein 
Rac were identified to be the components responsible for ROS production in 
phagocytes (Royer-Pokora, Kunkel et al. 1986; Teahan, Rowe et al. 1987; Abo, Pick 
et al. 1991; Wientjes, Hsuan et al. 1993). In addition, ROS production using similar 
oxidase system is present in many other cell types, such as fibroblasts, vascular 
smooth muscle, endothelial cells and various tumor cells (Meier, Cross et al. 1991; 
Szatrowski and Nathan 1991; Griendling, Minieri et al. 1994; Li and Shah 2003). The 
current NOX family includes seven NOX isoforms (NOX1-5, DUOX1-2). They all 
share conserved structures such as NADPH-binding and  flavin adenine dinucleotide 
(FAD)-binding domains and six conserved transmembrane domain (Bedard and 
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Krause 2007). However, the members differ in their tissue distribution, mechanism of 
action, and types of ROS produced. For example, it is understood that the activation 
of NOX5 and DUOX1-2 requires Ca
2+ 
and no other subunits, while NOX1 and 
NOX2 activation requires Rac and other subunits (Cheng, Diebold et al. 2006). In 
contrast to superoxide-generating NOX1 and NOX2, NOX4 produces hydrogen 
peroxide (Takac, Schroder et al. 2011). The assembly of functional NOX complex is 
mostly on the plasma membrane (Bayraktutan, Blayney et al. 2000); however, some 
recent studies have reported functional NOX in other cellular compartments. NOX4 
was recently found to localize to the mitochondria in rat mesangial cells and kidney 
cortex (Block, Gorin et al. 2009), mouse cardiac myocytes (Kuroda, Ago et al. 2010), 
and chronic myeloid leukemia cells overexpressed with Bcl-2 (Velaithan, Kang et al. 
2011). Localization of NOX4 in the nucleus has been reported as well (Kuroda, 
Nakagawa et al. 2005).  
 
4.2.3 Other sources 
Other than the membrane-associated oxidases, soluble xanthine oxidase, aldehyde 
oxidase, dihydroorotate dehydrogenase, flavoprotein dehydrogenase and tryptophan 
dioxygenase can also produce ROS during catalytic cycling (Freeman and Crapo 
1982). However, their physiological roles are not well studied. Besides the 
mitochondria and plasma membrane, ER is another site for ROS production. The ER-
residing enzymes such as NADPH-cytochrome P450 reductase (CPR) catalyze 
reactions to detoxify lipid-soluble drugs and harmful metabolites (Aust, Roerig et al. 
1972; Capdevila, Chacos et al. 1981). However, the intermediates in the catalytic 
cycle can sometimes reduce oxygen rather than its appropriate substrates, which 
results in superoxide generation. Apart from that, superoxide can also be generated 
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from direct leakage of electrons from CPR to oxygen (Santos, Tanaka et al. 2009). To 
counter the increase in intracellular ROS, cells also employ a few extra-
mitochondrial anti-oxidant enzymes to maintain the original redox status, such as 
Cu/Zn SOD, catalase, gluthathione (GSH) peroxidase, GSH reductase and non-
enzymatic activities of α-tocopherol, β-carotene, ascorbate and glutathione (Droge 
2002).  
 
4.3 ROS: role in oncogenesis and cell death 
The cellular effects of ROS depend on its type and intensity present in the 
intracellular milieu (Mates, Segura et al. 2008). A pro-oxidant environment in cancer 
cells was first observed in 1985, where it was shown that presence of SOD1 
(Cu/ZnSOD), a superoxide scavenging cytosolic enzyme, reversed the clastogenic 
process induced by patients’ serum; in reverse, high oxygen tensions increased 
transformation frequency in irradiated mouse embryonic cells (Emerit and Cerutti 
1981). Another piece of evidence supporting the role of ROS in oncogenesis comes 
from the observations on SOD2 (MnSOD). The expression of MnSOD expression is 
lower in tumor cells compared to their normal counterparts and the reduction in 
MnSOD level enhances the invasiveness of tumor cells (Weydert, Roling et al. 2003). 
On the contrary, increased expression of this protein inhibited the tumor malignancy 
(Zhao, Xue et al. 2001). In addition, ROS acts as important second messengers to 
promote cell growth and survival by regulating mitogen-activated protein kinases 
(MAPKs) and redox-regulated transcription factors such as NF-kB and activator 
protein-1 (AP1) (Bubici, Papa et al. 2006; Clerkin, Naughton et al. 2008). Our lab has 
also provided some convincing evidence by establishing that dominant negative form 
of Rac1 (Rac1N17) reduced superoxide production from NOX complex and 
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increased sensitivity of NIH3T3 fibroblast cells to apoptotic triggers (Pervaiz, Cao et 
al. 2001).  
 
Despite mounting experimental evidence suggesting the role of ROS in oncogenesis 
and cell survival, its role in regulating cell death is also well established. The mode of 
cell death is dependent on the type and concentrations of ROS present inside the cells. 
Generally, excessive amount of ROS leads to necrosis as a result of modifications of 
essential intracellular proteins and DNA damage (Takeda, Shirato et al. 1999; 
Teramoto, Tomita et al. 1999; Saito, Nishio et al. 2006). On the other hand, moderate 
amount of ROS is found to induce apoptosis through depletion of anti-oxidant 
defenses and selective oxidation or activation of molecules regulating cell death 
responses (Takeda, Shirato et al. 1999; Teramoto, Tomita et al. 1999; Saito, Nishio et 
al. 2006). One such example is hydrogen peroxide, where intermediate 
concentrations (< 500 µM in most systems) triggers apoptosis and doses higher than 
500 µM induces necrosis (Burdon, Alliangana et al. 1995). A few mechanisms have 
been proposed for hydrogen peroxide-mediated apoptosis. Previous work in the lab 
has demonstrated that cytosolic acidification is accompanied by exogenous or 
endogenous increase in hydrogen peroxide level to create a permissive intracellular 
milieu for apoptosis to occur (Pervaiz and Clement 2002). Other groups have 
reported that hydrogen peroxide promotes dimerization of apoptosis signal-regulating 
kinase 1 (ASK1) or activation of JNK, which is followed by engaging the intrinsic 
apoptotic machinery (Gotoh and Cooper 1998; Inoshita, Takeda et al. 2002; 




5. Signaling Pathways: AKT and MAPKs 
The ability for cells to respond to extracellular stimuli is largely attributed to the 
interplays of intercellular signaling networks. These signaling pathways serve to 
relay, amplify and integrate signals to mount an appropriate response of a cell. Here, 
we focus on two groups of intracellular signaling pathways: AKT and mitogen-
activated protein kinases (MAPK), and discuss their roles in cancer progression and 
cell death.   
 
5.1 AKT 
5.1.1 AKT signaling cascade  
AKT is also known as protein kinase B (PKB). This serine/threonine kinase plays an 
important role in various cellular processes, for example insulin response, glucose 
metabolism, cell proliferation and survival (Lawlor and Alessi 2001). The AKT 
family is made of three widely expressed isoforms (AKT1, 2 and 3). They all contain 
an N-terminal PtdIns(3,4,5)P3- (PIP3) and PtdIns(3,4)P2 (PIP2)-binding pleckstrin 
homology (PH) domain and a C-terminal kinase catalytic domain. Following 
stimulations from cytokines, growth factors, insulin and attachment to extracellular 
matrix, AKT binds to PIP3 or PIP2 generated by upstream class 1 phosphoinositide 
3-kinases (PI3K). Then AKT is recruited to the peripheral membrane that allows for 
AKT activation by phosphorylation at two residues (Cantrell 2001). Phosphorylation 
at Thr308 is mediated by 3-phosphoinositide dependent protein kinase 1 (PDK1) and 
the second phosphoylation happens at Ser473 by multiple kinases such as 
mammalian target of rapamycin (mTORC2) or DNA-dependent protein kinase 
(DNA-PK) (Alessi, Deak et al. 1997; Alessi 2001; Sarbassov, Guertin et al. 2005; Lu, 
Huang et al. 2006). In the later stage, active AKT then translocates to the nucleus to 
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activate the downstream substrates. Other than kinases, phosphatases also play an 
important role in regulating AKT activity. One of them is PtdIns(3,4,5)P3 3-
phosphatase (PTEN), loss of which leads to AKT hyperactivation and is observed in 
many cancers (Maehama, Taylor et al. 2001). Currently, around fifty AKT substrates 
have been identified to be involved in the regulation of AKT-mediated cellular 
processes (Hers, Vincent et al. 2011). 
 
5.1.2 AKT in cancer 
The importance of AKT in oncogenesis is demonstrated by the frequent mutations of 
multiple signaling components of the PI3K/AKT pathway in human cancers, such as 
loss of PTEN and amplification of PI3K, which happen in over 30% of human 
cancers (Fresno Vara, Casado et al. 2004). Other than the gene alterations of this 
pathway in cancer, AKT also promotes tumor development via its downstream 
targets. For example, AKT inhibits apoptosis by inactivating the pro-apoptotic BAD 
and pro-caspase-9 (Cardone, Roy et al. 1998; Downward 1999); it also activates NF-
kB signalling by phosphorylating IkB kinase (IKK) to induce transcription of anti-
apoptotic genes (Ozes, Mayo et al. 1999). In addition, AKT promotes proliferation by 
allowing cell cycle progression through downregulation of p21 and p27 and 
stabilizing cyclin D1 (Diehl, Cheng et al. 1998; Sun, Lesche et al. 1999). AKT 
signalling also promotes angiogenesis, invasion and metastasis to allow tumor 
progression (Lawlor and Alessi 2001; Fresno Vara, Casado et al. 2004). Due to its 
important roles in tumorigenesis, drugs that are able to downregulate the PI3K/AKT 
pathway are promising anti-tumor agents, for example PI3K inhibitors wortmannin 
and LY294002 are found to have anti-tumor properties in vitro and in vivo (Powis, 





5.2.1 ERK signaling cascade 
ERK is one of the major MAPKs. It is involved in multiple cellular and physiological 
processes, such as cell cycle control, cell differentiation, proliferation, survival, 
migration and senescence (Rubinfeld and Seger 2005). Two genes, ERK1 and ERK2, 
encode ERK protein and they are expressed as p44 and p42 (Boulton, Nye et al. 
1991). Both proteins share 84% amino acid sequence homology and are functionally 
redundant (Lloyd 2006). The activation of ERK happens through the classical three-
tier kinase signaling module for all MAPKs, which consists of mitogen activated 
protein kinase kinase kinase (MAPKKK), mitogen activated protein kinase kinase 
(MAPKK) and MAPK (Johnson and Lapadat 2002). In a typical ERK signaling 
cascade, following exposure of extracellular factors such as various cytokines, 
growth factors and neurotransmitters, MAPKKK, such as Raf-1 will be recruited to 
the plasma membrane and mediate the phosphorylation and activation of MAPKK 
such as MEKs. Subsequently, MEKs lead to the activation of ERK through a dual 
phosphorylation at Thr and Tyr residues within a Thr-Glu-Tyr motif (Chang, 
Steelman et al. 2003).  
 
In general, ERK recognizes the consensus sequence Pro-Leu-Ser/Thr-Pro and 
phosphorylates Ser/Thr residues on its substrates (Gonzalez, Raden et al. 1991). The 
classical substrates of ERK are nuclear transcription factors, for example the ternary 
complex factors (TCFs) that include E twenty-six (ETS)-like transcription factors 
such as Elk-1, SAP-1 and SAP-2 and the activator protein-1 (AP-1) family members 
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c-Jun, c-Fos and activating transcription factor 2 (ATF2). Other than transcriptional 
factors, ERK also phosphorylates multiple cytosolic proteins such as the ribosomal 
S6 kinase, mitogen and stress-activated protein kinase (MSK) and MAPK interacting 
kinase (MNK). In addition, feedback inhibition is also an important regulatory 
mechanism for ERK signaling, where ERK can phosphorylate its upstream activators 
such as Raf, MEKs, GEFs and son of sevenless (SOS) (Langlois, Sasaoka et al. 1995; 
Eblen, Slack-Davis et al. 2004; Dougherty, Muller et al. 2005). 
 
5.2.2 ERK in cancer and cell death 
Conventionally, ERK activation is associated with cell proliferation and oncogenic 
transformation. Tumor development following activation of ERK signaling has been 
demonstrated in both in vitro and in vivo models (Kyriakis, App et al. 1992; Sobczak, 
Galabova-Kovacs et al. 2008). On the contrary, tumor progression can be blocked 
with inhibition of the ERK cascade (Murphy, Makonnen et al. 2006; Ouyang, Knauf 
et al. 2006). In addition, MEK1, the upstream activator of ERK, is also found to be 
implicated in malignant transformation. Constitutive activation of MEK1 induced 
oncogenesis whereas dominant negative form of MEK1 reversed tumor formation 
(Cowley, Paterson et al. 1994; Manser, Leung et al. 1994; Seger, Seger et al. 1994). 
More importantly, ERK activation promotes oncogenesis by integrating mitogenic 
signals. For example, ERK-mediated activation of Elk-1 could continue to induce 
activation of c-Fos, which is predominantly involved in cell cycle progression and 
growth (Marais, Wynne et al. 1993; Whitmarsh, Shore et al. 1995). 
 
Despite its established role in pro-survival effects, ERK activation has recently been 
shown to be involved in cell death in certain cellular contexts. One example is in 
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DNA damage-induced cell death, abrogation of ERK activity reduced apoptosis (Lee, 
Fang et al. 2000; Wang, Martindale et al. 2000; Tang, Wu et al. 2002). Our lab has 
also reported that ERK activation mediates autophagy and apoptosis in cancer cells 
upon exposure to a novel compound (Wong, Iskandar et al. 2010).   
 
5.3 JNK 
5.3.1 JNK signaling cascade 
Another important MAPK family member is the c-Jun NH2-terminal kinase (JNK), 
also known as the stress-activated protein kinase (SAPK). JNK is implicated in the 
regulation of multiple cellular processes, for example diabetes, metabolism, lifespan, 
autophagy and apoptosis (Weston and Davis 2007). JNKs family consist of ten 
isoforms derived from three different genes, Jnk1 (MAPK8, four isoforms), Jnk2 
(MAPK9, four isoforms) and Jnk3 (MAPK10, two isoforms). JNK1 and JNK2 are 
ubiquitously expressed, while JNK3 expression is specific to tissues such as brain, 
heart and testis (Kyriakis, Banerjee et al. 1994; Gupta, Barrett et al. 1996; Yang, 
Kuan et al. 1997; Weston, Lambright et al. 2002). Every isoform has a different 
substrate recognition and activation profile. However, they are all expressed as either 
46kDa or 54kDa, with the difference of a COOH terminal extension (Pulverer, 
Kyriakis et al. 1991). The activation of JNK happens through a dual phosphorylation 
of Thr and Tyr residues within a Thr-Pro-Tyr motif, which is a common response to 
assaults from various cytokines, UV radiation, oxidative stress and osmotic shock 
(Davis 2000; Weston and Davis 2002; Weston, Lambright et al. 2002). The precise 
biological outcome from JNK activation varies from different stimuli and cellular 
contexts, but most of the cellular effects are attributed to the activation of AP-1 
proteins. It is found that JNK specifically phosphorylates AP-1 transcription factor 
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family member c-Jun on Ser-63 and Ser-73 residues by binding to its N-terminus 
activation domain (Pulverer, Kyriakis et al. 1991; Hibi, Lin et al. 1993). Other than 
activating c-Jun, JNK is also observed to phosphorylate other AP-1 family members 
such as JunB, JunD and ATF-2 (Ip and Davis 1998).  
 
5.3.2 JNK and cell death 
Activation of JNK signaling in apoptosis is quite well observed and the underlying 
mechanism is context-dependent. One important discovery to address this issue is the 
temporal control of JNK activation that determines the biological responses. Multiple 
reports have showed that early and transient JNK activation contributes to cell 
survival, while prolonged and sustained JNK activation promotes apoptosis (Chang, 
Kamata et al. 2006; Lin 2006; Ventura, Hubner et al. 2006). The identification of 
downstream substrates of JNK activation provides great insight into the mechanisms 
in JNK-mediated apoptosis. One of them is H2AX, a histone H2A variant; it is shown 
that H2AX phosphorylation by JNK is required for caspase-activated DNase (CAD)-
mediated DNA fragmentation in UV-triggered cells (Lu, Zhu et al. 2006). Fas-L is 
another important downstream target of JNK (Le-Niculescu, Bonfoco et al. 1999). 
Other than that, multiple components of the mitochondrial death pathway are 
proposed to be regulated by JNK signaling. Depends on the cellular contexts, Bcl-2 
family members Bax, Bcl-2, Bcl-xL, Mcl-1, Bad, Bmf and Bim can be 
phosphorylated by JNK to promote apoptotic responses (Lei and Davis 2003; Putcha, 
Le et al. 2003; Becker, Howell et al. 2004; Liu and Lin 2005; Kim, Ryu et al. 2006). 
In addition, Bim expression can also be transcriptionally-upregulated following 
activation of its transcription factors c-Jun and FOXO3a downstream of JNK 
activation (Harris and Johnson 2001; Putcha, Moulder et al. 2001; Whitfield, Neame 
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et al. 2001; Gilley, Coffer et al. 2003; Essers, Weijzen et al. 2004). Besides that, the 
production of a novel cleaved form of Bid (jBid) in a JNK-dependent manner also 
contributes to the activation of intrinsic pathway (Deng, Ren et al. 2003).  
 
Some recent evidence has also suggested that JNK is involved in other forms of cell 
death such as necrosis and autophagy. One paper has reported that JNK plays a role 
in TNF-mediated necrosis through ROS production under the condition of NF-κB 
inhibition (Ventura, Cogswell et al. 2004). Another example linking JNK to 
autophagy regulation comes from the observation that targeted deletion of 
Jnk3 protected damaged neurons that underwent autophagic cell death following 
cerebral ischemia-hypoxia (Kuan, Whitmarsh et al. 2003; Adhami, Liao et al. 2006). 
Collectively, JNK has shown to play important roles in multiple forms of cell death.  
 
5.3.3 JNK in cancer 
The role of JNK in tumorigenesis is quite controversial. Both tumor-promoting and 
tumor-suppressing activities of JNK have been demonstrated, which is probably due 
to the fact that JNK can be pro-survival or pro-apoptotic depending on the stimulus 
or cellular context. Several lines of evidence support the role of JNK in tumor 
development. One of them is that Ras-mediated oncogenic transformation can be 
effectively blocked by ablation of the c-jun gene or mutations at the JNK 
phosphorylation sites (Nateri, Spencer-Dene et al. 2005). In addition, another study 
has reported that JNK promoted hepatocarcinogenesis induced by chemical 
carcionogens (Sakurai, Maeda et al. 2006). It has been proposed that the pro-
oncogenic role of JNK may be associated to its link with cell survival.   
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On the contrary, other studies have demonstrated the tumor suppressor role of JNK. It 
is proposed that the tumor suppression effects may be mediated by JNK’s association 
with apoptosis (Kennedy and Davis 2003). One possible mechanism is through 
MKK4, an upstream activator of both JNK, which has been suggested as a potential 
tumor suppressor. Loss of function mutations of MKK4 is present in ~5% of human 
cancers (Whitmarsh and Davis 2007). In addition, suppression of MKK4 exhibited 
increased metastasis in lung, ovarian and prostate carcinomas (Yamada, Hickson et 




MATERIALS AND METHODS 
1 Cell lines and cell culture 
HCT116 WT (p53+/-), p53-/- and Bax-/- colorectal carcinoma cells were generously 
provided by Dr. Bert Vogelstein (The Johns Hopkins University School of Medicine, 
Baltimore, MD, USA) and maintained in McCoy 5A (Gibco Invitrogen Corporation, 
Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS, Hyclone, 
Irvine, CA, USA), 1% L-glutamine, and 1% penicillin/streptomycin (Hyclone, 
ThermoScientific, Waltham, MA, USA). SHEP-1 neuroblastoma cell line and A549 
non-small cell lung carcinoma cell line were purchased from American Type Culture 
Collection (ATCC, Rockville, MD, USA), and were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM, Hyclone, Logan, Utah, USA) supplemented with 10% 
fetal bovine serum and 1% penicillin/streptomycin. M14 melanoma cells stably 
transfected with an empty pIREShyg (M14 pIRES) or the same vector encoding the 
myc-RacV12 protein (M14 RacV12) were generated from our lab and maintained in 
DMEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. 
In addition, the culture medium for M14RacV12 cells was supplemented with 250 
μg/ml selection antibiotic hygromycine. RKO colorectal carcinoma cell line, MDA-
MB-231 breast cancer cell lines was purchased from ATCC and maintained in 
Roswell Park Memorial Institute 1640 medium (RPMI, Hyclone, Logan, Utah, USA) 
supplemented with 1% L-glutamine, 1% penicillin/streptomycin and 10% FBS. All 
cell lines were maintained in a humidified incubator at 37°C with 5% CO2. 
 
2 Reagents and chemicals 
Simvastatin, GGTI-298, FTI-277, NSC23766 and PAK1-PBD beads were purchased 
from Merck Millipore (Billerica, MA, USA). Mevalonate, GGPP, FPP, SP600125, 
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Tiron, Tempol, DPI, MTT, Lucigenin, crystal violet, bromophenol blue, Tween 20, 
Triton X-114, EDTA, DTT, glycine, BSA, DMSO, Squalene, ATP releasing buffer, 
cycloheximide and actinomycin D were purchased from Sigma Aldrich Co (St Louis, 
MO). EHT1864 was purchased from Tocris biosciences (Bristol, UK). Rhotekin-
RBD beads were brought from Cytoskeleton, Inc (Denver, CO, USA). Pan-caspase 
inhibitor zVAD-fmk was purchased from Alexis Biochemicals (Lausane, 
Switzerland). Fluorogenic substrates of caspase-3, -8 and -9 were purchased from 
Biomol (Plymouth Meeting, PA, USA). Protein A agarose beads and glutathione 
beads were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
Coomassie Blue was purchased from Pierce Biotechnology (Rockford, IL, USA). 10x 
PBS, 10x SDS, Tris-HCl buffer (pH7.4) were purchased from NUMI Media 
Preparation Facility (NUS, Singapore).  
 
3 Plasmids and siRNAs 
Plasmids: pIRES1hyg vector and pIRESRacN17 plasmids were generously provided 
by Dr. Marie-Véronique Clément (NUS, Singapore).  
 
siRNAs: ON-TARGETplus SMARTpool siRNAs (a mixture of 4 siRNAs in a single 
reagent) targeting RhoA, Rac1, Cdc42 as well as siRNA negative control (non-
homologous to any known gene sequence) were purchased from Dharmacon 
Technologies (ThermoFisher Scientific, Lafeyette, CO). One single siRNA sequence 
targeting Bim was purchased from Qiagen (Duesseldorf, Germany). Three unique 
26mer siRNA duplexes targeting Bim and siRNA negative control were purchased 
from Origene (Rockville, MD, USA).  
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4 Transfection of plasmids and siRNAs 
The Calcium Phosphate Mammalian Transfection Kit (Clonetech Laboratories Inc., 
Palo Alto, CA) was used for transfection of plasmids or siRNAs into HCT116 cells. 
Cells to be transfected were grown to 40% confluency in 24-well tissue culture plates 
(for crystal violet assay, seeded at 0.12 x 10
6
 cells/well) or 12-well plates (for 
Western blot analysis and Lucigenin assay, seeded at 0.2 x 10
6
 cells/well). Before 
performing transfection, the cell culture medium was changed to fresh DMEM 
supplemented with 10% FBS, 1% L-glutamine and 1% penicillin/streptomycin. On 
12-well plates, 1 μg of plasmids were used per well for all expression plasmids. For 
siRNAs, 10 nM was used per sample for siRNAs targeting Bim (three independent 
sequences: Bim#1, #2 and #3); 35 nM was used for siRNA targeting RhoA and 
Cdc42, while 100 nM was used for siRNA targeting Bim (another sequence: Bim#0) 
and Rac1. Transfection mixture contained calculated amounts of DNA or siRNAs, 
sterile dH2O and 6.2 μl of 2.5 mM CaCl2, which summed up to a total amount of 50 
μl per 12 well. For a 24-well, the calculation was halved. The DNA-CaCl2 or siRNA-
CaCl2-containing solution was then mixed with an equal volume of the DNA 
precipitation buffer (2x HEPES-buffered saline) in a drop-wise manner with gentle 
vortexing. The mixture was then incubated for 20 mins at room temperature followed 
by adding drop-wise into the cells (50 μl per 24-well, 100 μl per 12-well). After 14-
18 h of incubation, cell were washed with 1x phosphate buffered saline (PBS) and 
recovered in cell culture medium used for maintenance. Downstream procedures 
were carried out at least 30 h from the time of adding transfection reagents. 
 
5 Determination of cell viability by crystal violet assay 
HCT116 cells are seeded in 24-well tissue culture plates (0.12 x 10
6
 cells/well) or 12-
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well plates (0.2 x 10
6
 cells/well) for two days prior to any treatments and cytotoxicity 
caused was determined by crystal violet assay. After drug treatment, cells were 
washed once with 1x PBS followed by addition of 0.2 ml of crystal violet solution to 
each well and incubated for 10 mins. Crystal violet stain was retained inside cells that 
were attached to the plates, while the excess crystal violet solution was washed away 
using distilled water. The remaining crystals were then dissolved in a 1% SDS in 1x 
PBS solution and absorbance was determined by reading at wavelength 595nm using 
a TECAN spectrophotometer (Tecan Trading AG, Switzerland). The optical density 
(OD) obtained is proportional to the number of viable cells. Cell viability is 
calculated as percentage relative to the untreated control cells. Same protocol was 
used for other types of cancer cells such as RKO, A549, MDA-MB-231 and SHEP-1 
cells. 
Crystal violet solution: 0.75% crystal violet in 50% (v/v) ethanol with 1.75% 
formaldehyde and 0.25% NaCl. Stored at room temperature. 
 
6 Determination of cell viability by MTT assay 
Cell viability was also determined by the 3-(4,5-dimethyl-2- thiazolyl)-2,5-
diphenyltetrazolium bromide (MTT) assay. HCT116 were seeded in 24-well plates 
(0.12 x 10
6
 cells/well) and cultured for two days before drug treatment. At the end of 
drug treatment, all cells in the same well were collected and re-plated in a 96-well 
plate (100 μl of medium per well) and incubated with 100 μl MTT (3 mg/ml) per 96-
well at 37°C for 2 h. Following that, the formazan crystals formed were spun down at 
3,000 rpm by centrifugation for 15 mins. The resultant supernatant was aspirated off 
and the crystals formed were dissolved with 250 μl dimethyl sulfoxide (DMSO). 
Absorbance was measured with a TECAN sprectrophotometer (Tecan Trading AG, 
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Switzerland) at 570nm. Cell viability is calculated as percentage relative to the 
untreated control cells. 
 
7 Colony forming assay 
After 30 h of drug treatment, cells were washed with 1x PBS and trypsinized. 10,000 
cells per treatment were replated in a 6-well plate or a 100mm dish in complete tissue 
culture medium. Cells were then left to form colonies over a period of 7 days (for 6-
well plates) or 14 days (for 100mm dishes). Colonies formed were stained with 
crystal violet. The number of colonies formed was counted manually. 
 
8 DNA fragmentation assay by propidium iodide staining 
HCT116 were plated in 12-well tissue culture plates (0.2 x 10
6
 cells/well) for two 
days before drug treatment. Following treatment, the DNA content of the cells was 
analyzed using propidium iodide (PI) staining. Cells were harvested on ice and 
pelleted down by centrifugation at 1,500 rpm for 5 mins. After washing once with 
ice-cold 1x PBS, cells were immediately fixed with 70% (v/v) ethanol while 
vortexing, to prevent clumping of cells. The fixed cells were incubated for at least 30 
mins at 4°C. Then the cells were washed twice with ice-cold 1x PBS and resuspended 
in 500 μl of PI/RNase solution (contains 10 μg/ml PI and 250 μg/ml RNase A) for 1 h 
at 37°C. At least 10,000 events were analyzed for DNA content with flow cytometry 
(CyAn ADP, Beckman Coulter, USA) with the excitation set at 488nm and emission 
at 610nm. Data collected were analyzed with the WinMDI software (Windows 
multiple document interface for flow cytometry, Beckman Coulter Inc., Sunnyvale, 
CA). In a DNA analysis, the sub-G1 population represents the hypodiploid DNA 
content which is in the extreme left of histograms.  
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9 Caspase activity assay 
HCT116 were plated in 12-well tissue culture plates (0.2 x 10
6
 cells/well) for two 
days before drug treatment. Fluorogenic substrates were used to determine caspase-3, 
-8 and -9 activities; they are synthetic oligopeptides containing the caspase cleavage 
site where the C-terminal aspartic acid is replaced with 7-amino-4-trifluoromethyl 
coumarin (AFC). Cells were harvested on ice after treatment and lysed with 1x Cell 
Lysis Buffer (BD Pharmingen, San Diego, CA). Equal volume of cell lysates and 2x 
Reaction Buffer, together with 1 μl of the respective caspase substrate were added in 
a 96-well plate. The respective substrates for caspase-3, -8 and -9 are Ac-DEVD-
AFC, Ac-IETD-AFC and Ac-LEHD-AFC. The 96-well plate was then incubated at 
37°C for 1 h, and the fluorescence was measured with TECAN spectrophotometer 
(Tecan Trading AG, Switzerland) at excitation 400nm and emission 505nm. The 
amount of proteins in every sample was quantified by Coomassie Blue reagent and 
caspase activity was normalized with protein concentration and expressed as relative 
fluorescence unit (RFU)/μg protein. 
2x Reaction Buffer: 10mM HEPES (pH 7.4), 2mM EDTA, 6mM DTT, 10mM and 




10 Western blot analysis 
After drug treatment, whole cell lysates were harvested and lysed on ice using 1x 
RIPA lysis buffer. Cell lysates prepared from coimmunoprecipitation, isolation of 
GTP-bound GTPases, sucrose gradient centrifugation, mitochondrial and cytosolic 
fractionations were described in their respective sections (See section 12-15 
respectively). The collected cell lysate were spun down at 1,500 rpm for 5 mins to 
clear debris and protein concentration of the resultant supernatant was measured 
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using Coomassie Blue reagent. Briefly, 1.5 μl of the supernatant or protein standards 
and 200 μl of Coomassie Blue reagent were added in a 96-well plate. Absorbance 
was measured using TECAN spectrophotometer (Tecan Trading AG, Switzerland) at 
595nm. Protein amount ranging from 30 to 70 μg for different purposes were then 
mixed with 1x Laemmli loading dye and boiled at 100°C for 5 mins. Following that, 
the samples were subjected to sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE). Different percentages of gels containing 8, 10, 12 or 
15% (v/v) acrylamide were used depending on the molecular weight of target 
proteins. Subsequently, wet transfer method was used to transfer the resolved 
proteins onto PVDF membranes (BioRad, CA, USA). The membranes were blocked 
with 5% (w/v) fat-free milk in Tris-buffered saline containing 0.1% (v/v) Tween 20 
(TBST) for 30 mins and washed with TBST for three times to remove excess milk. 
The membranes were then probed for the target proteins with the respective primary 
antibodies (refer to list of antibodies below) overnight at 4°C. On the next day, the 
membranes were washed with TBST for three times to remove unbound primary 
antibody and probed again using appropriate HRP-conjugated secondary antibody in 
5% (w/v) fat-free milk in TBST for 1 h at room temperature. After that, the 
membranes were washed with TBST for three times to remove any excess unbound 
secondary antibody, the proteins of interest were detected with Kodak Biomax MR 
X-ray film (Eastman Kodak Co., Rochestor NY) by enhanced chemiluminescence 
using the SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL, 
USA). For probing different proteins on the same membrane, the membranes were 
stripped with Restore Western Blot Stripping Buffer (Pierce, Rockford, IL, USA) and 
the same procedures were repeated. 
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(1) Buffers used in western blot analysis 
RIPA lysis buffer: 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% (v/v) Nonidet P40, 
0.25% deoxycholic acid, 1 mM EDTA supplemented with fresh protease inhibitors (5 
μg/ml leupeptin, 1 mM PMSF, 10 μg/ml aprotinine, 20 μg/ml pepstatin A) and a 




5x Laemmli Loading Buffer: 3.1 ml Tris-HCL (pH 6.8), 1 g SDS, 2 ml glycerol, 2.5 
ml β-Mercaptoethanol, 0.01 g Bromophenol Blue, topped up to 10 ml with 2.4 ml of 
dH2O. Stored at room temperature. 
 
10x Running Buffer for SDS-Page gel: 60 g Tris-base, 288 g glycine, 20 g SDS, 
topped up to 2 L with dH2O. Stored at room temperature. 
 
Transfer Buffer for western blot: 2.42 g Tris-base, 11.57 g glycine, 200 ml methanol, 
topped up to 1L with dH2O. Keep cold before use. 
 
TBS: 500 ml of 1 M Tris-HCl (pH 7.4) with 87.6 g of NaCl in 10 L of dH2O and 
stored at room temperature. 
 
TBST: 2 L TBS with 2 ml of Tween-20 and stored at room temperature. 
 
(2) Primary antibodies for western blot analysis 
Primary antibodies specific for RhoA, Cdc42, RhoGDIα, Bax, cytochrome c, VDAC, 
p53, Bcl-xL, β-actin and GAPDH were purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA, USA). Primary antibodies probing for Bim, Bid, phosphorylated-
AKT, AKT, phosphorylated-Erk, Erk, JNK, SOD1, PARP, myc-tag, caspase-3, 
caspase-8 and caspase-9 were purchased from Cell Signaling Technology (Danvers, 
MA). Primary antibody for Rac1 and phosphorylated-JNK were purchased from 
Merck Millipore (Billerica, MA). Primary antibody for Flotilin was purchased from 
Abcam (Cambridge, UK). 
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11 Coimmunoprecipitation (Co-IP)  
HCT116 were plated in 100mm tissue culture dishes (1.2 x 10
6
 cells/dish) for two 
days prior to drug treatment. Cells from two dishes receiving same treatments were 
pooled together for one sample. Cells were harvested on ice and washed once with 
ice-cold 1x PBS followed by lysing in Co-IP buffer on ice for 15 mins. The lysates 
were spun at 1,500 rpm for 5 mins to clear debris. The resultant supernatant was 
collected and pre-cleared with 25 μl protein A agarose beads on a rotator for 4 h at 
4
o
C. The beads were cleared away by centrifugation at 12,000 rpm for 5 mins at 4°C. 
Protein concentration of the supernatant (cell lysate) was determined using 
Coomassie Blue reagent. 1 mg of the cell lysate was incubated with 4 ug of rabbit 
polyclonal anti-RhoGDIα antibody for overnight on a rotator at 4°C. On the next day, 
30 μl protein A agarose beads were added to every sample and rotated for another 2 h 
at 4°C. The complexes were then washed with 0.5 ml ice-cold Co-IP buffer for three 
times. The resultant bead-protein complexes were mixed with 1x Laemmli loading 
dye and boiled at 100°C for 20 mins. The samples were then subjected to Western 
blot analysis as described above. 
Co-IP buffer: 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5% v/v Nonidet P40, 1 
mM EDTA with supplements of fresh protease inhibitors (5 μg/ml leupeptin, 1 mM 
PMSF, 10 μg/ml aprotinine, 20 μg/ml pepstatin A) and a phosphatase inhibitor (1 
mM Na3VO4). Stored at 4°C. 
 
12 Isolation of GTP-loaded RhoA, Rac1 and Cdc42 GTPases 
HCT116 were plated in 100mm tissue culture dishes (1.2 x 10
6
 cells/dish) for two 
days before drug treatment. Cells from two dishes were pooled together as one 
sample. Then cells were washed with 1x PBS and lysed in MLB buffer for 20 mins 
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on ice. Cell lysates were cleared by centrifugation at 1,500 rpm for 5 mins at 4°C. 
The resultant supernatant was collected and pre-cleared with 20 μl glutathione beads 
on a rotator for 20 mins at 4
o
C. The beads were cleared away by centrifugation at 
12,000 rpm for 5 mins at 4°C. Protein concentrations of the supernatants were 
determined by Coomassie Blue reagent and 800 μg of protein from each sample was 
used. The GTP-bound form of GTPases was isolated by their ability to interact with 
their specific effector protein binding domains. Hence, GTP-bound RhoA, Rac1 and 
Cdc42 were isolated by incubating the protein sample with 20 μg of GST-Rhotekin 
beads (for RhoA) or 10 μg GST-PAK beads (for Rac1 and Cdc42) on a rotator for 1 h 
at 4°C. The bead-protein complexes were washed with 0.5 ml ice-cold MLB buffer 
for three times. The resultant bead-protein complexes were mixed with 1x Laemmli 
loading dye and boiled at 100°C for 20 mins. The samples were then subjected to 
Western blot analysis as described above. Same protocol was used to assess GTP-
bound form of Rac1 in SHEP-1 cells.  
MLB buffer: 25 mM HEPES (pH 7.5), 10 mM MgCl2, 150 mM NaCl, 10% v/v 
glycerol, 1mM EDTA, 25 mM NaF, 1 mM Na3VO4, 10 μg/ml leupeptin and 10 μg/ml 
aprotinine. Stored at 4°C. 
 
13 Mitochondrial-cytoplasmic fractionation 
HCT116 were plated in 100mm tissue culture dishes (1.2 x 10
6
 cells/dish) for two 
days before drug treatment. Cells from at least three dishes were pooled together for 
one sample. Cells were harvested and washed once with ice-cold 1x PBS before 
incubation on ice for 7 mins with extraction buffer A. After incubation, cells were 
homogenized using a dounce homogenizer and passaged for 7 strokes before being 
centrifuged at 300 g for 5 mins at 4°C. The resultant supernatant was subjected to 
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another two rounds of centrifugation at 1,000 g for 10 mins. The remaining 
supernatant was transferred into a new microcentrifuge tube and centrifuged again at 
12,000 g for 15 mins at 4°C. The resultant pellet enriched with mitochondria was 
washed with Buffer A for another 15 mins at 12,000 g, followed by lysing with 
standard 1xRIPA lysis buffer supplemented with protease inhibitors. The supernatant 
was collected as the cytosolic fraction. Both fractions obtained were then subjected to 
protein concentration quantification and Western blot analysis. 
 
In this particular project, in order to assess the amount of Rho protein in the cytosol, 
we performed further purification from the above mitochondria-cytosol preparations 
to isolate cytosolic fractions without any contamination from light membranes. After 
isolating the mitochondrial fractions as stated above, the supernatant was subjected to 
ultracentrifugation at 100,000 g for 1 h at 4°C. The pellet obtained was enriched with 
light membrane fractions while the supernatant of our interest contained mainly 
cytosolic proteins. The cytosolic fraction obtained was then subjected to protein 
concentration quantification and Western blot analysis. 
Extraction buffer A (pH 7.4): 50 mM PIPES-KOH, 200 mM mannitol, 68 mM 
sucrose, 50 mM KCl, 5 mM EGTA, 2 mM MgCl2, 1 mM DTT  supplemented with 
fresh protease inhibitors (5 μg/ml leupeptin, 1mM PMSF, 10 μg/ml aprotinine, 20 
μg/ml pepstatin A) and a phosphatase inhibitor (1 mM Na3VO4). Stored at 4°C. 
 
14 Isolation of membrane lipid rafts by sucrose gradient ultracentrifugation 
HCT116 cells were seeded in 100mm tissue culture dishes (1.2 x 10
6
 cells/dish) for 
two days before drug treatment. Cells from at least five dishes were pooled together 
for one sample. Cells were then harvested and washed with ice-cold 1x PBS before 
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incubating in 500 μl HEPES buffer containing 1% Triton X-100 for 10 mins. Lysates 
were then frozen in -80°C and freeze-thawed on ice, followed by homogenizing for 
20 strokes with a dounce homogeniser. The homogenised lysates were centrifuged at 
400 g for 10 mins at 4°C to remove debris. The supernatant were then subjected to 20 
passes through a 27G syringe, which was followed by three times sonication (10sec 
pulses at 40V). Protein concentration was quantified and equal amount of proteins 
was used for subsequent ultracentrifugation. The lysates were transferred to a special 
5ml centrifuge tube and mixed with an equal volume of 80% sucrose (w/v) in HEPES 
buffer, followed by overlaying with 1.5 ml of 30% sucrose and 1.5 ml of 5% sucrose 
solutions. The sucrose gradient was centrifuged for 21 h at 4°C in a Beckman rotor at 
32,000 rpm and eight 0.5 ml fractions were harvested separately. 30 μl from fraction 
number 2-6 were used for subsequent Western blot analysis. 
HEPES Buffer: 25 mM HEPES (pH 7.4), 150 mM NaCl, 1% Triton X-100 and 1 
mM PMSF, 10 μg/ml aprotinin, 20 μg/ml pepstatin A and 10 μg/ml leupeptin. Stored 
at 4°C. 
 
15 Triton X-114 phase separation 
HCT116 cells were seeded in 100mm tissue culture dishes (1.2 x 10
6
 cells/dish) for 
two days before drug treatment. Cells from at least two dishes were pooled together 
for one sample. Cells were then harvested and washed with ice-cold 1x PBS before 
incubating in 500 μl lysis buffer containing 1% Triton X-114 followed by 
centrifugation at 13,000 g for 15 mins. The resultant supernatant was put inside 37°C 
incubator for 10 min, and micelles formed were pelleted by centrifugation at 13,000 g 
for 2 mins at room temperature. The aqueous supernatant was cooled to 4°C and the 
detergent pellet was topped up to the same volume as the aqueous fraction using lysis 
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buffer without Triton X-114. Equal volumes of lysates from both fractions were 
assessed by Western blot analysis.  
Lysis Buffer: 20 mM Tris, 150 mM NaCl. 
 
16 Measurement of superoxide by Lucigenin chemiluminescence assay 
HCT116 were seeded at 0.2 x 10
6 
cells/well in 12-well tissue culture plates for two 
days before drug treatments for specified durations. Cells were washed once with ice 
cold 1x PBS and trypsinized. Cell pellets were collected after spinning at 1,500 rpm 
for 5 mins. The pellet was quickly lysed with 450μl somatic ATP releasing buffer, 
400 μl of which was placed into the Sirius LB 9505 luminometer (Berthold) for 
quantification of chemiluminescence with 100 μl of 10 mM lucigenin solution. The 
remaining 50 μl was kept for protein quantification. The luminescence reading is 
normalized with the protein concentration and presented as relative light units (RLU) 
per μg protein. Same protocol was used to assess superoxide level in SHEP-1 cells. 
 
17 Measurement of superoxide by DHE dye 
HCT116 cells were seeded at 0.2 x 10
6
cells/well in 12-well tissue culture plates for 
two days before drug treatments for specified durations. Cells were then harvested on 
ice and washed once with ice cold 1x PBS. Subsequently, cell pellets were 
resuspended in 100 μl ice cold 1x PBS containing 10 μM Dihydroethidine (DHE) dye 
(Molecular Probes, Invitrogen corporation, CA) and incubated at 37°C for 20 mins in 
the dark. After that, cells were pelleted at 1,500 rpm for 5 mins and resuspended in 
1x PBS. At least 10,000 events were analyzed by flow cytometry with the excitation 
set at 590nm and emission at 619nm. Data collected were analyzed with the DAKO 
software (Beckman Coulter Inc., Sunnyvale, CA). Final fluorescence values obtained 
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were normalized against the untreated control and plotted as x fold increase in 
fluorescence over the untreated control. 
 
18 Statistical analysis 
All statistical analysis was based on at least three independent experiments, and the 
results were expressed as mean ± s.e.m unless otherwise stated. The paired Student’s 




1. Simvastatin activates the mitochondrial apoptotic pathway in 
HCT116 cells 
1.1 Simvastatin effectively reduces cell viability in a dose-dependent manner 
Significant clinical evidence has emerged to implicate statins as anti-tumor agents, 
showing activity in carcinomas of the prostate, colon and rectum, breast, lung, AML, 
multiple myeloma and skin (Chan, Oza et al. 2003; Demierre, Higgins et al. 2005; 
Hwang, Na et al. 2011). In this project, we aimed to explore the underlying 
mechanisms for simvastatin’s anti-tumor effects in human cancer cells. Firstly, we 
investigated if simvastatin possessed anti-cancer properties as described. HCT116 
colorectal cancer cells were treated with increasing doses of simvastatin (0-30 μM) 
for 24 and 48 h, and the resultant loss of cell viability was assessed by both crystal 
violet assay (Figure 1A) and MTT assay (Figure 1B). Crystal violet is able to stain 
the DNA, and upon solubilization it quantifies the relative density of cells still 
adhering to the culture dishes; while the reduction of MTT dye by active 
mitochondrial enzymes to formazan crystals is proportional to the amount of viable 
cells. Cell viability was determined by comparing to untreated control cells. Both 
assays demonstrated that 24 h simvastatin treatment has no profound effects on cell 
viability; however, incubation up to 48 h elicited effective loss in HCT116 cell 
viability (10 μM simvastatin: 65.72 ± 1.26% cell loss obtained by crystal violet assay 
and 58.69 ± 2.47% obtained by MTT assay). This inhibitory effect was also shown to 
be dose-dependent; at low dose of 3 μM simvastatin, there was about 25% cell 
viability loss while at 5 μM and 10 μM simvastatin, about 40% and 65% cells were 
not viable measured by crystal violet assay respectively. For subsequent experiments, 
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we selected simvastatin 3 or 10 μM as the main effective working concentrations to 



















Figure 1: Simvastatin effectively reduces cell viability of HCT116 cells. 
HCT116 cells were treated with various concentrations of simvastatin (0-30 μM) for 24 and 48 h. Cell 
viability was measured by (A) crystal violet assay and (B) MTT assay as described in Materials and 
Methods. In both panels, cell viability was expressed as % of untreated control. Data are shown as 
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1.2 Simvastatin inhibits long-term colony formation of HCT116 cells 
Following the short-term cell viability assessment, we went on to evaluate if the 
short-term cytotoxic effects of simvastatin translated into long-term suppression of 
their clonogenic abilities. HCT116 cells were treated with increasing doses of 
simvastatin (0-30 μM) for 30 h, and 10000 cells from each condition was replated 
onto a 6-well plate and allowed to form colonies for seven days. A dose-dependent 
reduction in colonies was observed after simvastatin treatment (Figure 2) (45.58 ± 
1.44% reduction after 3 μM simvastatin, 73.11 ± 4.43% reduction after 10 μM 
simvastatin compared to untreated control, p < 0.05). Moreover, a greater extent of 
reduction in long-term colony-formation was observed compared to the short-term 
viability loss at corresponding doses. As the colony forming assay detects cells that 
retained progeny-producing ability after chemotherapy treatment (Franken, 
Rodermond et al. 2006), out results indicate that simvastatin triggers reproducible 
























Figure 2: Simvastatin reduces clonogenic ability of HCT116 cells. 
HCT116 cells were treated with various concentrations of simvastatin (0-30 μM) for 30 h before being 
replated onto a 6-well plate (10000 cells/well) and allowed to form colonies over 7 days. Colonies 
formed were then stained with crystal violet. (A) Representative photos of colonies formed from one 
set of experiment are shown here. (B) Colonies formed were scored and expressed as % number of 
colonies formed by untreated control. The bars represent means ± s.e.m from three independent 




























1.3 Simvastatin-triggered cell death bears apoptotic hallmarks 
1.3.1 Cell death is accompanied by cell shrinkage and DNA fragmentation 
Having ascertained that simvastatin reduces cell viability effectively in HCT116 
cells, we proceded to assess if the observed anti-viability effect was a consequence of 
cell death or a mere cytostatic effect. Firstly, cells were observed under phase 
contrast microscope. Unlike control cells, simvastatin-treated cells were seen 
shrinking in size and rounding up (Figure 3A). Subsequently, we analyzed the DNA 
content of simvastatin-treated HCT116 cells using propidium iodide (PI) staining 
(Figure 3B). The intensity of fluorescence emitted is proportional to the amount of PI 
dye being incorporated into the DNA and can be detected by flow cytometry analysis 
(Suzuki, Fujikura et al. 1997). We observed that the sub-G1 population, which 
represented cells with fragmented DNA, was dose-dependently increased after 
simvastatin treatment (Figure 3C) (7.87 ± 0.84% sub-G1 population in control cells 
vs. 25.14 ± 1.17% with 3 μM simvastatin and 60.58 ± 2.64% with 10 μM simvastatin 
treatment, p < 0.05). This observation is consistent with the extent of loss of cell 
viability seen in Figure 1. Given that cell shrinkage and DNA fragmentation are 



































Figure 3: Simvastatin leads to cell shrinkage and DNA fragmentation in HCT116 cells. 
(A) HCT116 cells were treated with 10 μM simvastatin for 28 h and morphology of the cells was 
photographed under phase contrast microscope (Magnification: 200X). (B) Cells were treated with 3 
or 10 μM simvastatin for 48 h, DNA content was analyzed by flow cytometry after staining with 
propidium iodide (PI) as described in Materials and Methods. Cell cycle profiles obtained from one set 
of experiment are shown here. (C) The average percentages of cells in different cell-cycle phases are 
summarized in this table. Data are presented as means ± s.e.m from three independent experiments. *, 




Control Simva 3µM Simva 10µM 
Sub G1 7.87 ± 0.84 25.14 ± 1.17 * 60.58 ± 2.64 * 
G1 81.28 ± 1.28  67.84 ± 1.76  35.15 ± 1.79  
S 2.56 ± 0.3 3.56 ± 0.45 2.01 ± 0.44 
G2/M 7.87 ± 0.92 3.93 ± 0.04 2.20 ± 1.10 
 65 
1.3.2 Simvastatin induces effective proteolytic processing and activation of 
caspases 
The aforementioned observations of apoptotic hallmarks such as cell shrinkage and 
DNA fragmentation upon simvastatin treatment prompted us to investigate the 
involvement of caspases in simvastatin-triggered cell death. Caspases act as the main 
‘executioners’ of apoptosis by cleaving specific cellular substrates involved in 
cellular demise (Cohen 1997). We investigated the activities of three key caspases, 
namely caspase-9 and -8, which are initiator caspases involved in intrinsic or 
extrinsic apoptotic pathway respectively; and their downstream effector caspase-3. 
Western blot analysis revealed time-dependent proteolytic conversion of pro-caspase-
8 and -9 into catalytically active subunits as early as 28 h, and followed by 
processing of caspase-3 into 17- or 19 kDa fragments that peaked at 36 h post-
treatment (Figure 4A). Proteolytic processing of caspase-3 then resulted in cleavage 
of its downstream targets, evidenced by cleavage of poly-ADP-ribose polymerase 
(PARP) from 116 kDa to the 86 kDa fragment observed at 36 h (Figure 4B). 
 
To verify the western blot results, we also studied the activities of caspase-3, -8 and -
9 using their respective fluorescence-conjugated caspase substrates (DEVD-AFC, 
IETD-AFC and LEHD-AFC). This sensitive measurement method showed detectable 
activation of all three caspases after 36 h simvastatin treatment (Figure 4C) (5.67 ± 
0.73 fold increase for caspase-3, 3.75 ± 0.41 fold increase for caspase-8, 3.82 ± 0.38 
fold increase for caspase-9 after 10 μM simvastatin compared to untreated control, p 
< 0.05), which is consistent with the robust proteolytic processing of caspases 









































Figure 4: Simvastatin induces proteolytic processing and activation of caspases. 
HCT116 cells were treated with 3 or 10 μM simvastatin for the indicated duration before whole cell 
lysates were harvested for Western blot analysis. (A) Caspase-3, -8 and -9 and (B) PARP were 
immunoblotted using antibodies that recognize both the pro- and cleaved forms of the respective 
proteins. In both panels, β-actin or GAPDH was included as a loading control. (C) At 36 h post-
treatment, total cell lysates were used to assess caspase-3, -8, and -9 activation levels using 
fluorescence-conjugated substrates. Caspase activity was normalized to total protein and expressed as 
fold increase over untreated cells. The bars represent means ± s.e.m of three independent experiments. 




















































In agreement with the observed activation of caspases, preincubation of cells with the 
pan-caspase inhibitor zVAD-fmk for 2 h almost fully recovered viability of 
simvastatin treated-cells assessed by crystal violet assay (Figure 5A) (87.84 ± 5.43% 
cell viability with zVAD-fmk preincubation vs. 30.08 ± 6.51% cell viability with 10 
μM simvastatin alone, p < 0.05). This was supported by the ability of zVAD-fmk to 
completely inhibit caspase activity as evidenced by successful abrogation of 
simvastatin-induced PARP cleavage (Figure 5B). Taken together, these results 
(Figure 3-5) demonstrate that simvastatin induces apoptosis in HCT116 cells in a 
caspase-dependent manner, exemplified by caspase activation, PARP cleavage and 
























Figure 5: Pan-caspase inhibitor zVAD-fmk confers full protection to simvastatin-mediated cell 
death. 
HCT116 cells were preincubated with or without 100 μM zVAD-fmk for 2 h before treatment with 3 
or 10 μM simvastatin. (A) Cell viability after 48 h simvastatin treatment was measured by crystal 
violet assay. The bars represent means ± s.e.m of three independent experiments. *, p < 0.05 compared 




























1.4 Simvastatin activates the mitochondrial apoptotic pathway 
1.4.1 Simvastatin induces mitochondrial Bax translocation and release of pro-
apoptogenic factor cytochrome c into the cytosol 
Several reports have suggested the role of mitochondria in statin-mediated apoptosis 
in breast tumor cells (Herrero-Martin and Lopez-Rivas 2008), lymphoblasts and 
myeloma cells (Cafforio, Dammacco et al. 2005). Hence, to understand the apoptotic 
signaling in simvastatin-treated HCT116 cells, we tested the involvement of the 
mitochondrial/intrinsic apoptotic pathway. The rate-limiting step in the intrinsic 
pathway is considered to be the mitochondrial membrane permeabilization (MMP) 
upon trigger. The phenomenon involves the mitochondrial outer membrane 
permeabilization (MOMP), which is indicated by release of proteins that are 
normally confined to the intermembrane space (IMS), such as cytochrome c. The 
MOMP can be manifested by pro-apoptotic second messengers. For example, upon 
apoptotic trigger, mitochondrial translocation of Bcl-2 family member Bax has been 
reported as a common mechanism for the induction of MMP, where the full insertion 
of Bax oligomers forms mitochondrial permeability pores into the outer membrane 
that allows for subsequent release of the aforementioned IMS proteins (Kroemer and 
Reed 2000). 
 
Hence, we studied the subcellular translocation of cytochrome c and Bax after 
exposure to simvastatin. After 24 h simvastatin treatment, HCT116 cells were lysed 
and the cytosolic- and mitochondrial-enriched heavy membrane fractions were 
prepared. Simvastatin triggered MOMP in these cells, as evidenced by the release of 
IMS protein cytochrome c to the cytosol and, reciprocally, the translocation of 
cytosolic Bax to the mitochondria. VDAC and SOD1 were used as mitochondrial and 
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cytosolic markers respectively to ensure the clean isolation of both fractions (Figure 
6). Surprisingly, we also detected a small amount of cytochrome c in the cytosol 
without any apoptotic triggers. Similar observations have been made by others, and it 
has been speculated that the observed basal cytosolic cytochrome c is maintained in a 
reduced form, thereby unable to elicit an effective caspase activation cascade 












Figure 6: Simvastatin induces Bax translocation to mitochondria and cytochrome c release into 
the cytosol. 
HCT116 cells were treated with 10 μM simvastatin for 24 h, after which cells were harvested and 
fractioned to obtain mitochondrial and cytosolic fractions as described in Materials and Methods. 
Levels of cytochrome c and Bax were assessed by Western blot analysis. VDAC and SOD1 were used 
as mitochondrial and cytosolic marker, respectively. 
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1.4.2 MMP modulator protein Bax is essential for simvastatin-induced cell death 
To further validate the functional relevance of Bax in our cell death model, we 
compared the effect of simvastatin on HCT116 wildtype (HCT116 WT) and its 
counterpart in which Bax has been knocked out (HCT116 Bax-/-). Genetic 
invalidation of Bax protected cells to a large extent upon simvastatin treatment 
(Figure 7A) (33.28 ± 1.26% cell viability in WT cells vs. 72.12 ± 3.72% cell viability 
in Bax-/- cells after 10 μM simvastatin treatment, p < 0.05). This observation was 
also supported by abolished activation of caspase-3, -8 and -9 (Figure 7B) in Bax-/- 
cells compared to WT cells. In addition, PARP cleavage as a downstream event of 
caspase-3 activation was no longer observed in Bax-/- cells (Figure 7C). Taken 
together with the data on the translocation of cytochrome c and Bax, our findings 
indicate that the mitochondrial apoptotic pathway is the main death mechanism 






























Figure 7: Simvastatin-induced cell death requires Bax. 
(A) Absence or presence of Bax expression was confirmed in HCT116 WT and Bax-/- cell lines by 
Western blot analysis of basal cell lysates (right). Both cell lines were treated with various doses of 
simvastatin (0-30 μM) for 48 h and cell viability was measured by crystal violet assay (left). (B) Both 
cell lines were treated with 10 μM simvastatin for 36 h, and caspase-3, -8, and -9 activation levels 
were assessed using fluorescence-conjugated substrates. (C) PARP cleavage after treating with 10 μM 
simvastatin for the indicated duration was detected by Western blot analysis. β-actin was included as a 
loading control. In (A) and (B), data shown represents means ± s.e.m of three independent experiments. 
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1.5 Simvastatin-induced apoptosis is independent of p53 status 
The tumor suppressor protein p53 executes complex control over apoptosis by 
regulating transcription and cytosolic function of Bcl-2 family members including 
Bax and BH3-only members, PUMA and NOXA (Chipuk, Kuwana et al. 2004; 
Maddika, Ande et al. 2007). Hence, to assess the dependency of p53 in simvastatin-
mediated apoptosis, we compared the response of p53-null HCT116 cells (HCT116 
p53-/-) to its p53 wildtype counterpart (HCT116 WT) towards simvastatin treatment. 
The expression status of p53 in both cell lines was confirmed by Western blot 
analysis in Figure 8 (right). As illustrated by crystal violet results, both p53-/- and 
WT cells exhibited similar extent of decrease in cell viability after simvastatin 
treatment (Figure 8, Left). Even though we have to rule out the importance of this 
key molecule in our model, the observed sensitivity of HCT116 p53-/- cell line 








Figure 8: Simvastatin-induced cell death does not require p53. 
Absence or presence of p53 expression was confirmed in HCT116 WT and HCT116 p53-/- cell lines 
by Western blot analysis of basal cell lysates (right). Both cell lines were treated with various doses of 
simvastatin (0-30 μM) for 48 h and cell viability was measured by crystal violet assay (left). Data 
shown represents means ± s.e.m of three independent experiments. (n.s. is non-specific band).  
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2 Simvastatin induces apoptosis by activating RhoA and Rac1 in 
HCT116 cells 
2.1 Protein geranylgeranylation is essential in simvastatin-mediated apoptosis 
2.1.1 Simvastatin induces apoptosis via depletion of isoprenoid precursor GGPP 
Simvastatin is designed to selectively inhibit HMG-CoA reductase, the rate-limiting 
enzyme involved in the mevalonate pathway (Figure B in Introduction). Mevalonate 
is the precursor for cholesterol and some other biologically significant compounds 
such as the isoprenoids, which are reported to be responsible for the observed 
pleiotropic effects of statins (Werner, Nickenig et al. 2002). Hence, to examine the 
signaling mechanism for simvastatin-induced apoptosis in HCT116 cells, we felt it 
was important to first determine if the effect was through the inhibition of the 
mevalonate pathway. Cells were incubated with simvastatin in the presence or 
absence of mevalonate (MVA, 100 μM), geranylgeranylpyrophosphate (GGPP, 10 
μM) and farnesylpyrophosphate (FPP, 10 μM). Consistent with the observations in 
other cell types (Xia, Tan et al. 2001; Dimitroulakos, Marhin et al. 2002; van de 
Donk, Kamphuis et al. 2003; Zhong, Wang et al. 2003), pretreatment with MVA or 
GGPP, but not FPP, almost completely reversed cell death phenotype induced by 
simvastatin in HCT116 cells (Figure 9A) (Crystal violet assay: 92.01 ± 4.37% cell 
viability with MVA preincubation, 84.37 ± 5.19% with GGPP preincubation vs. 
33.28 + 1.26% with 10 μM simvastatin alone, p < 0.05; MTT assay: 94.98 ± 2.25% 
cell viability with MVA preincubation, 85.74 ± 5.46% with GGPP preincubation vs. 
42.31 ± 2.47% with 10 μM simvastatin alone, p < 0.05). In addition, morphological 
examination revealed that MVA or GGPP preincubation restored normal morphology 
to cells akin to untreated control (Figure 9B). The involvement of the isoprenoid 
GGPP in the cell death elicited by simvastatin was confirmed by two additional 
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assays that assessed the DNA fragmentation and caspase activation status. Here, the 
sub-G1 population, caspase-3 and PARP cleavage following simvastatin treatment 
was significantly reduced with MVA or GGPP preincubation (Figure 9C, 9D). These 
observations were further supported by long-term clonogenic assay (Figure 9E), 
where MVA or GGPP preincubation exerted cytoprotective effect in simvastatin-
treated cells. 
 
Considering that FPP is an upstream isoprenoid precursor for cholesterol, the 
inability of FPP preincubation to protect cells from simvastatin treatment indirectly 
suggests that simvastatin’s cytotoxic effect is cholesterol-independent. To confirm 
this notion, we pretreated cells with different concentrations of squalene, the 
immediate precursor of cholesterol, which has been used commonly to reverse 
cholesterol-mediated effects of statins (Michikawa and Yanagisawa 1999). Crystal 
violet data showed that squalene preincubation was unable to exert any protective 
effects in simvastatin-treated cells, similarly as FPP preincubation (Figure 10). The 
results confirm that the cytotoxic effects are cholesterol-independent. 
 
In summary, simvastatin effects were selectively reversed by incubating cells with 
either mevalonate or its metabolite GGPP but not by squalene or FPP. These results 
suggest that simvastatin’s apoptotic effects were mainly derived from depletion of 
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Figure 9: MVA or GGPP preincubation protect cells from simvastatin-mediated cell death. 
In all panels, HCT116 cells were preincubated with or without 100 μM MVA, 10 μM GGPP or 10 μM 
FPP for 2 h before treatment with 3 or 10 μM simvastatin. (A) Cell viability of treated cells was 
measured by (I) crystal violet assay or (II) MTT assay. The bars represent means ± s.e.m of three 
independent experiments. *, p < 0.05 compared with simvastatin treatment alone. (B) Cell morphology 
after 28 h treatment was photographed using phase contrast microscope (Magnification: 100X). (C) 
DNA content was analyzed after 48 h treatment by PI staining; percentage of cells in sub-G1 is 
indicated in the graph. (D) Caspase-3 and PARP cleavage was assessed after 36 h simvastatin 
treatment by Western blot analysis. (E) Photos of colonies formed after 30 h simvastatin treatment in 

















Figure 10: Squalene preincubation did not rescue cells after simvastatin treatment. 
HCT116 cells were preincubated with or without various doses of squalene (0-400 μM) for 2 h before 
treatment with 10 μM simvastatin for 48 h. Cell viability of treated cells was measured by crystal 
violet assay. The bars represent means ± s.e.m of three independent experiments. 
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2.1.2 Inhibitor of GGTase-I mimics the cytotoxic effects of simvastatin 
As detailed in the previous section, the impact of simvastatin treatment in cells 
seemed to be due to the depletion of cellular GGPP and subsequent inhibition of 
protein geranylgeranylation, as restoration of this isoprenoid could protect from 
simvastatin’s toxicity. Hence, we proposed that direct inhibition of the enzyme 
responsible for the transfer of geranylgeranyl-group to proteins ought to show similar 
cytotoxic effects. We tested the hypothesis with two inhibitors: 
geranylgeranyltransferase-I (GGTase-I) inhibitor GGTI-298 and farnesyltransferase 
(FTase) inhibitor FTI-277. Both inhibitors specifically block the transfer of the 
geranylgeranyl-group and farnesyl-group to their downstream targets, respectively. 
Cells were treated with 20 μM and 40 μM of GGTI-298 or FTI-277, and the 
cytotoxic effects of these two inhibitors were compared with 10 μM simvastatin 
alone. The cell viability data showed that GGTI-298 was able to illicit cell loss; while 
FTI-277 showed no significant cell death effects in HCT116 cells (Figure 11A) 
(Crystal violet assay: 61.76 ± 4.13% cell viability with 40 μM GGTI-298, 85.72 ± 
0.04% with 40 μM FTI-277 vs. 33.28 ± 1.26% with 10 μM simvastatin alone; MTT 
assay: 56.93 ± 9.02% cell viability with 40 μM GGTI-298, 86.22 ± 0.36% with 40 
μM FTI-277 vs. 42.31 ± 2.47% with 10 μM simvastatin alone). Morphological 
examination as well as proteolytic processing of caspase-3 (Figure 11B, 11C) also 
supported the notion that GGTI-298-treated cells exhibited apoptotic hallmarks 
comparable to simvastatin treatment. These observations corroborated well with the 
findings that GGPP preincubation, but not FPP, largely protected cells from 
simvastatin treatment, confirming that protein geranylgeranylation is more important 





























Figure 11: GGTI-298 mimics the cytotoxic effects of simvastatin. 
HCT116 cells were treated with simvastatin, GGTI-298 or FTI-277 at indicated doses. (A) Cell 
viability of treated cells after 48 h was measured by (I) crystal violet assay or (II) MTT assay. The bars 
represent means ± s.e.m of three independent experiments. (B) Cell morphology after 28 h treatment 
was photographed using phase contrast microscope (Magnification: 100X). (C) Caspase-3 cleavage 
after 36 h of treatment was assessed by Western blot analysis. GAPDH was used as loading control. 
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2.2 Changes in expression, localization and activities of three geranylgeranylated 
proteins, namely RhoA, Rac1 and Cdc42, after simvastatin treatment  
Prenylation is a lipid modification that involves isoprenoids FPP and GGPP to 
transfer either a farnesyl (15-carbon) or a geranylgeranyl (20-carbon) group to the C-
terminus of proteins. This post-modification is essential for membrane localization 
and participation of proteins in various signaling pathways (Zhang and Casey 1996). 
Considering the ability of GGPP to prevent simvastatin-induced apoptosis in 
HCT116 cells, we speculated the possible involvement of geranylgeranylated 
proteins in mediating the cell death response. We focused on three 
geranylgeranylated Rho family proteins, RhoA, Rac1 and Cdc42, as their role in 
cancer progression have been widely studied (Vega and Ridley 2008). Several 
important properties of these proteins were assessed after simvastatin treatment, 
namely protein expression, cellular localization and enzymatic activities. 
 
2.2.1 Simvastatin dramatically increases protein levels of RhoA and Cdc42 via 
blocking protein geranylgeranylation  
HCT116 cells were treated with 10 μM simvastatin over the indicated time intervals 
(2-20 h). Interestingly, we observed a dramatic increase in protein expression of 
RhoA and Cdc42 after 12 h simvastatin treatment and the levels were sustained till 
the end of the time course. The expression of Rac1 was increased very mildly by 
simvastatin treatment (Figure 12A). This increased protein content of Rho proteins 
after simvastatin treatment was fully blocked when cells were preincubated with 
MVA and largely prevented with GGPP pretreatment, while FPP-preincubated cells 
showed comparable levels of Rho proteins with cells treated with simvastatin alone 
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(Figure 12B). The results suggest that simvastatin affects protein expression of Rho 
proteins via inhibiting the post-translational geranylgeranylation process. 
 





















Figure 12: Simvastatin drastically increases protein expression of RhoA and Cdc42 via blocking 
protein geranylgeranylation. 
(A) HCT116 cells were treated with 10 μM simvastatin for the indicated durations. (B) Cells were 
preincubated with or without 100 μM MVA, 10 μM GGPP or 10 μM FPP for 2 h before treatment with 
10 μM simvastatin for 20 h. In both panels, protein level of RhoA, Rac1 and Cdc42 was assessed by 
Western blot analysis. GAPDH was included as a loading control.  
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2.2.2 Simvastatin increases expression of unprenylated RhoA, Rac1 and Cdc42 
After assessing the levels of RhoA, Rac1 and Cdc42 in total cell lysates, we then 
studied the amount of Rho proteins in their prenylated and unprenylated forms. We 
hypothesized that simvastatin would increase Rho proteins in their unprenylated form 
as the isoprenoids required for this post-modification were deprived. To quantify Rho 
prenylation, we extracted cells in the low cloud-point detergent Triton X-114 (Brusca 
and Radolf 1994), which separates cell lysates into an aqueous and detergent phase 
based on the hydrophobicity of the respective proteins. Previous work has shown that 
unprenylated Ras and Rho family proteins partition into the aqueous phase, while 
prenylated proteins partition into the detergent phase (Bordier 1981; Allal, Favre et 
al. 2000). In the absence of simvastatin, RhoA and Cdc42 were largely in the 
detergent phase while the majority of Rac1 was found in the aqueous phase. Treating 
HCT116 cells with 10 μM simvastatin for 12 and 20 h caused a progressive and 
dramatic increase of RhoA and Cdc42 and to a lesser extent of Rac1, to partition into 
the aqueous phase, indicating effective inhibition of Rho prenylation (Figure 13). The 
lack of GAPDH in the detergent phase demonstrated a clear separation of proteins 
from aqueous phase with the detergent phase. These results demonstrate that 




Figure 13: Simvastatin treatment increases Rho proteins in their unprenylated form. 
HCT116 cells were treated with 10 μM simvastatin for 12 and 20 h. Cells were extracted in 1% Triton 
X-114, and total cell lysates were separated into an aqueous supernatant and a detergent-containing 
pellet. Aliquots of total cell lysate (WCL), aqueous phase (containing unprenylated proteins), and 
detergent phase (containing prenylated proteins) were assayed by Western blot analysis to check for 
RhoA, Rac1 and Cdc42 protein expression. GAPDH blot demonstrated no contamination of the 
detergent pellet with proteins from the aqueous phase. 
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2.2.3 Simvastatin delocalizes RhoA, Rac1 and Cdc42 from the lipid rafts and 
increases their expression in the cytosol 
Next, we studied the localization of these Rho proteins after simvastatin treatment 
with focus on two cellular locations: the lipid rafts and the cytosol. The lipid rafts are 
microdomains within the plasma membrane that are enriched with sphingolipids and 
cholesterol (Simons and Ikonen 1997; Anderson 1998; Brown and London 1998). 
Lipid rafts can be isolated by virtue of their detergent insolubility and characterized 
by the presence of bona fide raft-associated proteins, such as flotillin after 
ultracentrifugation in a sucrose gradient density (Waugh and Hsuan 2009). Studies 
have shown that Rho GTPases are found to be associated within the lipid rafts of the 
plasma membrane (Golub, Wacha et al. 2004). Without the post-modification of 
geranylgeranylation after simvastatin treatment, we would expect unprenylated 
RhoA, Rac1 and Cdc42 to delocalize from the lipid rafts and accumulate in the 
cytosol. To test this hypothesis, we assessed the levels of RhoA, Rac1 and Cdc42 in 
the isolated lipid raft fraction and cytosolic fraction. The lipid raft was separated 
using sucrose gradient density centrifugation studies as mentioned earlier. As 
expected, all three Rho proteins decreased from the flotilin-positive raft fractions 
after 12 and 20 h of simvastatin treatment (Fraction number 3-5). A clear increase of 
RhoA and Cdc42 were also observed in the non-raft fraction after 20h treatment 
(Fraction number 6) (Figure 14A). Meanwhile, cytosolic proteins were isolated with 
high-speed centrifugation; dramatic increase of cytosolic RhoA and Cdc42 and to a 
lesser extent of cytosolic Rac1 was observed after 12 and 20 h simvastatin treatment. 
The accumulation was fully reversed with MVA preincubation (Figure 14B). In 
agreement with literature, simvastatin-induced unprenylated RhoA, Rac1 and Cdc42 
























Figure 14: Rho proteins decrease from the lipid rafts and accumulate in the cytosol after 
simvastatin treatment. 
(A) HCT116 cells were treated with 10 μM simvastatin for 12 and 20 h. The lipid raft containing 
fractions were prepared using sucrose gradient centrifugation as described in Materials and Methods. 
Equal volume of lysates from Fraction number 2-6 was subjected to Western blot analysis to check for 
protein levels of RhoA, Rac1 and Cdc42. Flotilin was used as the lipid raft marker. (B) Cells were 
treated with 10 μM simvastatin alone for 12 and 20 h or preincubated with 100 μM MVA for 2 h prior 
to simvastatin treatment for 20 h. Cells were then lysed and centrifuged at high speed to obtain 
supernatant containing cytosolic proteins as described in Materials and Methods. Protein levels of 
RhoA, Rac1 and Cdc42 were assessed by Western blot analysis. SOD1 was used as cytosolic marker. 
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2.2.4 Simvastatin increases GTP-loading of RhoA, Rac1 and Cdc42 by 
downregulation of GGPP synthesis 
The post-translational modification of prenylation is also required for Rho proteins to 
interact with both their activators and inhibitors (Hori, Kikuchi et al. 1991), an 
increase in unprenylated RhoA, Rac1 and Cdc42 could either increase or decrease the 
amount of functionally active (GTP-bound) Rho GTPases present in HCT116 cells. 
Hence, we aimed to measure the amount of RhoA, Rac1 and Cdc42 in GTP-bound 
form using a pull-down assay. We utilized the protein binding domain (PBD) of p21-
activated kinase (PAK), a downstream effector protein of Rac1 and Cdc42, to 
selectively pull down the active form of Rac1 and Cdc42; while the Rho binding 
domain (RBD) of Rhotekin protein was used to specifically pull down the active 
RhoA from cell lysates. Strikingly, the level of GTP-bound RhoA, Rac1 and Cdc42 
was significantly increased after 12 and 20 h of simvastatin treatment (Figure 15A, 
16A, 17A). Interestingly, the increased GTP-loading of RhoA and Cdc42 following 
simvastatin treatment was observed together with an increase in the respective 
protein expression. Moreover, pretreatment of HCT116 cells with GGPP inhibited 
the increase in RhoA-GTP, Rac1-GTP and Cdc42-GTP; in contrast, FPP-
preincubated cells showed comparable level of GTP loading as cells treated with 
simvastatin alone (Figure 15B, 16B, 17B). The findings suggest that simvastatin-
mediated inhibition of geranylgeranylation leads to increase in the GTP-loading of 






















Figure 15: Simvastatin increases GTP loading of RhoA by blocking protein geranylgeranylation. 
(A) HCT116 cells were treated with 10 μM simvastatin for (I) 3, 6 and 20 h or (II) 12 and 20 h. (B) 
Cells were preincubated with 100 μM MVA, 10 μM GGPP or 10 μM FPP for 2 h before treated with 
10 μM simvastatin for 20 h. In both panels, cells were lysed, and GTP-loaded RhoA was isolated with 
Rhotekin RBD-agarose beads as described in Materials and Methods. Isolated complexes were 
separated by Western blot analysis and probed with anti-RhoA antibody. Cell lysates were probed in 























Figure 16: Simvastatin increases GTP loading of Rac1 by blocking protein geranylgeranylation. 
(A) HCT116 cells were treated with 10 μM simvastatin for (I) 3, 6 and 20 h or (II) 12 and 20 h. (B) 
Cells were preincubated with 10 μM GGPP or 10 μM FPP for 2 h before treated with 10 μM 
simvastatin for 20 h. In both panels, cells were lysed, and GTP-loaded Rac1 was isolated with PAK 
PBD-agarose beads. Isolated complexes were separated by Western blot analysis and probed with anti-

















Figure 17: Simvastatin increases GTP loading of Cdc42 by blocking protein geranylgeranylation. 
(A) HCT116 cells were treated with 10 μM simvastatin for 12 and 20 h. (B) Cells were preincubated 
with 10 μM GGPP or 10 μM FPP for 2 h before treated with 10 μM simvastatin for 20 h. Cells were 
lysed, and GTP-loaded Cdc42 was isolated with PAK PBD-agarose bead. Isolated complexes and 
whole cell lysates were separated by Western blot analysis and probed with anti-Cdc42 antibody. 
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2.3 Simvastatin activates RhoA and Rac1 to mediate its apoptotic effects 
2.3.1 Blocking Rac1 by pharmacological inhibitors and expression of dominant 
negative plasmid rescues cells from simvastatin-induced cell death 
Intrigued by the observation that simvastatin treatment increased GTP-loading of 
RhoA, Rac1 and Cdc42, we went further to evaluate if the activation of Rho GTPases 
was important in simvastatin-induced cell kill. We first assessed the involvement of 
Rac1-GTP, utilizing pharmacological inhibitors and dominant negative plasmid to 
block Rac1 activity. Two structurally unrelated Rac1 inhibitors NSC23766 and 
EHT1864 were used. NSC23766 effectively blocks Rac-specific guanine nucleotide 
exchange factors (GEFs) while EHT1864 directly binds to Rac, both inhibitors then 
block GTP-loading of Rac1 and impair Rac1-mediated functions (Gao, Dickerson et 
al. 2004; Onesto, Shutes et al. 2008). HCT116 cells were pretreated with or without 
150 μM NSC23766 or 20 μM EHT1864 before treatment with 10 μM simvastatin. 
Notably, both Rac1 inhibitors significantly protected cells from simvastatin treatment 
as assessed by crystal violet assay (Figure 18A) (54.06 ± 1.47% cell viability with 
NSC23766 pretreatment, p < 0.05; 70.24 ± 6.93% with EHT1864 pretreatment, p < 
0.05 vs. 33.28 ± 1.26% with 10 μM simvastatin alone). In addition, cells pretreated 
with both Rac1 inhibitors were visibly healthier and more attached to the culture dish 
(Figure 18B). Reduced formation of cleaved-PARP was also observed after 
preincubation with both inhibitors compared to cells treated with simvastatin alone, 
and more pronounced reduction was seen with EHT1864 compared to NSC23766 
pretreatment (Figure 18C).  
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Figure 18: Pharmacological inhibitors of Rac1 rescue cells from simvastatin-induced cell death. 
HCT116 cells were preincubated with or without 150 μM NSC23766 or 20 μM EHT1864 for 2 h 
before treated with 10 μM simvastatin. (A) Cell viability of treated cells after 48 h was measured by 
crystal violet assay. The bars represent means ± s.e.m of three independent experiments. *, p < 0.05 
compared with simvastatin treatment alone. (B) Cell morphology after 28 h treatment was 
photographed using phase contrast microscope (Magnification: 100X). (C) PARP cleavage was 
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To further verify the importance of Rac1-GTP in simvastatin-mediated apoptosis, 
HCT116 cells were transfected with empty vector (pIRES) or dominant negative 
Rac1N17 plasmid that does not allow for GDP-GTP exchange before simvastatin 
treatment. Successful transfection was confirmed by expression of myc-tag that was 
only expressed in Rac1N17-transfected cells. In addition, the exogenously transfected 
Rac1 also appeared as a higher band compared to the endogenous Rac1 detected at 
21 kDa (Figure 19A). Despite that the proportion of exogenously-introduced Rac1 
was much lower than the endogenous level, Rac1N17-transfected cells displayed less 
sensitivity compared to empty vector-transfected cells upon simvastatin treatment 
measured by crystal violet assay (Figure 19A) (47.26 ± 5.14% with Rac1N17 
transfection vs. 29.15 ± 1.51% with empty vector-transfected cells after 10 μM 
simvastatin treatment, p < 0.05). This observation was supported by reduced PARP 
cleavage in Rac1N17-transfected cells compared to empty vector control (Figure 
19B). Furthermore, long-term colony-forming assays confirmed that Rac1N17-
transfection endowed cells with pronounce long-term survival advantage against 
simvastatin-triggered cell death (Figure 19C). Taking together with the observation 
that Rac1 inhibitor preincubation reduces simvastatin-mediated cell death, we 





























Figure 19: Dominant negative Rac1N17 transfection partially protects cells from simvastatin 
treatment. 
HCT116 cells were transfected with either pIRES empty vector or Rac1N17 plasmid using Calcium 
phosphate method as described in Materials and Methods. (A) Western blot analysis showed 
successful expression of Rac1 and Myc-tag 30 h post-transfection (right). Transfected cells were 
treated with 10 μM simvastatin for 48 h and cell viability was measured by crystal violet assay (left). 
The bars represent means ± s.e.m of three independent experiments. *, p < 0.05 compared with empty 
vector control cells receiving 10 μM simvastatin. (B) PARP cleavage was assessed 36 h post-treatment 
by Western blot analysis. GAPDH was included as a loading control. (C) Photos of colonies formed by 
empty vector- or Rac1N17-transfected cells after simvastatin treatment.  
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2.3.2 Knockdown of RhoA and Rac1, but not Cdc42, protects cells from 
simvastatin’s cytotoxic effects 
After establishing the relevance of Rac1 activation in simvastatin-mediated apoptosis 
in HCT116 cells, we continued to ascertain the involvement of activation of RhoA 
and Cdc42 observed after simvastatin treatment. We suppressed the expression of 
these proteins with targeted RNA interference (RNAi) knockdown. Firstly, we 
confirmed knockdown of RhoA, Rac1 and Cdc42 with or without simvastatin 
treatment by Western blot analysis. Simvastatin increased RhoA and Cdc42 protein 
content and the protein level was fully abrogated by siRNA transfection; while a 
small amount of Rac1 was still detected after siRNA treatment. Then the effects of 
these knockdown strategies on cell viability were assessed by crystal violet assay 
(Figure 20B). Notably, RhoA and Rac1 knockdown significantly reduced 
simvastatin-induced viability loss, while knockdown of either alone did not 
appreciably impact cell death (52.77 ± 1.81% cell viability with siRhoA, 50.17 ± 
4.04% cell viability with siRac1, p < 0.05 vs. 31.22 ± 1.11% cell viability with siCtrl 
after 10 μM simvastatin treatment). Interestingly, we did not observe any protection 
when Cdc42 was knocked down. The data confirms the involvement of active Rac1 
in simvastatin-mediated apoptosis and implicates the possible role of RhoA 















Figure 20: Knockdown of RhoA and Rac1, but not Cdc42, partially protects the cells from 
simvastatin's cytotoxic effects. 
RhoA, Rac1 or Cdc42 were successfully knocked down in HCT116 using Calcium phosphate method 
as described in Materials and Methods before treatment with 5 or 10 μM simvastatin for 48 h. Cell 
viability was measured by crystal violet assay. The bars represent means ± s.e.m of three independent 





























2.3.4 Simvastatin activates RhoA and Rac1 by decreasing their association with 
the cytosolic inhibitor RhoGDIα  
After identifying that simvastatin-mediated apoptosis was a function of active RhoA 
and Rac1, we explored further to understand the possible mechanism for the observed 
increase in GTP-loading. Under basal conditions, GDP-bound Rho proteins are 
associated primarily with guanine nucleotide dissociation inhibitors (RhoGDIs); after 
cellular stimulation, they dissociate from RhoGDIs and allow for GDP-GTP 
exchange (Dovas and Couchman 2005). Hence, we assessed the respective 
interaction of RhoA and Rac1 with the ubiquitous-expressed RhoGDIα using 
coimmunoprecipitation studies. The results showed that the RhoA-RhoGDIα and 
Rac1-RhoGDIα interactions were significantly decreased in simvastatin-treated 
HCT116 cells compared to untreated control (Figure 21A). This finding was quite 
striking considering the large increase in total RhoA after simvastatin treatment. 
Nonetheless, the observations suggest that the decreased interaction of RhoA and 
Rac1 with their cytosolic inhibitor could be a potential mechanism for the increase in 
GTP-loading of both proteins. 
 
Furthermore, it has been identified that geranylgeranylation of Rho proteins is 
required for their interaction with RhoGDIs (Di-Poi, Faure et al. 2001). Hence, we 
hypothesized that the interaction of RhoA or Rac1 with RhoGDIα would be restored 
with MVA or GGPP preincubation, but not FPP preincubation. As expected, the 
interactions were largely restored in MVA- or GGPP-preincubated cells (Figure 
21B). The observation corroborated well with the finding that MVA or GGPP 
preincubation reduced simvastatin-mediated apoptosis (Figure 9). Collectively, these 
data suggest that simvastatin decreases the respective association of RhoA and Rac1 
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with RhoGDIα through inhibiting protein geranylgeranylation, which then leads to 












































Figure 21: Simvastatin decreases the respective association of RhoA and Rac1 with RhoGDIα by 
blocking protein geranylgeranylation. 
HCT116 cells were treated with (A) simvastatin alone; or (B) preincubated with 100 μM MVA, 10 μM 
GGPP or 10 μM FPP for 2 h before treated with 10 μM simvastatin for 20 h. In both panels, cells were 
lysed, and RhoGDIα-RhoA, RhoGDIα-Rac1 complexes were immunoprecipitated with anti-RhoGDIα 
antibodies. Isolated complexes were separated by Western blot analysis and probed with anti-RhoA 
and anti-Rac1 antibodies. Protein loading was evaluated by stripping the blots and reprobing with anti-
RhoGDIα antibodies. Cell lysates were probed in parallel to monitor total cellular RhoA, Rac1 and 
RhoGDIα levels. GAPDH was included as a loading control. 
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2.4 Inhibiting newly synthesized RhoA and Rac1 diminishes the increase in 
active RhoA and Rac1, and protects cells from simvastatin-induced apoptosis 
Because protein prenylation is a post-translational modification, inhibition of protein 
synthesis should prevent prenylation-dependent apoptosis induced by simvastatin. To 
test this hypothesis, we assessed the effects of protein synthesis inhibitor 
cycloheximide on simvastatin-treated HCT116 cells. Interestingly, cells pretreated 
with all concentrations of cycloheximide were insensitive to simvastatin treatment 
(Figure 22A). However, high doses of cycloheximide (20 μg/ml) were found to be 
toxic to cells, while concentrations below 10 μg/ml displayed growth statutory 
effects. Cells were then pretreated with non-toxic doses of cycloheximide at 1.25 and 
5 μg/ml and we observed diminished PARP cleavage in cycloheximide-pretreated 
cells compared to simvastatin treatment alone (Figure 22B), confirming that 
simvastatin-mediated apoptosis is dependent on the presence of newly translated 
proteins.  
 
Previously we have established the essential role of GTP-bound RhoA and Rac1 in 
simvastatin-induced apoptosis. To confirm that cycloheximide pretreatment protected 
cells from simvastatin by blocking the synthesis of RhoA and Rac1, we looked at the 
effects of cycloheximide on RhoA and Rac1 activities. Cells were pretreated with 5 
μg/ml cycloheximide before 10 μM simvastatin treatment. The results showed that 
cycloheximide alone had no effect on the GTP-loading of RhoA or Rac1, but it 
completely prevented simvastatin-induced accumulation of RhoA-GTP and Rac1-
GTP (Figure 22C). These observations provide an explanation for cycloheximide’s 
protective effects, and also suggest that the newly synthesized RhoA and Rac1 are 

























Figure 22: Cycloheximide protects cells from simvastatin-induced cell death via blocking the 
GTP-loading of RhoA and Rac1. 
(A) HCT116 cells were preincubated with or without various concentrations of cycloheximide for 1h 
before treating with 10 μM simvastatin for 48 h. Cell viability was measured by crystal violet assay. 
The bars represent means ± s.e.m of three independent experiments. *, p < 0.05 compared with 
simvastatin treatment alone. (B) PARP cleavage was assessed 36 h post-treatment by Western blot 
analysis. GAPDH was included as a loading control. (C) Cells were pretreated with or without 5 μg/ml 
cycloheximide for 1h before treating with 10 μM simvastatin for 20 h. The GTP-loading of (I) RhoA 


























2.5 Simvastatin increases protein levels of RhoA and Cdc42 via protein synthesis 
2.5.1 Simvastatin upregulates RhoA and Cdc42 protein expression via mRNA 
and protein synthesis 
Curious about how simvastatin upregulated protein expression of RhoA and Cdc42 in 
HCT116 cells, we went on to determine the mechanism for the changes in protein 
levels. We first checked if the accumulation of these proteins is due to de novo 
protein synthesis. Cells were incubated with cycloheximide prior to the addition of 
simvastatin. Cycloheximide completely prevented the simvastatin-induced increase 
in Rho protein, also observed in Figure 22C, indicating that the accumulation of 
RhoA and Cdc42 was due to newly synthesized protein (Figure 23A). Furthermore, 
treatment with actinomycin D, an inhibitor of gene transcription, dose-dependently 
ablated simvastatin-mediated increase in RhoA and Cdc42 protein expression (Figure 
23B). The results suggest that mRNA and protein synthesis are involved in 




















Figure 23: Simvastatin-induced upregulation of RhoA and Cdc42 protein expression is blocked 
by transcription and protein synthesis inhibitors. 
HCT116 cells were pretreated with or without (A) cycloheximide (CHX) or (B) actinomycin D (ActD) 
at indicated concentrations for 1 h, followed by treatment with 10 μM simvastatin for 20 h. Lysates 
from Day 0 was collected prior to the above triggers. Protein levels of RhoA and Cdc42 were assessed 
by Western blot analysis. GAPDH was included as a loading control.  
  
 105 
2.5.2 Simvastatin does not affect the protein degradation rate of RhoA and 
Cdc42 
Despite the clear involvement of de novo protein synthesis in the regulation of RhoA 
and Cdc42 protein expression, previous studies have also proposed that prenylation 
selectively target Rho proteins for proteasomal degradation. Hence, inhibition of 
prenylation by statins might slow the degradation process and result in the increased 
protein levels (Von Zee and Stubbs 2011). We therefore explored if simvastatin 
regulated the protein expression of RhoA and Cdc42 via affecting their degradation 
rate. HCT116 cells were pretreated with cycloheximide and harvested at different 
time points. The decrease of both RhoA and Cdc42 protein levels was observed after 
16 h in cells treated with or without simvastatin, indicating that protein degradation 
rate was not likely to be a factor in affecting RhoA and Cdc42 protein level (Figure 
24). Taken together, these data indicate that de novo protein synthesis is the main 










Figure 24: Simvastatin does not affect the protein degradation rate of RhoA and Cdc42. 
HCT116 cells were either treated with cycloheximide 5 μg/ml alone or preincubated with 
cycloheximide for 1 h before addition of 10 μM simvastatin for the indicated durations. The levels of 
RhoA and Cdc42 were assessed by Western blot analysis. GAPDH was included as a loading control. 
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3. Simvastatin induces superoxide production as an early signal to 
initiate cell death in HCT116 cells 
After establishing that simvastatin induces active RhoA and Rac1 to mediate the 
apoptotic process, we set out to identify potential downstream targets involved in our 
cell death model. Reactive oxygen species (ROS), particularly superoxide came 
under investigation for a couple of reasons. Firstly, previous reports from our lab and 
other research groups have provided evidence that intracellular ROS participate in 
early signaling for apoptotic execution. Secondly, several reports have suggested the 
role of oxidative stress in statin-induced apoptosis in cancer cells (Laezza, Fiorentino 
et al. 2008; Sanchez, Rodriguez et al. 2008; Qi, Kim et al. 2010). Most importantly, 
both active RhoA and Rac1 have been found to be associated with superoxide 
production by regulating the activation of superoxide generator nicotinamide adenine 
dinucleotide phosphate-oxidase (NADPH) complex (Babior 1999; Bokoch and 
Diebold 2002; Kim, Diebold et al. 2004). Hence, we asked if superoxide might play a 
role in mediating the signal from the activation of RhoA and Rac1 to apoptosis upon 
simvastatin treatment in HCT116 cells. 
 
3.1 Simvastatin increases superoxide level in a time-dependent manner. 
We first monitored intracellular superoxide level using lucigenin chemiluminiscence 
assay. Lucigenin, bis-N-methylacridiniumdinitrate, has been used extensively as a 
luminescent indicator of superoxide production. Luminescence occurs via reaction 
between superoxide and the reduced form of lucigenin (lucigenin cation radical 
LCU+) to form an unstable dioxetane, whose decomposition yields acridone to emit 
light (Liochev and Fridovich 1997). HCT116 cells were treated with simvastatin over 
different duration (3-24 h), and the superoxide level was compared to that in the 
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untreated cells (Figure 25A). The results showed significant and sustained increment 
of superoxide production from 4 h up to 24 h post-treatment (1.2 ± 0.14 fold increase 
after 6 h treatment, 1.51 ± 0.08 fold increase after 24 h treatment compared to 
untreated cell, p < 0.05). The level of superoxide was maintained at around 1.5 fold 
increase at 8, 16, 20 and 24 h post-treatment.   
 
A second technique was used to confirm the superoxide production after simvastatin 
treatment, namely the dihydroethidium (DHE) assay. The DHE dye permeates the 
cell membrane freely and reacts with superoxide anions to form a red fluorescent 
product that intercalates with DNA. This dye is specific to superoxide as it is less 
prone to oxidation by other ROS molecules (Robinson, Janes et al. 2006; Zielonka, 
Vasquez-Vivar et al. 2008). HCT116 cells were treated with simvastatin for 16, 20 
and 24 h (Figure 25B). The results showed significant increase in fluorescence at all 
three times points. Density plot of cells after 24 h simvastatin treatment was 
displayed as cell size against the florescence detected, and it showed a right shift of 
cell population, which represented the increase in superoxide production. In addition, 
both assays showed comparable fold increase in superoxide level after simvastatin 



























Figure 25: Simvastatin increases superoxide level in HCT116 cells. 
HCT116 cells were treated with 10 μM simvastatin for the indicated duration. Intracelluar superoxide 
level was assessed by (A) lucigenin chemiluminesence assay and (B) DHE assay as described in 
Materials & Methods. The level of superoxide was expressed as fold increase over untreated cells. 
Density plots after 24 h simvastatin treatment were displayed as cell size (FS Lin) against DHE 
fluorescence (PE-Texas Red). The bars represent means ± s.e.m of three independent experiments. *, p 
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3.2 Superoxide scavengers confer cells resistance to simvastatin-induced cell 
death 
After determining the ability of simvastatin to generate superoxide, the next logical 
question was whether the production of superoxide was integral in the execution of 
cell death. To do this, we utilized three superoxide scavengers to reduce superoxide 
level in the cells. Diphenyleneiodonium (DPI), a known flavoenzyme inhibitor, 
inhibits the assembly of the superoxide-generator NADPH oxidase complex; while 
tempol and tiron are mimetics of superoxide dismutase (SOD), the enzyme 
responsible for clearing superoxide by converting it into hydrogen peroxide. HCT116 
cells were preincubated with the scavenger for 2h before treatment with simvastatin. 
All three scavengers successfully abrogated simvastatin-induced superoxide 
production (Figure 26A). Remarkably, preincubation with all superoxide scavengers 
largely reduced simvastatin-induced apoptosis (Figure 26B) (79.12 ± 1.71% cell 
viability with DPI preincubation, 77.98 ± 5.67% cell viability with tempol 
preincubation, 78.84 ± 7.02% cell viability with tiron preincubation vs. 33.28 + 
1.26% with 10 μM simvastatin alone, p < 0.05). The rescue effects were also shown 
by morphological examination, where cell shrinkage observed in simvastatin-treated 
cells was reversed with preincubation with the scavengers (Figure 26C). In addition, 
we also observed that proteolytic processing of caspase-3 as well as the activity 
levels of caspase-3, -8, -9 were significantly reduced in superoxide scavenger-
pretreated cells compared to cells treated with simvastatin alone (Figure 26D, E).  All 
the observations support the notion that superoxide plays an essential role in 


















































































































Figure 26: Superoxide scavengers protect cells from simvastatin-mediated cell death. 
HCT116 cells were preincubated with or without 5 μM DPI, 2.5 mM tempol or 10 mM tiron for 2 h 
before treatment with 3 or 10 μM simvastatin. (A) Successful inhibition of superoxide production after 
24 h treatment was measured by lucigenin chemiluminesence assay. DPI/tempol/tiron-mediated rescue 
of cell death was assessed by (B) cell viability measured by crystal violet assay,(C) morphological 
examination after 28 h treatment with phase-contrast microscopy (Magnification: 100X). (D) (I) 
Proteolytic processing of caspase-3 and (II) Activities of caspase-3, -8 and -9 were assessed after 36 h 
of simvastatin treatment. The bars represent means ± s.e.m of three independent experiments. *, p < 





3.3 Simvastatin induces superoxide production involving GTP-bound RhoA and 
Rac1 
3.3.1 Simvastatin increases superoxide level by blocking protein 
geranylgeranylation  
In the earlier sessions, we have confirmed that simvastatin-induced apoptosis was 
dependent on protein geranylgeranylation. Stimulated by the identification of 
superoxide in the cell death mechanism, we were interested to find out the 
relationship between superoxide production and the geranylgeranylation process. 
Cells were preincubated with different isoprenylation precursors: MVA, GGPP or 
FPP before simvastatin treatment and superoxide level of treated cells were assessed 
by lucigenin chemiluminescence assay (Figure 27A). It was observed that the 
increased superoxide production by simvastatin alone was fully blocked in cells 
preincubated with MVA and GGPP; while FPP preincubation did not reduce 
superoxide level induced by simvastatin. Of note, preincubation with different 
compounds alone had no significant changes in superoxide level. To further confirm 
the involvement of geranylgeranylated proteins in inducing superoxide production 
after simvastatin treatment, we treated cells with GGTI-298 or FTI-277 (Figure 27B). 
In agreement with the rescuing effects of GGPP preincubation on superoxide level, 
GGTI-298 treatment increased superoxide production, but not FTI-277 (1.46 ± 0.21 
fold increase after simvastatin treatment, 1.36 ± 0.27 fold increase after GGTI-298 
treatment and 1.06 ± 0.01 fold increase after FTI-277 treatment compared to 
untreated cell). Our findings indicate that simvastatin-mediated superoxide 
























Figure 27: Simvastatin induces superoxide production via blockage of GGPP synthesis.  
(A) HCT116 cells were preincubated with or without 100 μM MVA, 10 μM GGPP or 10 μM FPP for 
2h before treatment with 10 μM simvastatin for 24 h; (B) Cells were treated with simvastatin, GGTI-
298 or FTI-277 at indicated doses for 24 h. In both panels, superoxide level was then assessed by 
lucigenin chemiluminesence assay. The bars represent means ± s.e.m from three independent 

















































































3.3.2 Blocking RhoA and Rac1 activities inhibits simvastatin-mediated 
superoxide production 
Since our data suggested that simvastatin induced superoxide production via blocking 
protein geranylgeranylation, we explored whether the earlier-identified RhoA and 
Rac1 activation was directly involved in superoxide production. To that end, we 
utilized multiple ways to block the activation of RhoA and Rac1 in HCT116 cells 
(the same tools used in the experiments of Figure 18-20) and monitored the 
superoxide level after simvastatin treatment. Pretreatment with Rac1 inhibitor 
NSC23766 significantly reduced superoxide level compared to cells treated with 
simvastatin alone (Figure 28A). In addition, introduction of dominant-negative Rac1 
plasmid Rac1N17 exerted the same reducing effects on the superoxide level (Figure 
28B). Rac1 inhibitor and Rac1N17 plasmid transfection alone reduced 10%-15% 
superoxide level compared to untreated cells. Transient knockdown of Rac1 or 
RhoA, but not Cdc42 also attenuated simvastatin-induced superoxide production 
(Figure 28C). These observations imply that simvastatin-mediated activation of 



























Figure 28: Blocking Rac1 and RhoA activation abrogates simvastatin-mediated superoxide 
production. 
(A) HCT116 cells were preincubated with or without 150 μM NSC23766 for 2 h before treatment with 
10 μM simvastatin; (B) Cells were transfected with either pIRES empty vector or Rac1N17 plasmid as 
previously described and confirmed in Figure 19A. (C) RhoA, Rac1 or Cdc42 were knocked down in 
HCT116 cells as previously described and confirmed in Figure 20A. In all panels, superoxide level 
was then assessed after 24 h of simvastatin treatment at 10 μM by lucigenin chemiluminesence assay. 
The bars represent means ± s.e.m from three independent experiments. *, p < 0.05 compared with 






















































































































3.3.3 Simvastatin-mediated superoxide production does not affect protein levels 
of Rho proteins 
The evidence provided so far indicates that simvastatin induces activation of RhoA 
and Rac1, which then activates the downstream superoxide generation and eventually 
leads to apoptosis. In this regard, there is evidence from prior studies for redox 
regulation of Rho GTPases (Mitchell, Hobbs et al. 2012). Hence, we were interested 
to determine whether simvastatin-induced superoxide production might regulate 
RhoA, Rac1 and Cdc42 in a feedback manner. Since we have shown that the Rho 
proteins activated upon simvastatin treatment were newly synthesized (Figure 22), 
we checked the protein levels of RhoA, Rac1 and Cdc42 after preincubation with 
superoxide scavenger DPI or tempol followed by simvastatin treatment. The results 
showed that both DPI and tempol pretreatment did not modulate Rho protein 
expression after simvastatin treatment (Figure 29). The findings suggest that 
simvastatin-induced superoxide production is downstream of the activation of Rho 














Figure 29: Superoxide scavengers do not affect Rho protein expressions after simvastatin 
treatment. 
HCT116 cells were preincubated with or without 5 μM DPI or 2.5 mM tempol for 2 h before treating 
with 10 μM simvastatin for 24 h, protein levels of RhoA, Rac1 and Cdc42 were assessed by Western 




4. Simvastatin activates stress response JNK pathway to mediate the 
cell death response in HCT116 cells 
To identify the signaling pathways that hold a role in simvastatin-induced apoptosis, 
we then evaluated the potential involvement of MAPKs (mitogen-activated protein 
kinases) and AKT signaling cascades. These signaling pathways are activated 
through phosphorylation of the kinases on specific residues and they mediate the 
effects of a wide array of biological processes, such as cellular proliferation, 
differentiation, cell survival and cell death (Seger and Krebs 1995; Kennedy, Wagner 
et al. 1997). More importantly, growing evidence is suggesting that both Rho 
GTPases and ROS are potent regulators of MAPKs and AKT pathways (Hall 2005; 
Kamata, Honda et al. 2005; Clerkin, Naughton et al. 2008). Hence, we set out to 
identify if one or more of these signaling pathways were affected and responsible for 
the apoptotic response following simvastatin treatment.    
 
4.1 Simvastatin activates JNK signaling by blocking protein geranylgeranylation  
HCT116 cells were treated with 10 μM simvastatin for the indicated duration. The 
phosphorylation status of MAPK family members ERK and JNK, as well as survival 
pathway AKT was assessed by Western blot analysis. Dephosphorylation of AKT 
and ERK (p42 and p44) started from 6 h and became more obvious and sustained 
from 9 to 18 h post-treatment. On the contrary, stress-activated JNK signaling was 
upregulated after simvastatin treatment, which was shown by the increased and 
sustained phosphorylation of JNK (p54 and p46) at both Thr183 and Tyr185 residues 






Figure 30: Simvastatin dephosphorylates AKT and ERK but induces JNK phosphorylation. 
HCT116 cells were treated with 3 or 10 μM simvastatin for the indicated duration. The phosphorylated 
and total protein levels of AKT, ERK and JNK were assessed by Western blot analysis. GAPDH was 
included as a loading control.  
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To assess the involvement of these kinases in our model, we first studied if the 
phosphorylation or dephosphorylation effects after simvastatin treatment were 
downstream of the geranylgeranylation process. Cells were incubated with different 
isoprenylation precursors: MVA, GGPP or FPP, before treatment with simvastatin. 
Although MVA preincubation fully reversed the dephosphorylation of AKT and 
ERK upon simvastatin treatment, neither GGPP nor FPP preincubation had any effect 
on simvastatin-induced dephosphorylation process (Figure 31A), suggesting that 
simvastatin’s effects on AKT or ERK might not be of primary importance in the cell 
death response that is identified to be dependent on protein geranylgeranylation. 
Interestingly, JNK pathway stood out as a potential downstream target, where 
phosphorylation of JNK was fully blocked with MVA preincubation and largely 
prevented with GGPP pretreatment, while FPP preincubation did not reduce 
simvastatin-induced JNK phosphorylation (Figure 31B). Furthermore, JNK 
phosphorylation was also observed in cells treated with GGTI-298, which 
specifically blocks protein geranylgeranylation, but not in cells with FTI-277 
treatment. These observations suggest that JNK signaling pathway might be involved 




























Figure 31: Simvastatin activates JNK pathway via blocking protein geranylgeranylation. 
(A) HCT116 cells were preincubated with or without 100 μM MVA, 10 μM GGPP or 10 μM FPP for 2 
h before treatment with 10 μM simvastatin for 24 h, phosphorylated and total protein levels of (I) AKT, 
ERK and (II) JNK were assessed by Western blot analysis. (B) Cells were treated with simvastatin, 
GGTI-298 or FTI-277 alone at indicated doses for 24 h. Phospho-JNK level was assessed by Western 
blot analysis. GAPDH was included as a loading control. 
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4.2 JNK inhibitor SP600125 rescues simvastatin-induced cell death phenotype  
To confirm the functional relevance of JNK activation in our model, we performed 
experiments to effectively block JNK activation with the use of pharmacological 
inhibitor SP600125, a competitive inhibitor of ATP binding to JNK kinase (Bennett, 
Sasaki et al. 2001). Successful inhibition of the JNK signaling was shown as the 
decreased phosphorylation of its downstream effector c-Jun (Figure 32A). 
Remarkably, pretreatment with SP600125 reversed cell death phenotype induced by 
simvastatin in HCT116 cells to a large extent measured by crystal violet assay 
(Figure 32B) (61.23 ± 2.3% cell viability with SP600125 preincubation vs. 33.28 ± 
1.26% with 10 μM simvastatin alone, p < 0.05). In addition, morphological 
examination also revealed that SP600125 preincubation restored normal morphology 
to cells akin to untreated control (Figure 32C). The observation was further 
confirmed in long-term clonogenic assay, where SP600125 pretreatment exerted 
cytoprotective effect in simvastatin-treated cells (Figure 32D). All these observations 








































Figure 32: JNK inhibitor SP600125 partially rescues cells from simvastatin-induced cell death. 
HCT116 cells were preincubated with or without SP600125 at indicated doses for 2 h before treatment 
with 10 μM simvastatin. (A) Successful inhibition of JNK signaling was confirmed by downregulation 
of phospho-c-Jun levels shown by Western blot analysis. β-actin was included as a loading control. 
(B) Cell viability after 48 h simvastatin treatment was measured by crystal violet assay. The bars 
represent means ± s.e.m from three independent experiments. *, p < 0.05 compared with simvastatin 
treatment alone. (C) Cell morphology aft 28 h treatment was examined with phase-contrast 
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4.3 Simvastatin-mediated JNK activation is downstream of RhoA and Rac1 
activation and superoxide production 
Having shown earlier that JNK was robustly activated by simvastatin and it was a 
critical signal for apoptosis, an important question been whether the activation of 
JNK was linked to simvastatin-induced activation of RhoA and Rac1 and increased 
superoxide production in any way. Hence, we first checked the status of JNK 
phosphorylation after blockade of RhoA and Rac1 activities or superoxide production. 
Then we assessed the impact of inhibiting JNK signaling on the status of Rho 
GTPases and superoxide production.  
 
4.3.1 Blocking RhoA and Rac1 activities prevents simvastatin-induced JNK 
activation 
To assess the relevance of simvastatin-induced JNK activation to the activation of 
RhoA and Rac1, we utilized aforementioned ways (pharmacological inhibition of 
Rac1, expression of dominant negative Rac1N17, and gene silencing of RhoA or 
Rac1) to inhibit RhoA or Rac1 activity and studied their effects on JNK 
phosphorylation on both Thr183 and Tyr185 residues. As shown in Figure 33, 
pretreatment with Rac1 inhibitors NSC23766 and EHT 1864 and silencing of RhoA 
almost fully inhibited JNK phosphorylation upon simvastatin treatment (Figure 33A, 
B). Although cells transfected with exogenously-introduced dominant negative Rac1 
mutant and Rac1 knockdown did not show as prominent reduction in phosphorylated 
JNK as compared to other methods, the discrepancy was probably due to the 
relatively low transfection efficiency seen in Figure 19A and 20. Overall, these 


























Figure 33: Blocking RhoA and Rac1 activation downregulates JNK activation after simvastatin 
treatment. 
(A) HCT116 cells were preincubated with or without (I) 150 μM NSC23766 or (II) 20 μM EHT1864 
for 2 h before simvastatin treatment; (B) Cells were transfected with either pIRES empty vector or 
Rac1N17 plasmid as previously described and confirmed in Figure 19A. (C) RhoA or Rac1 were 
knocked down in HCT116 cells as previously described and confirmed in Figure 20A. In all panels, 
phospho-JNK level after treatment with 10 μM simvastatin for 24 h was assessed by Western blot 
analysis. GAPDH was included as a loading control.  
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4.3.2 Inhibiting superoxide production prevents simvastatin-mediated JNK 
activation 
After establishing that simvastatin-induced JNK activation was a downstream target 
of active RhoA and Rac1, we then set out to study the link between JNK 
phosphorylation and superoxide production after simvastatin treatment. HCT116 
cells were preincubated with superoxide scavengers DPI, tempol or tiron before 
simvastatin treatment, and the ability of these scavengers to block JNK activation 
was assessed. Western blot results revealed that all three scavengers significantly 
reduced JNK phosphorylation on both Thr183 and Tyr185 residues (Figure 34). The 
observation suggests that JNK activation is likely to be downstream of superoxide 














Figure 34: Superoxide scavengers inhibit simvastatin-mediated JNK activation. 
HCT116 cells were preincubated with or without (A) 5 μM DPI or (B) 2.5 mM tempol or 10 mM tiron 
for 2 h before treating with 10 μM simvastatin for 24 h. Phospho-JNK protein expression was assessed 
by Western blot analysis. GAPDH was included as a loading control.  
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4.3.3 Inhibiting JNK signaling did not affect simvastatin-induced changes in 
Rho protein expression and superoxide level 
Having demonstrated that simvastatin activated JNK signaling to mediate the 
apoptotic response, and identified that JNK activation was downstream of RhoA and 
Rac1 activation and superoxide production, we then checked the effects of JNK 
signaling on Rho status and superoxide production upon simvastatin treatment. Cells 
were pretreated with SP600125 to inhibit JNK signaling as previously shown in 
Figure 32. This pretreatment did not have any impacts on the protein levels of RhoA, 
Rac1 and Cdc42 upon simvastatin treatment (Figure 35A). In addition, inhibiting 
JNK signaling did not affect the increase in intracellular superoxide level induced by 
simvastatin (Figure 35B). In summary, the studies indicate that simvastatin-mediated 
JNK signaling is a downstream event of RhoA and Rac1 activation and superoxide 























Figure 35: JNK inhibitor does not affect simvastatin-mediated upregulation of Rho proteins and 
superoxide production. 
HCT116 cells were preincubated with or without 10 μM SP600125 for 2 h before treatment with 10 
μM simvastatin for 24 h. (A) The levels of RhoA, Rac1 and Cdc42 were assessed by Western blot 
analysis. GAPDH was included as a loading control. (B) Superoxide level was assessed by lucigenin 
chemiluminesence assay. The bars represent means ± s.e.m from three independent experiments. 
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5. Simvastatin upregulates the expression of pro-apoptotic Bcl-2 
family member Bim-EL to induce apoptosis 
The identification of JNK pathway as a key signaling component in mediating 
simvastatin’s apoptotic response has prompted us to identify its potential downstream 
effectors in HCT116 cells. JNK has been identified to promote mitochondria-
mediated apoptosis by transcriptional upregulation of pro-apoptotic genes or by 
directly affecting the activities of mitochondrial pro- and anti-apoptotic proteins 
through distinct phosphorylation events (Dhanasekaran and Reddy 2008). One group 
of the proteins regulated by JNK is the Bcl-2 family members, whose role in the 
initiation of mitochondrial apoptotic pathway is well established (Gross, McDonnell 
et al. 1999). Hence, we continued to explore the potential involvement of Bcl-2 
family members in our cell death model.  
 
5.1 Simvastatin upregulates protein level of Bim-EL 
The impact of simvastatin treatment on the protein levels of selected Bcl-2 family 
members, namely, Bcl-xL, an anti-apoptotic protein; and Bim and Bid, BH-3 only 
members which can directly and indirectly activates Bax (Czabotar, Colman et al. 
2009) were assessed. Two other BH-3 only members, PUMA and NOXA, were not 
studied as we established earlier that the cell death was independent of p53 (Figure 8), 
and these members are found to be critical mediators of p53-dependent apoptosis (Yu 
and Zhang 2005). HCT116 cells were treated with 10 μM simvastatin for varying 
duration. Western blot analysis showed that simvastatin did not affect protein levels 
of Bcl-xL and Bid. No signs of cleaved-Bid (t-Bid) at 15 kDa were observed after 
simvastatin treatment. Interestingly, simvastatin increased protein expression of pro-
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apoptotic protein Bim, in its extra long form (Bim-EL). This upregulation was 













Figure 36: Simvastatin increases Bim-EL expression. 
HCT116 cells were treated with 10 μM simvastatin for the indicated duration. Bcl-xL, Bid and extra-




5.2 Knockdown of Bim-EL protects cells from simvastatin-induced apoptosis 
To ascertain if simvastatin-mediated apoptosis was a function of increased Bim-EL 
protein expression, we suppressed the expression of this protein with RNAi 
knockdown. Firstly, we confirmed successful knockdown of Bim-EL with one single 
siRNA sequence (siBim#0) assessed by Western blot analysis. Then the effects on 
cell viability were illustrated by crystal violet assay (Figure 37A). Notably, Bim-EL 
knockdown significantly rescued cells from simvastatin-induced viability loss (66.58 
± 6.63% cell viability with siBim#0 vs.32.6 ± 1.57% with siCtrl after 10 μM 
simvastatin treatment, p < 0.05). We then extended our study from one single siRNA 
sequence (siBim#0) to another three independent siBim sequences (siBim#1, #2, #3). 
All three sequences were able to fully abolish simvastatin-induced increase in Bim-
EL protein level. Corroborating well with the cell viability data, the extent of 
caspase-3 and PARP cleavage was greatly reduced in cells knocked down with Bim-
EL compared to cells transfected with scrambled siRNA (siCtrl) after simvastatin 




























Figure 37: Knockdown of Bim-EL partially reduces simvastatin-mediated cell death. 
(A) Bim-EL was successfully knocked down in HCT116 using single siRNA sequence (siBim#0) 
before treatment with 10 μM simvastatin for 48 h. Cell viability was measured by crystal violet assay. 
The bars represent means ± s.e.m of three independent experiments. *, p < 0.05 compared with siCtrl-
transfected control cells receiving simvastatin treatment. (B) Bim-EL was knocked down using 
another three independent sequences (siBim#1, 2, 3) before simvastatin treatment for 36 h; Caspase-3, 
PARP and Bim-EL level were assessed by Western blot analysis. In both panels, β-actin or GAPDH 
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5.3 Simvastatin increases Bim-EL protein expression downstream of the 
RhoA/Rac1-Superoxide-JNK signaling cascade 
After confirming that Bim-EL was an important target in simvastatin-mediated 
apoptosis, we continued to investigate the relationship of Bim-EL upregulation in 
relevance to the previously identified RhoA/Rac1-superoxide-JNK signaling cascade. 
We employed a bidirectional approach where we first checked Bim-EL protein level 
after blockage of RhoA, Rac1, superoxide production or JNK activation; then we 
studied the effects of Bim-EL gene silencing on the status of Rho, JNK and 
superoxide production.   
 
5.3.1 Simvastatin upregulates Bim-EL via blocking protein geranylgeranylation  
Firstly, we studied the effects of protein geranylgeranylation on simvastatin-induced 
Bim-EL upregulation. Cells were preincubated with MVA, GGPP or FPP before 
simvastatin treatment; Western blot analysis revealed that Bim-EL upregulation was 
fully blocked with MVA and GGPP preincubation, while FPP preincubation had 
comparable Bim-EL level with cells treated with simvastatin alone (Figure 38A). The 
finding was further supported by the observation that GGTI-298 alone increased 
Bim-EL expression, but not FTI-277 treatment (Figure 38B). The results suggest that 
protein geranylgeranylation is an upstream event of simvastatin-induced Bim-EL 
upregulation.  
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Figure 38: Simvastatin mediates Bim-EL upregulation via blocking protein geranylgeranlyation. 
HCT116 cells were either (A) preincubated with or without 100 μM MVA, 10 μM GGPP or 10 μM 
FPP for 2 h before treatment with 10 μM simvastatin for 24 h; (B) Cells were treated with simvastatin, 
GGTI-298 or FTI-277 alone at indicated doses for 24 h. In both panels, Bim-EL protein expression 




5.3.2 Blocking RhoA and Rac1 activites prevents Bim-EL upregulation by 
simvastatin 
Subsequently, we looked at the effects of increased GTP-loading of RhoA or Rac1 on 
the Bim-EL status after simvastatin treatment. As shown in Figure 39, inhibiting 
Rac1 activity using inhibitor NSC23766 and EHT1864 (Figure 39A), dominant 
negative mutant transfection (Rac1N17) or gene silencing significantly reduced Bim-
EL level upon simvastatin treatment. Similar result was observed in cells knocked 
down of RhoA (Figure 39C). Our findings support that active RhoA and Rac1 are 
upstream signals for simvastatin-mediated Bim-EL upregulation. Considering that 
Bim-EL is a known pro-apoptotic Bcl-2 family member, the ability to reduce Bim-EL 
level with RhoA and Rac1 inhibition corroborates with the previous finding that 






























Figure 39: Blocking RhoA and Rac1 activities abrogates simvastatin-induced Bim-EL 
upregulation. 
(A) HCT116 cells were preincubated with or without (I) 150 μM NSC23766 or (II) 20 μM EHT1864 
for 2 h before simvastatin treatment; (B) HCT116 cells were transfected with either pIRES empty 
vector or Rac1N17 plasmid as previously described and confirmed in Figure 19A. (C) RhoA, Rac1 or 
Cdc42 were knocked down in HCT116 cells as previously described and confirmed in Figure 20A. In 
all panels, Bim-EL level after treatment with 10 μM simvastatin for 24 h was assessed by Western blot 
analysis. GAPDH was included as a loading control.  
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5.3.3 Blocking superoxide production abrogates simvastatin-mediated Bim-EL 
upregulation 
Next, to explore the link between Bim-EL expression and superoxide production in 
simvastatin-treated HCT116 cells, cells were preincubated with superoxide 
scavengers: DPI, tempol and tiron before simvastatin treatment. Western blot results 
showed that the protein level of Bim-EL in cells pretreated with superoxide 
scavengers was significantly reduced compared to that in cells treated with 
simvastatin alone (Figure 40). It suggests that superoxide production is likely to be an 













Figure 40: Superoxide scavengers block simvastatin-induced Bim-EL upregulation. 
HCT116 cells were preincubated with or without (A) 5 μM DPI or (B) 2.5 mM tempol or 10 mM tiron 
for 2 h before treatment with 3 or 10 μM simvastatin for 24h. Bim-EL protein expression was assessed 
by Western blot analysis. β-actin was included as a loading control.  
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5.3.4 Simvastatin-induced increase in Bim-EL is downstream of JNK activation 
Thereafter, we looked at the relationship between JNK activation and Bim-EL 
upregulation in simvastatin-treated HCT116 cells. Cells were pretreated with 
SP600125 to block JNK signaling before simvastatin treatment. As shown in Figure 
41, SP600125 significantly blocked simvastatin-induced Bim-EL expression, putting 








Figure 41: JNK inhibitor SP600125 prevents Bim-EL upregulation upon simvastatin treatment. 
HCT116 cells were pretreated with 10 μM SP600125 for 2 h before treating with 3 or 10 μM 
simvastatin for 24 h. Bim-EL protein expression was assessed by Western blot analysis. β-actin was 
included as a loading control. 
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5.3.5 Bim-EL silencing did not affect Rho protein expression, superoxide level 
and JNK activation after simvastatin treatment 
Lastly, previous results suggested that simvastatin-mediated Bim-EL was the 
downstream event of the previously established RhoA/Rac1-superoxide-JNK 
signaling cascade in HCT116 cells. To elucidate if there was any feedback 
mechanism from Bim-EL upregulation, we studied the effects of Bim-EL knockdown 
on Rho proteins, superoxide production and JNK phosphorylation in response to 
simvastatin treatment. HCT116 cells were transfected with Bim-EL siRNA followed 
by simvastatin treatment, and the protein expression of RhoA, Rac1, Cdc42 and 
phospho-JNK were assessed by Western blot analysis, while superoxide level was 
assessed by lucigenin chemiluminiscence assay. As shown in Figure 42, successful 
knockdown of Bim-EL did not affect RhoA, Rac1 and Cdc42 protein levels upon 
simvastatin exposure (Figure 42A). In addition, the increase in superoxide production 
(Figure 42B) and JNK phosphorylation (Figure 42C) were also observed in cells 
knocked-down with Bim-EL following simvastatin treatment. These observations 
demonstrate that Bim-EL is the bona fide downstream target of RhoA/Rac1-






























Figure 42: Knockdown of Bim-EL does not affect the protein expression of Rho, superoxide 
production and JNK activation. 
Bim-EL was knocked down in HCT116 cells using different siRNA sequences before treatment with 
10 μM simvastatin for 24 h. (A) The levels of RhoA, Rac1, Cdc42 and (C) phospho-JNK level was 
assessed by Western blot analysis. GAPDH was included as a loading control. (B) Superoxide level 
was assessed by lucigenin chemiluminesence assay. The bars represent means ± s.e.m of three 
independent experiments. 
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5.4 Simvastatin-induced Bim-EL upregulation is observed in HCT116 Bax-/- 
cells 
So far, we established that Bim-EL was the downstream signaling component in our 
cell death model; however, how Bim-EL led to the activation of the intrinsic pathway 
remained unanswered. In the literature, Bim was identified to be able to directly 
activate Bax or act indirectly by antagonizing the pro-survival Bcl-2 proteins, thereby 
allowing Bax activation to proceed, a key step for apoptosis (Czabotar, Colman et al. 
2009). Hence, in our model, we hypothesized that Bim-EL upregulation should be 
upstream of Bax signaling in response to simvastatin treatment. Both HCT116 WT 
and Bax-/- cells were treated with 10 μM simvastatin for 6, 24 and 32 h, and we 
observed comparable level of Bim-EL content in both cell lines after 24 and 32 h of 
simvastatin treatment (Figure 43). The data suggests that simvastatin-mediated 
upregulation of Bim-EL is an upstream event of Bax signaling, which eventually 
leads to cell death. 
 
Figure 43: Simvastatin-induced Bim-EL upregulation is upstream of Bax signaling. 
Both HCT116 WT and Bax-/- cells were treated with 10 μM simvastatin for the indicated duration. 
Bim-EL was detected by Western blot analysis. β-actin was included as a loading control.  
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5.5 Simvastatin increases Bim-EL level via protein synthesis 
5.5.1 Simvastatin upregulates Bim-EL content via mRNA and protein synthesis 
To understand the biology of how simvastatin upregulated Bim-EL protein 
expression in HCT116 cells, we first looked at the possible involvement of mRNA 
and protein synthesis. Inhibiting de novo protein synthesis with cycloheximide 
blocked simvastatin-dependent increase in Bim-EL protein expression (Figure 44A). 
In addition, treatment with actinomycin D, an inhibitor of gene transcription, ablated 
simvastatin-dependent increase in Bim-EL expression (Figure 44B). The results 
suggest that mRNA and protein synthesis are involved in the increased Bim-EL level 






















Figure 44: Simvastatin-mediated upregulation of Bim-EL protein level is blocked by 
transcription and protein synthesis inhibitors. 
HCT116 cells were pretreated with or without various doses of (A) cycloheximide or (B) actinomycin 
D for 1 h, followed by treatment with 10 μM simvastatin for 24 h. Bim-EL protein level was assessed 




5.5.2 Simvastatin does not affect the protein degradation rate of Bim-EL 
Besides mRNA and protein synthesis, protein degradation can also impact the 
changes in protein level. Similar to Figure 24, we conducted half-life studies using 
cycloheximide to see if simvastatin treatment affected the protein degradation rate of 
Bim-EL. HCT116 cells were pretreated with cycloheximide alone and cell lysates 
were collected at different intervals, decrease of Bim-EL protein level was observed 
after 16 h. In the presence of both cycloheximide and simvastatin, Bim-EL was 
shown to start decreasing at 16 h as well (Figure 45), suggesting that simvastatin 
treatment is not likely to affect the stability of Bim-EL, instead the de novo protein 









Figure 45: Simvastatin does not affect the protein degradation rate of Bim-EL. 
HCT116 cells were either treated with 5μg/ml cycloheximide alone or preincubated with 
cycloheximide for 1h before addition of 10 μM simvastatin for the indicated durations. The levels of 










6 Simvastatin’s cytotoxic effects is conserved in many cancer types 
6.1 Simvastatin induces cell death in other cancer cells by inhibiting protein 
geranylgeranylation  
Not restricting ourselves to only one cancer model, we extended the studies of 
simvastatin-mediated anti-tumor property in four other cancer cell lines, which 
include another colorectal cancer cell line RKO, non-small lung cancer cell line 
A549, neuroblastoma cancer cell line SHEP-1 and breast cancer cell line MDA-MB-
231. Cells were treated with increasing doses of simvastatin (0-30 μM) for 24 or 48 
h. Resultant loss of cell viability was assessed by crystal violet assay (Figure 46A). 
Dose-dependent reduction of cell viability was achieved after 24 h treatment for 
A549, SHEP-1 and MDA-MB-231 cells and 48 h for RKO cells. For all cell lines, 10 
μM simvastatin induced about 50% cell loss. The preliminary data suggest that 
simvastatin’s cytotoxic effect is a general phenomenon in different cancer types.   
 
We then went on to determine if simvastatin’s cytotoxic effect observed in other 
cancer cell lines was an effect of inhibition of protein geranylgeranylation. Cells were 
incubated with simvastatin in the presence or absence of MVA, GGPP or FPP. 
Remarkably, similar to HCT116 cells, pretreatment with MVA and GGPP, but not 
FPP, largely reversed cell death phenotype induced by simvastatin in RKO, A549, 
SHEP-1 and MDA-MB-231 cells (Figure 46B). The observations suggest that protein 
geranylgeranylation is the more important post-translational modification in 
mediating simvastatin’s cytotoxic effects across different cancer cell lines.  
 145 
A-I                                                                                    II    
 









































Figure 46: Simvastatin effectively reduces cell viability of other cancer cell lines via blocking 
protein geranylgeranylation. 
Four other cancer cell lines: (I) RKO, (II) A549, (III) MDA-MB-231 and (IV) SHEP-1 cells were (A) 
treated with various concentrations of simvastatin (0-30 μM) for 24 or 48 h, or preincubated with 100 
μM MVA, 10 μM GGPP or 10 μM FPP for 2 h before treatment with 10 μM simvastatin for 24 or 48 h. 
In all panels, cell viability was measured by crystal violet assay. In all panels, cell viability was 
expressed as % of untreated control. Data are shown as means ± s.d. of two independent experiments.  
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6.2 Simvastatin induces apoptosis in SHEP-1 cells via Rac1-Superoxide-JNK 
signaling cascade  
After establishing that simvastatin induced cell death in multiple cancer types via 
blocking protein geranylgeranylation, we were interested to check if the novel 
signaling cascade (RhoA/Rac1-Superoxide-JNK-Bim-EL) identified in HCT116 cells 
could be extended to other cancer cell lines as well. Hence, to provide evidence that 
this novel mechanism is not a HCT116 cell line-exclusive effect, we continued to 
study the role of these main players in simvastatin-induced cell death of SHEP-1 
neuroblastoma cells. 
  
6.2.1 Simvastatin induces apoptosis in SHEP-1 cells 
Firstly, to have a better understanding on the mode of cell death, we checked the 
status of caspase-3 and PARP cleavage in SHEP-1 cells after simvastatin treatment. 
Western blot results revealed a clear increase in the cleaved form of caspase-3 as well 
as its downstream substrate PARP. In addition, the observed cleavage of both 
proteins was fully inhibited in MVA- and GGPP-, but not FPP-preincubated cells 
(Figure 47). The protective effects of MVA and GGPP preincubation were consistent 
with the cell viability data shown in Figure 46 B-III. Furthermore, we also observed 
upregulation of Bim-EL following simvastatin treatment that was fully reversed by 
MVA and GGPP pretreatment. The upregulation of caspase signaling and Bim-EL in 
SHEP-1 cells indicates that apoptosis is likely to be the main mode of cell death 













Figure 47: Simvastatin treatment upregulates Bim-EL and activates caspase signaling in SHEP-1 
cells via inhibiting protein geranylgeranylation. 
SHEP-1 cells were preincubated with or without 100 μM MVA, 10 μM GGPP or 10 μM FPP or 2 h 
before treatment with 10 μM simvastatin. Protein level of Bim-EL, caspase-3 and PARP cleavage after 
20 h treatment was assessed by Western blot analysis. GAPDH was included as a loading control. (n.s. 
means non-specific band). 
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6.2.2 Simvastatin increases GTP-loading of Rac1, which is responsible for the 
cell death phenotype 
In HCT116 cells, we identified active Rho GTPases as downstream targets of protein 
geranylgeranylation to mediate simvastatin’s apoptotic effects. Hence, we studied the 
GTP-loading status of Rac1 and its potential involvement in the cell death signaling 
in SHEP-1 cells. Using PAK-pulldown assay, we measured GTP-bound Rac1 in the 
cell lysates. Interestingly, we also observed an increase in GTP-bound Rac1 in 
SHEP-1 cells. And the increment was observed as early as 3 h post-treatment and 
lasted even after 20 h simvastatin treatment (Figure 48A).  
 
Then we continued to explore if inhibition of Rac1 activity would have any effects on 
simvastatin-induced cell death in SHEP-1 cells. Rac1 inhibitor NSC23766 was used 
to block Rac1 activity. Western blot results showed reduced PARP cleavage in cells 
pretreated with NSC23766 before addition of simvastatin as compared to cells treated 
with simvastatin alone (Figure 48B). The findings suggest that activation of Rac1 is 
involved in mediating the apoptotic effects of simvastatin in SHEP-1 cells; it also 
provides evidence that simvastatin’s ability to activate Rho GTPases is not a 















Figure 48: Simvastatin-mediated Rac1 activation is responsible for cell death in SHEP-1 cells. 
(A) SHEP-1 cells were treated with 10 μM simvastatin for 3, 6 and 20 h, GTP-loading of Rac1was 
prepared as described in Figure 15 and 16 and assessed by Western blot analysis. (B) Cells were 
pretreated with 100 μM NSC23766 for 2 h before treatment with 10 μM simvastatin for 20 h. PARP 




6.2.3 Simvastatin increases superoxide production downstream of Rac1 
activation to mediate the apoptotic response 
After confirming that simvastatin-mediated Rac1 activation was involved in the cell 
death signaling in both HCT116 and SHEP-1 cells, we continued to study the next 
molecule of interest, superoxide, which was found to be the downstream target of 
active Rho-GTPases following simvastatin treatment in HCT116 cells. Hence, we 
first monitored the superoxide level in SHEP-1 cells using lucigenin 
chemiluminiscence assay (Figure 49A). The results showed significant and sustained 
increase in superoxide production from 2 h up to 20 h treatment (1.35 ± 0.1 fold 
increase after 6 h treatment, 1.4 ± 0.01 fold increase after 20 h treatment compared to 
untreated cell). 
 
Next, to verify the relevance of superoxide in the cell death process, SHEP-1 cells 
were preincubated with various doses of superoxide scavenger tiron for 2 h before 
simvastatin treatment. A dose-dependent reduction of PARP cleavage was observed 
in tiron-pretreated cells (Figure 49B), indicating that simvastatin-induced superoxide 
production plays an essential role in mediating the cell demise. Furthermore, 
preincubation with Rac1 inhibitor NSC23766 not only rescued the cell death 
phenotype shown in Figure 48, it also reduced the superoxide level akin to untreated 
cells (Figure 49C), suggesting that Rac1 activation is upstream of superoxide 

























Figure 49: Preincubation of superoxide scavenger inhibits simvastatin-induced PARP cleavage in 
SHEP-1 cells, and simvastatin-mediated superoxide production is downstream of Rac1 
activation. 
(A) SHEP-1 cells were treated with 10 μM simvastatin for the indicated durations. Intracellular 
superoxide level was monitored by lucigenin chemiluminescence assay. (B) Cells were preincubated 
with various concentrations of tiron for 2 h before treatment with 10 μM simvastatin for 20 h; PARP 
cleavage was assessed by Western blot analysis. GAPDH was included as a loading control. (C) Cells 
were pretreated with 100 μM NSC23766 for 2 h before treatment with 10 μM simvastatin for 6 h. 
Superoxide level was monitored by lucigenin chemiluminescence assay. Data are shown as means ± 





6.2.4 Simvastatin activates JNK pathway downstream of Rac1-superoxide 
cascade to relay the cell death signal  
Next, we evaluated the involvement of JNK signaling in simvastatin-mediated cell 
death in SHEP-1 cells, as JNK activation has been found to be the target downstream 
of Rho GTPases activation and superoxide production in HCT116 cells. Similar to 
HCT116 cells, simvastatin also upregulated stress-related JNK signaling after in 
SHEP-1 cells, which was shown by the increased phosphorylation at Thr183 and 
Tyr185 residues. The effect was fully reversed by MVA and GGPP preincubation, 
but not FPP, indicating that JNK activation is downstream of protein 
geranylgeranylation (Figure 50A). To confirm the functional relevance of JNK 
activation in the SHEP-1 model, we effectively block JNK activation with 
pharmacological inhibitor SP600125. Successful inhibition of JNK signaling was 
shown as the decreased phosphorylation of JNK itself (Figure 50B). Remarkably, 
pretreatment with SP600125 also effectively blocked PARP cleavage (Figure 50B), 
confirming its role in mediating the cytotoxic effects of simvastatin in SHEP-1 cells. 
 
To understand the link of JNK activation to the observed upregulation of Rac1 
activity and superoxide production in SHEP-1 cells, we showed that inhibiting Rac1 
activity with Rac1 inhibitor NSC23766 fully blocked JNK phosphorylation (Figure 
50C). In addition, reduction of superoxide production by tiron also decreased JNK 
phosphorylation (Figure 50D). These results imply that JNK activation is 
downstream of Rac1 activation and superoxide production in SHEP-1 cells. 
 
Collectively, we showed that in SHEP-1 cells, simvastatin unconventionally activates 
Rac1 and induces downstream superoxide production and JNK activation, which 
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eventually leads to cell death. This mechanism is very similar to what we have 
identified in HCT116 cells upon simvastatin treatment, suggesting that simvastatin-
mediated activation of Rho GTPases and its downstream signaling cascade might be 
a common mechanism in simvastatin-sensitive cancer cells.  
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Figure 50: JNK inhibitor SP600125 protects simvastatin-treated SHEP-1 cells, and simvastatin-
mediated JNK activation is downstream of Rac1 activation and superoxide production. 
(A) SHEP-1 cells were preincubated with or without 100 μM MVA, 10 μM GGPP or 10 μM FPP for 2 
h before treatment with 10 μM simvastatin for 6 h. Phospho-JNK level was assessed by Western blot 
analysis. (B) Cells were preincubated with various concentrations of SP600125 for 2 h before 
treatment with 10 μM simvastatin for 20 h; PARP cleavage and phospho-JNK level was assessed by 
Western blot analysis. (C) Cells were pretreated with 100 μM NSC23766 for 2 h before treatment with 
10 μM simvastatin for 20 h. Phospho-JNK level was assessed by Western blot analysis.(D) Cells were 
preincubated with various concentrations of tiron for 2 h before treatment with 10 μM simvastatin for 
20 h; Phospho-JNK level was assessed by Western blot analysis. In all panels, GAPDH was included 
as a loading control. 
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DISCUSSION 
Statins are HMG-CoA reductase inhibitors that have been widely used as cholesterol-
lowering agents to treat hyperlipidemia in the clinic. It has been shown to be 
beneficial in both primary and secondary prevention of cardiovascular diseases, 
making it one of the most frequently used drugs. In the last decade, increasing 
experimental data has demonstrated the anti-cancer properties of statins, including 
activity towards carcinomas of the prostate, colon and rectum, breast, lung, AML, 
multiple myeloma and skin (Chan, Oza et al. 2003; Ukomadu and Dutta 2003; Jiang, 
Zheng et al. 2004; Demierre, Higgins et al. 2005; Campbell, Esserman et al. 2006; 
Fromigue, Hay et al. 2006; Hwang, Na et al. 2011). These positive experimental 
observations have prompted epidemiological studies and clinical trials to assess the 
clinical efficacy of statins for treating cancers. However, so far the conclusions are 
controversial. Some studies have suggested preventive and therapeutic effects of 
statins against cancers (Blais, Desgagne et al. 2000; Poynter, Gruber et al. 2005; 
Shannon, Tewoderos et al. 2005; Boudreau, Yu et al. 2007; Khurana, Bejjanki et al. 
2007; Khurana, Sheth et al. 2007), while other studies fail to draw such conclusions 
(Kim, Kim et al. 2001; Kaye and Jick 2004; Lersch, Schmelz et al. 2004). Hence, it is 
still early to recommend statins for anti-cancer indications in patients until further 
investigations into their exact mechanisms and overall benefits are undertaken. In this 
project, we sought to uncover the underlying signaling networks responsible for 
simvastatin-induced anti-tumor effects in human cancer cells.  
 
1 The cell death mechanism in simvastatin-treated cancer cells 
To begin these studies, we first tested the cytotoxic potential of simvastatin in several 
cancer cell models. As expected, simvastatin caused significant reduction in cell 
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survival of five cancer cell lines from disparate cancer origins, namely, two 
colorectal cancer carcinoma HCT116 and RKO, non-small lung carcinoma A549, 
neuroblastoma SHEP-1 and breast carcinoma MDA-MB-231 (Figure 1 & 46A). 
Further studies done in HCT116 cells showed both cytostatic and cytotoxic effects of 
simvastatin (Figure 1). In addition, we observed that the short-term growth inhibitory 
effects of simvastatin translated into drastically compromised long-term clonogenic 
ability of cancer cells (Figure 2). Statin-mediated anti-proliferative effects have been 
well observed in multiple cancer cell lines either by induction of G1 arrest or G2/M 
arrest (Jakobisiak, Bruno et al. 1991; Crick, Andres et al. 1998; Graaf, Richel et al. 
2004). Multiple cell cycle regulators are involved in mediating the cytostatic effects 
of simvastatin, such as downregulation of cyclin-dependent kinases (Cdk) activities 
or overexpression of Cdk inhibitors (p27 and p21) (Lee, Ha et al. 1998; Weiss, 
Ramirez et al. 1999; Ukomadu and Dutta 2003). In some models, the anti-
proliferative and pro-cell death effects of statins occur as exclusive events depending 
on the concentrations of statins used (Denoyelle, Vasse et al. 2001). Here, we 
observed signs of both events in a time-dependent manner in simvastatin-treated 
HCT116 cells. Previous studies have suggested potential candidate regulators for 
modulating both growth arrest and cell death response after statin treatment. For 
example, statin-induced overexpression of p27 contributes to apoptosis in multiple 
cancer cell types, while conversely, lovastatin-induced growth arrest and apoptosis in 
NIH-3T3 cells was postponed after overexpression of cyclin E (Katayose, Kim et al. 
1997; Ghosh, Moyer et al. 1999). Although we did not focus on the role of cell cycle 
regulation in mediating the cytotoxic effects of simvastatin in our study, these cell 
cycle regulators remain as attractive targets to be explored in future studies. 
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A variety of studies have indicated that the main mode of statin-mediated cancer cell 
death is apoptosis, which as noted above is generally preceded by cell cycle arrest 
(Herrero-Martin and Lopez-Rivas 2008; Kamigaki, Sasaki et al. 2011; Tu, Kang et al. 
2011). Very recently, statins have been found to activate autophagy in some cancer 
cell lines, and there is speculation that this process contributes as well to statin-
induced cell death (Parikh, Childress et al. 2010; Asakura, Izumi et al. 2011). In this 
study, however, our investigations revealed that the molecular events in simvastatin-
induced cell death were consistent with classical apoptosis. Firstly, morphological 
changes such as cell shrinkage during apoptosis were observed in simvastatin-treated 
cells (Figure 3A). Secondly, simvastatin induced proteolytic cleavage and activation 
of initiator caspases (caspase-8 and -9), followed by activation of downstream 
executioner caspase-3, which resulted in PARP cleavage (Figure 4) as well as nuclear 
DNA fragmentation (Figure 3). The cleaved fragment of PARP also possesses 
classical apoptotic features to invalidate its DNA repair function (Berger and Petzold 
1985). Lastly, the almost complete protection of cells by pretreatment with pan-
caspase inhibitor zVAD-fmk confirmed that simvastatin induces cell death via a 
caspase-dependent pathway (Figure 5). 
 
Further exploration implicated mitochondria in the cell death signaling elicited by 
simvastatin in HCT116 cells. This was first evidenced by the initiation of 
mitochondrial membrane permeabilization (MMP) following simvastatin treatment; 
MMP is commonly regarded as the “point of no return” to cellular demise upon 
initiation (Kroemer, Galluzzi et al. 2007). Simvastatin induced mitochondrial 
translocation of Bax as well as release of pro-apoptotic protein cytochrome c to the 
cytosol, which is responsible for the assembly of apoptosome and downstream 
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caspase-9, and subsequently caspase-3 activation (Figure 6). Further comparison 
between HCT116 wildtype and its Bax knockout counterpart showed that Bax-/- cells 
were much less sensitive to simvastatin treatment, confirming that MMP modulator 
Bax-mediated mitochondrial apoptotic pathway is the major mechanism responsible 
for simvastatin’s apoptotic effects (Figure 7). In addition, signs of the 
extrinsic/receptor-mediated apoptotic pathway were also observed after simvastatin 
treatment as evidenced by caspase-8 activation (Figure 4A). The extrinsic pathway 
can engage the mitochondria via caspase-8-dependent cleavage of BH-3 only protein 
Bid in type II cells, where truncated-Bid binds and activates Bax/Bak (Scaffidi, Fulda 
et al. 1998). However, that was not the case here as we did not observe the formation 
of t-Bid after simvastatin treatment (Figure 36). Hence, we propose that simvastatin-
induced apoptotic signaling in HCT116 cells is primarily executed through the 
intrinsic pathway, with minor apoptotic effects contributed by the extrinsic signaling. 
This observation is consistent with several other reports showing the importance of 
mitochondrial apoptotic pathway in breast tumor cells (Herrero-Martin and Lopez-
Rivas 2008), lymphoblasts and myeloma cells (Cafforio, Dammacco et al. 2005) 
upon exposure of statins. On the other hand, our data indicates that direct 
involvement of the tumor suppressor p53 in statin-induced apoptosis is likely to be 
limited. One report showed that lovastatin was able to induce mitochondrial-mediated 
apoptosis involving cytochrome c release in p53-mutant breast cancer cells (Shibata, 
Ito et al. 2004). This is consistent with our finding that p53 knockout colorectal 
cancer cells were equally if not more sensitive to simvastatin treatment compared to 
its wildtype counterpart (Figure 8). These observations highlight the therapeutic 
potential of statins in cancers with p53 mutations or deficiency.  
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Sustained proliferative signaling and resistance to cell death are two important steps 
during tumor development (Hanahan and Weinberg 2011), and we have 
demonstrated that simvastatin is able to overcome the resistance to apoptosis and 
effectively induce cell death in multiple cancer cell types. Taken together with the 
previous studies that have established the resistance of normal cells to statin 
treatment (Newman, Clutterbuck et al. 1994; Newman, Clutterbuck et al. 1997; 
Dimitroulakos, Nohynek et al. 1999), our findings regarding the anti-tumor activities 
of simvastatin highly suggest its potential as a tumor-selective chemotherapy. To 
translate the promising anti-tumor effects of simvastatin observed in vitro to in vivo 
models, one important factor to address is whether the concentrations at which anti-
proliferative and pro-apoptotic effects are observed in vitro can be achieved clinically. 
In our study, we observed that IC50 of simvastatin is around 5-10 μM in all five 
cancer cell lines tested (Figure 1 and 46A). Moreover, 3 μM simvastatin showed 
more pronounced effect in long-term, inducing around 50% inhibition in clonogenic 
ability of HCT116 cells (Figure 2). Clinical trials involving another closely related 
member of HMG-CoA reductase inhibitors lovastatin showed that administration in 
doses from 25 mg/kg daily results in peak drug plasma concentration around 3.9 μM 
in cancer patients (Thibault, Samid et al. 1996). Trials using even higher doses of 
statins can reach plasma concentration higher than 10 μM, and the occurrence of 
myopathy (a side effect of high dose statin treatment) can be prevented by 
ubiquinone supplementation. These findings indicate that the main concentrations of 
simvastatin used in our study (3 or 10 μM) to induce anti-proliferative and pro-
apoptotic effects are within the therapeutically achievable dose ranges, and the 
downstream signaling networks identified in this project would also be 
physiologically relevant.  
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2 Identification of novel mechanisms in regulating Rho GTPases and 
its role in simvastatin-mediated apoptosis 
2.1 Geranylgeranylation is the more important form of isoprenylation in the 
anti-tumor effects of simvastatin 
Statins work by reversibly inhibiting the HMG-CoA reductase, the enzyme 
catalyzing the conversion of HMG-CoA to mevalonate (Rodwell, Nordstrom et al. 
1976). Several downstream metabolites in the mevalonate pathway are suggested to 
be involved in establishing statins’ anti-tumor effects. Cholesterol is one of them as 
shown by a handful studies that linked cholesterol-regulated lipid raft signaling to the 
chemopreventive effects of statins. For instance, simvastatin has been shown to 
induce apoptosis in prostate cancer cells by depleting raft cholesterol level and inhibit 
AKT signaling both in vitro and in vivo (Zhuang, Kim et al. 2005). To test the 
involvement of cholesterol in our model, we preincubated HCT116 cells with 
cholesterol precursor squalene before simvastatin treatment. However, restoration of 
sterols with squalene failed to protect simvastatin-induced cell death (Figure 10), 
indicating that the cytotoxic effects are likely to be independent of cholesterol 
synthesis. This observation is consistent with several other studies suggesting the 
importance of other downstream moieties instead of cholesterol. For example, 
geranylgeranylpyrophosphate (GGPP) and farnesylpyrophosphate (FPP) are 
responsible for the post-modification of intracellular Ras and Rho GTPases, which in 
turn regulate its downstream effectors to mediate cell proliferation, differentiation, 
and apoptosis (Goldstein and Brown 1990; Liao and Laufs 2005). In addition, 
inhibitors that specifically block the enzymes responsible for protein farnesylation 
(farnesyltransferase) and geranylgeranylation (geranylgeranyltransferase I), namely 
FTIs and GGTIs, were developed as anti-cancer drugs primarily because of the 
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identification of Ras superfamily members’ contribution to tumor development 
(Berndt, Hamilton et al. 2011). In this study, we obtained evidence that simvastatin 
induced cell death in all five cancer cell lines via depletion of the isoprenoid GGPP. 
The conclusion came from studies showing that cells preincubated with GGPP 
exhibited almost full recovery from simvastatin-induced cell death, whereas FPP 
preincubation had minimal protective effects (Figure 9, 46B). Although FPP lies 
upstream of GGPP in the mevalonate pathway, the conversion requires another 
molecule isopentenyl PPi, which is also depleted after statin exposure, providing an 
explanation as to why the addition of FPP is unable to restore protein 
geranylgeranylation and show protective effects (Mo and Elson 2004; Demierre, 
Higgins et al. 2005). Additional experiments in HCT116 cells further demonstrated 
that a specific inhibitor of GGTase I (GGTI-298), but not of FTase (FTI-277), 
mimicked the cytotoxic effects of simvastatin (Figure 11), confirming the importance 
of geranylgeranylation over farnesylation in simvastatin-induced apoptosis. 
 
Our observations, as with previous reports (Xia, Tan et al. 2001; Dimitroulakos, 
Marhin et al. 2002; van de Donk, Kamphuis et al. 2003; Zhong, Wang et al. 2003), 
show that statins’ cytotoxic effects on cancer cells were mainly attributed to the 
inhibition of downstream protein geranylgeranylation. Implications of this 
observation are multi-fold. It directly suggests that the functional consequences after 
loss of geranylgeranylation are more severe than loss of farnesylation. This could be 
simply due to the fact that much more proteins undergo geranylgeranylation than 
farnesylation inside cells (Reid, Terry et al. 2004). Another plausible explanation was 
proposed by Martin Bergo’s group based on their observation that inhibition of 
GGTIase-I activity reduced K-ras-induced lung tumor formation and promoted 
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survival of the mice (Sjogren, Andersson et al. 2007). They argued that 
geranylgeranylated proteins may have higher avidity to the membrane surfaces 
because of the more hydrophobic nature of the geranylgeranyl lipid compared to the 
farnesyl lipid. Hence, inhibition of protein geranylgeranylation could have a greater 
cellular effects compared with loss of protein farnesylation. More significantly, our 
observations highlight the critical involvement of one or more geranylgeranylated 
proteins, for example, Rho, Rac, and Cdc42, in the growth and survival of 
transformed cells (discussed in more detail in the next section). The findings that 
protein geranylgeranylation is more important than farnesylation in cell survival calls 
for re-evaluation of the clinical relevance of FTIs as an anti-cancer monotherapy. 
FTIs were primarily developed to target Ras proteins, the most frequently mutated 
oncogene identified in cancers. However, the efficacy of the FTI drugs was found to 
be limited, especially in solid tumors (Konstantinopoulos, Karamouzis et al. 2007; 
Sousa, Fernandes et al. 2008). Our study also provided evidence that HCT116 cells 
with oncogenic K-Ras mutation were not responsive to FTI-277 treatment; instead, 
simvastatin or GGTI-298 alone showed better cell kill (Figure 11). The observation 
might be explained by the discovery that K- and N-Ras can become 
geranylgeranylated when treated with FTIs (Rowell, Kowalczyk et al. 1997; Whyte, 
Kirschmeier et al. 1997). Hence, regimes that target both forms of isoprenylation, 
such as statins or combination of FTIs and GGTIs, could represent a better strategy to 
induce cell death in a boarder range of cancers.  
 
2.2 Non-canonical regulation of Rho GTPases by simvastatin 
As mentioned previously, farnesylation and geranylgeranylation are post-
translational modifications involving the addition of an isoprenoid lipid to the C-
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terminus of the proteins. It is generally understood that the post-modification is 
necessary for the proper localization and function of target proteins (Van Aelst and 
D'Souza-Schorey 1997). The importance of geranylgeranylation in simvastatin-
induced apoptosis prompted us to identify its candidate substrates. We then focused 
on three widely studied Rho GTPases, namely RhoA, Rac1 and Cdc42, which 
mediate various housekeeping functions inside the cells, including cytoskeletal 
rearrangements, cell morphology, polarity, migration, proliferation and survival (Van 
Aelst and D'Souza-Schorey 1997; Schmitz, Govek et al. 2000; Aznar and Lacal 
2001). In addition, mounting evidence is suggesting their role in cancer development, 
for example overexpression or hyperactivity of Rho GTPases are well observed in 
multiple types of human tumors (summarized in Table 2 in Introduction) (Jaffe and 
Hall 2002; Sahai and Marshall 2002; Gomez del Pulgar, Benitah et al. 2005).  
 
2.2.1 Inhibiting geranylgeranylation increases GTP-loading of Rho GTPases 
By inhibiting HMG-CoA reductase, statins reduce the endogenous pool of isprenoids 
required for membrane localization and function of Rho GTPases (Winter-Vann and 
Casey 2005). Hence, we hypothesize that the Rho proteins would be unprenylated 
and unable to reside in the plasma membrane following simvastatin treatment. Using 
detergent Triton X-114, we separated Rho proteins into unprenylated and prenylated 
forms. As expected, increases in RhoA, Rac1 and Cdc42 levels in their unprenylated 
form were observed after simvastatin treatment (Figure 13). On top of that, these 
unprenylated RhoA, Rac1 and Cdc42 delocalized from the lipid raft region of plasma 
membrane in a time-dependent manner following simvastatin treatment. 
Correspondingly, increases in soluble RhoA, Rac1 and Cdc42 protein levels were 
observed in the cytosol compared to untreated controls (Figure 14). Supplementing 
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cells with mevalonate to restore the prenylation process elicited a detectable decline 
in the accumulated cytosolic RhoA, Rac1 and Cdc42 content. 
 
Our initial assumption was that cytosolic localized RhoA, Rac1 and Cdc42 should 
not be GTP-loaded, as membrane localization was thought to be critical for activation 
of the GTPases. Contrary to our expectations, however, we observed increased GTP-
bound forms of RhoA, Rac1 and Cdc42, and also increases in total protein levels of 
RhoA and Cdc42. Addition of GGPP but not FPP prevented GTP-loading of RhoA, 
Rac1 and Cdc42 in response to simvastatin treatment (Figure 15-17). These data 
demonstrate that inhibition of geranylgeranylation paradoxically leads to increased 
GTP-loading of Rho proteins. To provide a mechanistic basis to these observations, 
we propose that simvastatin-mediated inhibition of geranylgeranylation prevented 
Rho proteins from interacting with its negative regulator, Rho GDP-dissociation 
inhibitor (RhoGDI). RhoGDIs are responsible for sequestering geranylgeranylated 
GDP-bound Rho proteins in a cytosolic complex and for preventing the guanine 
nucleotide exchange (Dransart, Olofsson et al. 2005). It has been identified that the 
essential interaction sites involve the C-terminal geranylgeranyl moiety of Rho 
proteins and a hydrophobic region on RhoGDIs (Di-Poi, Faure et al. 2001). Hence, it 
is plausible to hypothesize that lack of geranylgeranylation would prevent this 
interaction. Indeed, we observed that the respective associations of RhoA and Rac1 
with RhoGDIα, the most ubiquitously expressed form of RhoGDIs, were 
significantly reduced in simvastatin-treated cells. In addition, supplementing cells 
with MVA or GGPP reversed the interaction (Figure 21). We propose that the 
decreased association between Rho proteins and their cytosolic inhibitor leads to the 
accumulation of GTP-bound Rho proteins, possibly due to spontaneous exchange of 
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GDP to GTP, as the intracellular GTP level is way higher than GDP (Carlucci, Rosi 
et al. 1997), or it possibly involves the catalytic activities of GEFs (Orita, Kaibuchi et 
al. 1993).  
 
In addition to geranylgeranylation, we speculate that a second mechanism may exist 
in regulating Rho-RhoGDI interaction based on previous studies (Mehta, Rahman et 
al. 2001; Knezevic, Roy et al. 2007), which demonstrated that phosphorylation of 
RhoGDIα disrupted its association with Rho proteins and resulted in activation of 
Rho GTPases. Interestingly, several kinases that phosphorylate RhoGDIα are also the 
downstream effectors of Rho GTPases. For example, p21-activated kinase 1 (PAK1), 
an effector of both Rac and Cdc42, phosphorylated RhoGDIα at Ser101 and Ser174 
to allow for Rac activation upon platelet-derived growth factor or epidermal growth 
factor stimulation (DerMardirossian, Schnelzer et al. 2004). This study highlighted 
the possibility that PAK1-mediated disruption of Rac-RhoGDI interaction may be a 
mechanism for the initiation of Rac activation or a positive feedback response to 
further amplify the Rac signaling. Hence, future investigation can test if RhoGDIα 
phosphorylation also plays a role in simvastatin-mediated activation of RhoA and 
Rac1 by disrupting their interaction with RhoGDIα.   
 
The widely held notion that statins affect Rho GTPases activation by inhibiting their 
localization via blocking geranylgeranylation is being re-examinered on several 
fronts. Growing evidence is accumulating that statins are able to increase Rho 
proteins in their GTP-bound form regardless of their localizations. The observation 
has not only been seen in the cancer cells used in our studies, but also in BV-2 
microglia, THP-1 monocytes, myeloid lineage cells, PC12 pheochromocytoma cells 
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and N2a mouse neuroblastoma cells, demonstrating a common effect in multiple cell 
types (Cordle, Koenigsknecht-Talboo et al. 2005).  
 
2.2.2 Activation of RhoA and Rac1 by simvastatin mediates cell kill 
Although the Rho proteins in simvastatin-treated cells were unprenylated, we found 
that the cytosolic GTP-loaded RhoA and Rac1, but not Cdc42, were functional to 
activate a downstream signaling cascade (involving superoxide production, JNK 
activation and Bim-EL upregulation, discussed in the later sections), which 
eventually led to cell death in simvastatin-treated HCT116 cells. This conclusion was 
supported by the observations that inhibition of RhoA or Rac1 activity using 
pharmacological inhibitors, gene silencing or expression of dominant negative 
mutant, substantially restored survival of cancer cells after simvastatin treatment 
(Figure 18-20). Preliminary data in SHEP-1 cells also showed similar observations, 
where simvastatin increased GTP-loading of Rac1 and inhibition of which reduced 
apoptotic hallmarks (Figure 48).  
 
Despite that statins increase GTP-bound Rho proteins in multiple cell types as 
mentioned in the above section, our study is the first report showing that 
unprenylated yet GTP-bound Rho proteins are functional to mediate cancer cell 
death, suggesting that unprenylated Rho can interact with effectors to mediate 
downstream signaling events. Interestingly, another report complemented our 
observation by demonstrating that unprenylated RhoA, B and C can partially 
stimulate the classical serum response element (SRE)-dependent transcription in 
lovastatin-treated human erythroleukemia cells, albeit significantly less than 
prenylated Rho proteins (Turner, Zhuang et al. 2008). Functional activity of 
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unprenylated Rho proteins has been seen in non-cancer models as well. One study 
showed that mice with GGTase-I deficiency accumulated high levels of GTP-bound 
RhoA, Rac1 and Cdc42, which then hyperactivate macrophages and induce erosive 
arthritis (Khan, Ibrahim et al. 2011). Another study demonstrated that N-
Bisphosphonates (N-BPs), which prevents prenylation by targeting another enzyme 
(farnesyl diphosphate synthase, responsible for FPP synthesis) in the mevalonate 
pathway, inhibited bone resorption by activation of p38 pathway downstream of the 
unprenylated GTP-loaded Rac (Dunford, Rogers et al. 2006).  
 
Our data provided compelling evidence that the induction of GTP-loaded RhoA and 
Rac1 is required for simvastatin-mediated cell death. However, inhibiting RhoA or 
Rac1 activity alone was unable to confer as extensive protection as preincubation 
with GGPP. We propose that it is possible that inhibition of both RhoA and Rac1 
would show an additive or even synergistic protection, or other geranylgeranylated 
proteins may be contributing to the cell kill by simvastatin treatment. These 
possibilities can be explored in future investigations. 
 
2.2.3 Beyond the post-translational modification of Rho GTPases by simvastatin 
In addition to the intriguing discovery of Rho GTPase activation following 
simvastatin treatment, we observed that the levels of Rho GTPases were also elevated 
by such treatment. In our model, simvastatin enhanced protein expression of RhoA 
and Cdc42 drastically. The effects were shown to be time-dependent; the increment 
in protein level was obvious from 12 h onwards and lasted throughout the whole time 
course (Figure 12A). Mevalonate fully reversed the RhoA and Cdc42 overexpression, 
and GGPP largely prevented the upregulation effects after simvastatin treatment 
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(Figure 12B). Previous studies have proposed that post-translational 
geranylgeranylation made Rho proteins more susceptible to proteasomal degradation; 
hence, inhibition of geranylgeranylation by statins might slow the degradation 
process and result in the increased protein content (Stamatakis, Cernuda-Morollon et 
al. 2002; Von Zee and Stubbs 2011). However, we did not observe any changes in 
protein stability of RhoA and Cdc42 in our model. A chase experiment was 
performed with protein synthesis inhibitor cycloheximide and the results showed that 
both proteins decreased at the same time with or without simvastatin treatment, 
indicating that simvastatin did not change the half-life of these proteins (Figure 24). 
Instead, de novo synthesis of mRNA and protein was more likely to be responsible 
for the increased protein expression, as pretreatment with transcription inhibitor 
actinomycin D or cycloheximide dose-dependently reduced protein levels of RhoA 
and Cdc42 induced by simvastatin (Figure 23). 
 
An impact of statin treatment on transcriptional control of Rho GTPases has been 
observed in a few recent papers. One study reported that lovastatin treatment 
increased expression of RhoA and RhoB in human trabecular meshwork cells (Von 
Zee, Richards et al. 2009); while another study showed that lovastatin and 
atorvastatin treatment induced Rac and Cdc42 expression in ovarian cancer cells 
(Liu, Liang et al. 2009). Neither studies reported any functional relevance of the 
increased Rho proteins; instead they suggested that the upregulation of Rho proteins 
is merely a feedback response to the induced abrogation of Rho GTPase activities. 
However, we demonstrate that simvastatin-induced upregulation of Rho proteins is 
important in mediating the cell death signal. Cells treated with cycloheximide were 
insensitive to simvastatin treatment, indicating the importance of newly synthesized 
 170 
proteins in the apoptotic response (Figure 22A, B). Moreover, cycloheximide reduced 
the GTP-bound form of RhoA and Rac1, the two Rho GTPases responsible for 
simvastatin-mediated apoptosis (Figure 22C). These observations demonstrated that 
the newly synthesized unprenylated Rho proteins are those that accumulated in the 
GTP-bound form. This novel finding of transcriptional control of Rho proteins by a 
process involves geranylgeranylation and its relevance in mediating the cytotoxic 
effects of simvastatin could help better understand the cellular consequences due to 
inhibition of geranylgeranylation. Considering that a large number of proteins 
undergo geranylgeranylation and the signaling networks are highly complex, it is 
very likely that one of the affected targets is a component involved in the control of 
transcription of Rho proteins, such as coactivators, corepressors or transcription 
factors. However, the understanding of transcription of Rho proteins is very limited. 
Two mechanisms have been proposed by recent papers: the first is by the action of 
the small non-coding RNA, or microRNA, miR-31 which suppresses RhoA at post-
transcriptional level (Valastyan, Reinhardt et al. 2009). Another recent study 
provided the first clue of transcription factors involved in RhoA gene regulation; it 
was shown that RhoA transcription was orchestrated by the Myc-Skp2-Miz1-p300 
transcriptional complex in cancer cells (Chan, Lee et al. 2010). Future studies to 
better understand the transcriptional regulation of Rho GTPases would possibly 
provide a new angle to interpret statins’ anti-tumor effects and understand the 
molecular basis of Rho overexpression observed in certain tumors. 
 
Collectively, our study is the first to show that post-translational modification by 
geranylgeranylation can impact Rho GTPases at both transcriptional and post-
translational level; the resultant non-canonical activation of Rho GTPases produces 
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species that are functional in meditating apoptotic effects of simvastatin in cancer 
cells. Our results along with that presented by other studies challenge the view that 
inhibiting geranylgeranylation is a means to block the activity of Rho family proteins. 
On the contrary, inhibiting the process may be stimulating both their expression and 
activities. Future investigations can be focused on characterizing the status of Rho 
GTPases in cancer cells that respond to statin treatment in a geranylgeranylation-
dependent way, the understanding of which will be fundamental to identify the 
molecular features required for the non-canonical regulation of Rho GTPases across 
different cell types and to provide mechanistic insights to statins’ anti-cancer effects.  
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3 The involvement and significance of superoxide production 
3.1 Unprenylated RhoA and Rac1 in superoxide production 
To further explore the mechanism of how activation of RhoA and Rac1 mediate the 
cell death response, we identified superoxide production as a downstream event of 
simvastatin treatment. A time-dependent increase of superoxide production was 
observed as early as 3 h and sustained from 8 to 24 h following simvastatin treatment 
(Figure 25). Importantly, abrogation of superoxide production via different types of 
superoxide-specific scavengers DPI, tempol and tiron invariably protected cancer 
cells from simvastatin-induced apoptosis, as assessed by morphological rescue and 
caspases involvement, as well as positive readout from the viability assay (Figure 
26). Moreover, simvastatin-mediated superoxide production was downstream of the 
geranylgeranylation process, based on the observations that GGPP preincubation 
reversed the superoxide increment accompanying simvastatin treatment, whereas 
GGTI-298 induced superoxide production (Figure 27).  
 
Inhibition of RhoA and Rac1, but not Cdc42, using the aforementioned tools was also 
able to abrogate simvastatin-stimulated superoxide production, which was consistent 
with the cell viability data showing that these manipulations protected cells from 
simvasstatin-induced cell death (Figure 18-20). In addition, evidence from SHEP-1 
cells also suggested that superoxide was a downstream event of Rac1 activation 
induced by simvastatin (Figure 49). It is not surprising to associate activated Rac1 
and RhoA with superoxide production, both of which have been found to activate the 
superoxide generator NADPH oxidase (NOX). Studies in phagocytic cells have 
shown that Rac enhances the activity of NOX2 to produce superoxide by assembly of 
a multimolecular complex at the plasma membrane consisting of membrane 
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components NOX2 and p22phox, together with cytosolic components p40phox, 
p47phox, p67phox and Rac. P67phox is proposed to be the Rac effector protein in the 
NADPH oxidase complex, which directly interacts with GTP-loaded Rac (Diekmann, 
Abo et al. 1994; Babior 1999; Bokoch and Diebold 2002). Other evidence also 
supports the role of RhoA in regulating superoxide formation through the NADPH 
oxidase complex during phagocytosis, most likely via phosphorylation of p47phox 
(Kim, Diebold et al. 2004). Hence, the current knowledge on Rho GTPases-mediated 
superoxide production from the NADPH oxidase complex is a promising mechanism 
to be explored in our model. Indeed, our data suggested that the NADPH oxidase 
complex is a main source of superoxide production, as evidenced by the protective 
effect from NOX inhibitor DPI (O'Donnell, Tew et al. 1993) (Figure 26). In addition, 
our preliminary data showed that gene silencing of NOX2 significantly reduced 
superoxide level and protected cells from simvastatin-induced cellular insult 
(Appendix A). Hence, we propose that the unprenylated yet activated RhoA and 
Rac1 can engage the NADPH oxidase complex to generate superoxide in 
simvastatin-treated cells, which then leads to cancer cell death. Our finding is 
supported by another report showing that bacterially-expressed unprenylated Rac can 
effectively activate the oxidase system in a cell-free assay (Heyworth, Knaus et al. 
1993). Together with our report, it directly questioned the necessity for membrane-
localized Rac to activate the NADPH oxidase complex. 
Currently, one important question that remains to be addressed is the site for the 
assembly of the functional NADPH oxidase complex in simvastatin-treated cancer 
cells, other than the plasma membrane. With the expanding of the NOX family from 
the phagocyte NOX2 to the current seven members identified in non-phagocytic cells 
(NOX1-5 and DUOX1-2), substantial evidence is suggesting the distribution of NOX 
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in other cellular compartments (Meier, Cross et al. 1991; Szatrowski and Nathan 
1991; Griendling, Minieri et al. 1994; Li and Shah 2003). For example, in smooth 
muscle cells, NOX2 is found to colocalize with the perinuclear cytoskeleton (Li and 
Shah 2002). Functional NOX4 was recently found to localize to mitochondria in rat 
mesangial cells and kidney cortex (Block, Gorin et al. 2009), mouse cardiac 
myocytes (Kuroda, Ago et al. 2010), and chronic myeloid leukemia cells that 
overexpress Bcl-2 (Velaithan, Kang et al. 2011). Functional role of NOX4 has also 
been suggested in the endoplasmic reticulum (ER) and the nucleus from the 
observations made in vascular smooth muscle and endothelial cells (Hilenski, 
Clempus et al. 2004; Kuroda, Nakagawa et al. 2005). These pilot studies have 
provided evidence for activation of NOX in intracellular compartments. The tools 
and methods used in these studies can be applied to identify the intracellular 
formation of the NADPH oxidase complex following activation of RhoA and Rac1 
upon simvastatin treatment in the future.   
 
3.2 Statin induces oxidative stress specifically in cancer cells  
In our model, we established the role of superoxide in simvastatin-mediated killing as 
various superoxide scavengers were able to abrogate simvastatin-induced apoptosis 
(Figure 26). Hence, we propose that simvastatin-mediated accumulation of 
superoxide induces intrinsic oxidative stress and leads to cancer cell death. Earlier 
publications from the lab have shown that the slight alterations in the intracellular 
superoxide level lead to a mild “pro-oxidant” state in the cells, which is permissive 
for cell proliferation as reviewed in (Pervaiz and Clement 2007). However, we argue 
that an excessive amount of superoxide production would be detrimental to cells via 
several mechanisms. One possibility is that massive accumulation of superoxide 
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inside the cells would inactivate critical metabolic enzymes or initiate lipid 
peroxidation, which results in irreversible cellular injury and ultimately cell death. 
The same mechanism is used by the anti-cancer agents that target superoxide 
dismutase (SOD), which also results in superoxide accumulation and selectively kills 
cancer cells as reviewed in (Huang, Feng et al. 2000). It is also possible that 
superoxide acts as the initiator ROS, which is then converted into effector ROS/RNS, 
such as hydrogen peroxide, hydroxyl radical or peroxynitrite, to mediate the 
apoptotic effects. In addition, NOX-mediated superoxide production has been shown 
to further amplify the total level of ROS from NOS uncoupling (Verhaar, Westerweel 
et al. 2004) or the activation of xanthine oxidase (Li and Shah 2004), which may 
further facilitate the oxidative stress-mediated cellular effects. 
 
Several groups have also demonstrated the involvement of oxidative stress in statin-
induced apoptosis in cancer cells, specifically murine CT26 colon cancer (Qi, Kim et 
al. 2010), K-ras transformed thyroid cells (Laezza, Fiorentino et al. 2008), and MCF-
7 breast cancer cells (Sanchez, Rodriguez et al. 2008), suggesting that it might be a 
common mechanism in statin-sensitive cancer cells. However, the anti-oxidant 
effects of statins have also been well-established in improving endothelial functions 
and mediating its cardioprotective effects (Stoll, McCormick et al. 2004). To provide 
a possible explanation of the opposing observations, it is interesting to notice a 
pattern whereby statins exert anti-oxidative effects in non-cancerous cells but induce 
oxidative stress in multiple cancer types. We hypothesize that this oxidative stress 
response induced by statins might be a possible tumor-selective mechanism that 
mediates statins’ anti-tumor effects. If this hypothesis holds true, then the molecular 
basis of how statins differentially regulate oxidative stress in different cell types 
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would be a subject to explore. One possible mechanism may be the non-canonical 
regulation of the Rho GTPases by statins shown in our study, where unprenylated yet 




4. The involvement and significance of JNK signaling 
4.1 JNK is the downstream mediator in simvastatin-induced apoptosis 
Our data support the importance of JNK pathway in mediating simvastatin-induced 
apoptosis in HCT116 cells. Simvastatin elicited JNK activation by fostering 
phosphorylation at Thr183 and Tyr185 without increasing its expression, and this 
activation is a sustained and prolonged process which was observed as early as 3 h 
post-treatment and persisted throughout the time course of analysis (Figure 30).   
 
It has been suggested that the kinetics of JNK activation play a role in determining its 
biological function. Early and transient activation of JNK mediates cell survival, 
while sustained JNK activation caused by cytotoxic drugs or cellular insults has been 
shown to trigger apoptosis (Chang, Kamata et al. 2006; Lin 2006; Ventura, Hubner et 
al. 2006). It is well documented that transcriptional-dependent or -independent role of 
JNK can both contribute to apoptosis. For example, activation of c-Jun downstream 
of JNK signaling can lead to transcription of pro-apoptotic genes such as Fas-L and 
Bim (Faris, Latinis et al. 1998); on the other hand, JNK can phosphorylate pro- or 
anti-apoptotic proteins such as p53 and Bcl-2 to exert apoptotic functions (Milne, 
Campbell et al. 1995; Maundrell, Antonsson et al. 1997). Indeed, in this study, the 
observed sustained JNK activation was required for cell death as JNK inhibitor 
SP600125 (Bennett, Sasaki et al. 2001) significantly protected cells from simvastatin-
induced apoptosis and reduction in colony formation potential in HCT116 cells 
(Figure 32); similar responses were also observed in simvastatin-treated SHEP-1 
cells (Figure 50).  
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In accordance with our findings that JNK represents an important mediator in 
controlling simvastatin-induced apoptotic signaling cascade, several other studies 
have also highlighted the importance of JNK signaling in mediating statin-induced 
cell death in human breast cancer cells (Koyuturk, Ersoz et al. 2007), C6 glioma cells 
(Koyuturk, Ersoz et al. 2004), salivary adenoid cystic cancer cells (Zhang, Wang et 
al. 2010) and ovarian cancer cells (Liu, Liang et al. 2009). Additionally, we found 
that JNK activation in response to simvastatin treatment is specifically associated 
with geranylgeranylation, which was shown by inhibition of JNK phosphorylation by 
mevalonate and GGPP preincubation but not FPP, as well as induction of JNK 
phosphorylation by GGTI-298 (Figure 31). 
 
Other than JNK activation, we also observed changes in cell survival signaling 
pathways ERK and AKT, evidenced by dephosphorylation at Thr202/Tyr204 for 
ERK and Ser473 for AKT. Dephosphorylation of ERK and AKT by simvastatin was 
only reversed by mevalonate preincubation, but not affected by either GGPP or FPP 
(Figure 31A). Since the geranylgeranylation process was found to be essential in 
mediating the apoptotic response, we conclude that ERK and AKT, unlike JNK, are 
not the major signaling components to convey the death signal after simvastatin 
treatment. Indeed some studies have suggested that statin-mediated changes in ERK 
and AKT were modulated via cholesterol-dependent lipid raft signaling (Roy, Kung 
et al. 2011).  
 
4.2 Upstream signals for simvastatin-mediated JNK activation  
This study highlighted the role of superoxide in activating JNK pathway. JNK 
phosphorylation was fully abrogated following inhibition of superoxide production 
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and its upstream activation signal RhoA or Rac1 activity in HCT116 cells (Figure 33, 
34). Additional evidence from SHEP-1 cells also showed that inhibiting Rac1 activity 
or superoxide production reduced JNK activation following simvastatin treatment 
(Figure 50). Despite this being the first report of superoxide-mediated JNK activation 
in simvastatin-treated cancer cells, various oxidants and ROS-producing agents have 
previously been shown to mediate JNK activation, such as hydrogen peroxide, 
arsenite trioxide, UV radiation and cadmium chloride (Meier, Rouse et al. 1996; 
Dent, Yacoub et al. 2003; Leonard, Harris et al. 2004; Conde de la Rosa, Schoemaker 
et al. 2006).  
 
JNK can be activated via two mechanisms, one is from the activation of a MAPKKK-
MAPKK-JNK kinase cascade (Lin and Dibling 2002), or it can be regulated by JNK 
inactivating phosphatases. Here, we propose a few candidate targets which might be 
modulated by oxidative stress to activate JNK pathway in our model. Apoptosis 
signal-regulating kinase 1 (ASK1) is a MAPKKK implicated in ROS-mediated JNK 
activation. The critical role of ASK1 in ROS-mediated apoptosis has been shown 
both in vitro and in vivo, and superoxide or hydrogen peroxide production has been 
identified as the major mechanism for various anti-cancer drugs to regulate ASK1-
mediated cell death (Du, Suzuki et al. 2001; Tobiume, Matsuzawa et al. 2001; 
Machino, Hashimoto et al. 2003; Goldman, Chen et al. 2004). In addition, ASK1 
knockout mice are more resistant to oxidative and ER stress-induced apoptosis while 
exhibiting a significantly lower level of JNK activation as compared to wild type 
mice (Matsuzawa, Nishitoh et al. 2002). Other than activating kinases, JNK can be 
regulated by MAPK phosphatase (MKPs) as well. It is worth noting that MKP-1 has 
been suggested to play an important role in cancer cell survival, downregulation of 
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which is implicated in cancer prevention and chemosensitization (Liao, Guo et al. 
2003; Chen, Huang et al. 2005; Wang, Zhou et al. 2007; Wu 2007). A recent paper 
showed that superoxide-mediated MKP1 degradation was the main mechanism for 
JNK-mediated lung cancer cell death induced by a plant-derived flavonoid luteolin 
(Bai, Xu et al. 2012). Hence, whether simvastatin-mediated oxidative stress affects 
any kinases or phosphatases, thereby activating JNK, remains an avenue for future 
investigations.  
 
The significance of superoxide-mediated JNK activation is demonstrated by its 
ability to modulate cell death response after simvastatin treatment. A large body of 
evidence in the literature supports the notion that ROS-mediated JNK activation is 
able to induce apoptosis. For example, our lab has established that the pharmacologic 
agent LY303511 sensitizes neuroblastoma cells to TRAIL via hydrogen peroxide-
mediated JNK activation and upregulation of death receptor (Shenoy, Wu et al. 
2009). Another study showed that TNFα induced caspase-
dependent ROS accumulation and prolonged JNK activation, which was followed by 
apoptotic and necrotic cell death in various tumor cells (Nakajima, Kojima et al. 
2008). Together with our observations, we propose that ROS-mediated JNK 
activation may be a common mechanism utilized by other types of statins or ROS 





5. The involvement and significance of pro-apoptotic protein BIM 
5.1 Increase in Bim-EL content mediates simvastatin’s apoptotic effects  
Initiation of mitochondrial apoptotic pathway is always orchestrated by the interplays 
between pro-survival and pro-apoptotic Bcl-2 family proteins (Gross, McDonnell et 
al. 1999). In our study, when HCT116 cells were treated with simvastatin over a 
period from 16 to 32 h, we did not observe any changes in pro-survival protein Bcl-
xL and cleavage of pro-apoptotic protein Bid. However, the level of pro-apoptotic 
BH3-only protein Bim was markedly elevated after simvastatin treatment (Figure 
36). Moreover, reduction of Bim-EL expression with four individual siRNA 
sequences significantly protected cells from simvastatin-induced apoptosis, as shown 
by an increase in cell viability and reduced caspase-3 and PARP cleavage (Figure 
37). Considering that complete inhibition of Bim-EL by siRNA transfection did not 
completely protected the cells, it seems that other factors other than Bim-EL may 
contribute to simvastatin-induced apoptosis. Nonetheless, it does appear that the 
increased Bim-EL level accounts for the major component in mediating the apoptotic 
effects of simvastatin in HCT116 cells. The results also support the hypothesis that 
chemotherapy which tilts the balance of Bcl-2 family proteins to the pro-apoptotic 
side may confer cells susceptible to apoptosis. Previous studies have demonstrated 
that Bim is a unique BH3 protein that is able to directly induce the conformational 
changes of Bax and Bak, or indirectly activates Bax and Bak by neutralizing the anti-
apoptotic Bcl-2 proteins, which precedes apoptosis (Czabotar, Colman et al. 2009). 
We also showed that simvastatin increased Bim-EL content in Bax knockout 
HCT116 cells comparable to that in the wildtype cells, suggesting that Bim-EL acts 
upstream of the Bax signaling to assist apoptosis (Figure 43). Our findings are among 
the first few to demonstrate the importance of Bim-EL upregulation in statin-
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mediated cancer cell death, together with the report of Jang et al showing that Bim-
EL upregulation is essential in lovastatin-induced glioblastoma cell death (Jiang, 
Zheng et al. 2004). There is a third report that also showed induction of Bim in 
ovarian cancer by lovastatin. However, that study did not further address the 
relevance of Bim in the cell death mechanism (Liu, Liang et al. 2009).  
 
5.2 The mechanism for simvastatin-mediated Bim-EL upregulation 
Previously, we have established that simvastatin triggers apoptosis via depletion of 
GGPP. Here, we observed that cells preincubated with GGPP, but not FPP, fully 
prevented accumulation of Bim-EL after simvastatin treatment (Figure 38), 
suggesting that the increase in Bim-EL content was regulated primarily by 
geranylgeranylation, but not farnesylation. We then identified that RhoA/Rac1-
Superoxide-JNK signaling cascade contributes to the induction of Bim-EL expression 
in response to simvastatin treatment. Separate inhibition of RhoA or Rac1 activation 
(Figure 39), superoxide production (Figure 40) and JNK activation (Figure 41) 
successfully abrogated Bim-EL expression after simvastatin treatment. The 
observation of JNK-mediated Bim-EL upregulation was also made in lovastatin-
treated ovarian cancer cells (Liu, Liang et al. 2009).  
 
The role of JNK-Bim-EL signaling pathway in apoptosis has been very well 
characterized in the nervous system upon withdrawal of nerve growth factor (NGF), 
where JNK regulates the apoptotic activity of Bim-EL via increasing Bim-EL 
expression or JNK-mediated phosphorylation of Bim-EL at Ser65 (Harris and 
Johnson 2001; Putcha, Moulder et al. 2001; Becker, Howell et al. 2004). 
Transcriptional factors that drive Bim transcription, such as c-Jun and Forkhead box 
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3a (FOXO3a), are identified to be downstream targets of JNK activation, providing 
possible mechanisms for JNK-mediated transcriptional control of Bim upregulation 
(Whitfield, Neame et al. 2001; Wang, Chen et al. 2012). On the other hand, the 
phosphorylation status of Bim-EL has been found to affect its protein expression by 
modulating its stability. Phosphorylation by ERK facilitated proteosomal degradation 
of Bim-EL and promoted cell survival (Ley, Balmanno et al. 2003). However, the 
role of JNK-mediated Bim-EL phosphorylation in its degradation has been 
controversial. To further understand whether Bim-EL upregulation is due to 
transcriptional or post-translational control, we showed that both actinomycin D and 
cycloheximide attenuated the increased Bim-EL protein content, in support of the 
role of de novo Bim-EL protein synthesis (Figure 44). Moreover, we did not observe 
any changes in the degradation rate of Bim-EL with or without simvastatin treatment, 
indicating that the stability of Bim-EL remained intact (Figure 45). This observation 
also indirectly excludes the possibility of phosphorylation-mediated changes in Bim-
EL protein expression. In summary, we propose that JNK-mediated transcriptional 
control of Bim-EL is the main mechanism responsible for simvastatin-induced 
apoptosis in HCT116 cells, possibly involving the transcriptional factors c-Jun and 
FOXO3a. In line with the hypothesis, our preliminary data showed phosphorylation 
of c-Jun and upregulation of FOXO3a, following JNK activation upon simvastatin 
treatment (Appendix B). Due to the unsuccessful attempts to detect endogenous Bim-
EL phosphorylation at Ser65 in our experiments, we did not explore the possible role 
of phosphorylated Bim-EL in mediating simvastatin’s apoptotic effects. Future 
studies are required to address this aspect of Bim regulation by JNK.  
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Our study is the first to explore the mechanisms responsible for Bim upregulation 
induced by statins. Preliminary studies in M14 melanoma cells stably transfected 
with constitutively-active Rac1 also showed that simvastatin activated a more 
pronounced Rac1-JNK-Bim signaling cascade, corresponding to more efficient 
PARP cleavage, compared to M14 cells stably transfected with empty vector. 
Together with the signaling cascade we have established in simvastatin-treated 
HCT116 cells, our data in M14 cells further supports the notion that the JNK-Bim 
cascade may be a common mechanism activated by Rac1 signaling to mediate cell 
death (Appendix C). To support this proposal, a recent study also demonstrated a role 
of Rac-JNK-Bim axis in c-Myc-induced apoptosis in mammary epithelial cells MCF 































Figure 51: Molecular mechanism of simvastatin-mediated apoptosis in HCT116 cells.  
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This is a novel report providing mechanistic insights for simvastatin’s anti-tumor 
effects in human cancer cells. Our findings from a combination of breast carcinoma, 
colorectal carcinoma, lung carcinoma, melanoma and neuroblastoma models confirm 
that the potent tumorcidal activity of simvastatin treatment is not restricted to one but 
multiple cancer types. Our data in colorectal cancer cells demonstrate that apoptosis 
is the main mechanism mediated by simvastatin, which is further identified as Bax- 
and caspase-dependent. This study also reinforces that simvastatin exerts effects via 
inhibiting the mevalonate pathway, and highlights the importance of the downstream 
protein geranylgeranylation over farnesylation in mediating the cytotoxic effects, as 
exogenously-added GGPP prevents cell death while GGTI-298 exhibits similar 
effects as simvastatin. Further investigations on the potential involvement of 
geranylgeranylated proteins show that active RhoA and Rac1 are required and 
responsible for cellular demise in the wake of simvastatin treatment. Suppression of 
RhoA and Rac1 activity largely abolished the apoptotic hallmarks. This is most 
intriguing in view of the fact that inhibition of geranylgeranylation is normally 
associated with inhibition of Rho GTPases functions. We provide a possible 
explanation that simvastatin-mediated increase in GTP-loaded RhoA and Rac1 are 
due to decreased association with their cytosolic sequester RhoGDIα by inhibiting 
geranylgeranylation. The functionality of RhoA and Rac1 were further evidenced by 
their ability to mediate production of superoxide and activation of JNK pathway in 
response to simvastatin treatment. Superoxide represents a central initiator of the 
simvastatin-elicited cellular signaling pathway, which kick-starts the apoptotic 
process by activating the MAPK family member JNK. The function of JNK in 
apoptosis has been well established and in this study we identify that simvastatin 
induces the expression of extra-long form of Bim (Bim-EL) in a JNK-dependent 
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manner. Suppression of Bim-EL expression significantly prevents simvastatin-
induced apoptosis. In summary, our results unveil a novel signaling cascade 
consisting of players such as RhoA, Rac1, superoxide, JNK and Bim-EL that is 
responsible for simvastatin’s cytotoxicity in colorectal cancer cells. We also establish 
that most of the players are critically involved in simvastatin-mediated 
neuroblastoma cell death, suggesting that this molecular mechanism might be 
activated in other cancer cells sensitive to simvastatin treatment.  
 
Taken together, our data demonstrates the tremendous potential of simvastatin to 
induce cancer cell death. Together with the advantages that statins can be introduced 
into clinical practice quickly and enjoy a favorable safety profile with uncommon but 
well-characterized side effects, they represent attractive targets in the search of 
tumor-specific and efficient anti-cancer agents. Further, the molecular players 
identified in this project not only provide novel potential targets for therapeutic 
manipulation, also lays the foundation to explore the role of statins as an adjuvant in 
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Appendix A: Knockdown of NOX2 reduces simvastatin-induced cell death. 
In both panels, HCT116 cells were transfected with 100 nM of either control siRNA or NOX2 siRNA 
for 30 h before performing subsequent experiments. (A) Superoxide production after 10 μM 
simvastatin treatment for 24 h was measured by lucigenin chemiluminesence assay.  (B) Cell viability 
after 48 h simvastatin treatment was measured by crystal violet assay. The bars represent means ± s.d. 


































































Appendix B: Simvastatin increases phosphorylation of c-Jun and FOXO3a expression. 
HCT116 cells were treated with 10 μM simvastatin treatment for the indicated duration; protein 
expression of phospho-JNK, phospho-c-Jun and FOXO3a was measured by Western blot analysis. β-














Appendix C: A more efficient Rac1-JNK-BIM-cell death signaling cascade is observed in 
M14RacV12 cells compared to M14pIRES cells. 
M14 melanoma cells were stably transfected with parental pIREShyg vector (M14pIRES) or the 
pIREShyg vector encoding for a myc-tagged constitutively active mutant of Rac (M14RacV12). Both 
cell lines were treated with 10 μM simvastatin treatment for 48 h. Protein expression of cleaved-
PARP, phospho-JNK, Bim-EL and Rac1 (the upper arrow is myc-tagged Rac1) was measured by 
Western blot analysis. GAPDH was included as a loading control.  
 
